Uses of anti-sortilin antibodies
Patent Information
- Application Number
- JP2023533608
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-25
- Filing Date
- 2021-12-01
- Publication Date
- 2024-12-09
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current therapeutic antibodies targeting Sortilin face challenges in administration, particularly for neurodegenerative diseases like Alzheimer's and Parkinson's, with intravenous delivery being cumbersome and subcutaneous delivery often inadequate, necessitating improved dosing and administration methods for patient compliance.
Administration of anti-Sortilin antibodies at specific doses (at least 6 mg/kg) via intravenous infusion or subcutaneous injection, with defined dosing frequencies (every 4-8 weeks) to increase progranulin levels in cerebrospinal fluid and plasma, using antibodies with defined hypervariable regions (HVRs) and human IgG1 isotype.
The method significantly increases progranulin levels in both plasma and cerebrospinal fluid, providing therapeutic benefits for neurodegenerative diseases with sustained pharmacodynamic effects over weeks, enhancing patient compliance and treatment convenience.
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 120,670, filed December 2, 2020, and U.S. Provisional Application No. 63 / 271,658, filed October 25, 2021, the entire contents of which are incorporated herein by reference.
[0002] Submitting a sequence listing as an ASCII text file The contents of the following submission in an ASCII text file are incorporated by reference in their entirety as part of this specification: Sequence Listing in Computer Readable Form (CRF) (Filename: 735022003640SEQLIST.TXT, Recorded: November 29, 2021, Size: 55,902 bytes).
[0003] Field The present disclosure relates to therapeutic uses of anti-Sortilin antibodies. [Background technology]
[0004] background Sortilin is a type I transmembrane protein that functions as a receptor for several ligands and also functions in sorting designated cargo from the trans-Golgi network (TGN) to late endosomes and lysosomes for degradation. Sortilin binds to the secreted protein progranulin (PGRN) and targets it for lysosomal degradation, thereby negatively regulating extracellular progranulin levels (Hu, F et al. (2010) Neuron 68, 654-667). Consistent with this, sortilin deficiency significantly increases plasma progranulin levels in both in vivo mouse models and in vitro human cells (Carrasquillo, MM et al., (2010) Am J Hum Genet 87, 890-897; Lee, WC et al., (2014) Hum Mol Genet 23, 1467-1478). Furthermore, sortilin polymorphisms have been shown to be strongly associated with progranulin serum levels in humans (Carrasquillo MM et al., (2010), Am J Hum Genet. 10; 87(6):890-7).
[0005] Progranulin (PGRN), encoded by the GRN gene, is a secreted growth factor-like trophic and anti-inflammatory protein that also acts as an adipokine involved in diet-induced obesity and insulin resistance (Nguyen DA et al., (2013). Trends in Endocrinology and Metabolism, 24, 597- 606).
[0006] Progranulin deficiency accounts for approximately 25% of all inherited forms of frontotemporal dementia (FTD), an early-onset neurodegenerative disease. Patients with heterozygous loss-of-function mutations in progranulin have approximately 50% reduced extracellular levels of the protein and invariably develop FTD, making progranulin the causative gene for this disease (Baker, M et al., (2006) Nature 442, 916-919; Carecchio M et al., (2011) J Alzheimers Dis 27, 781-790; Cruts, M et al., (2008) Trends Genet 24, 186-194; Galimberti, D et al., (2010) J Alzheimers Dis 19, 171-177).
[0007] Progranulin has also been implicated in Parkinson's disease. The GRN Parkinson's disease risk allele is associated with reduced progranulin levels in plasma, cerebrospinal fluid, and the brain. Furthermore, homozygous loss-of-function progranulin causes neuronal ceroid lipofuscinosis, and heterozygous loss-of-function progranulin causes frontotemporal dementia (FTD), which can present with parkinsonism (Smith et al., Am J Hum Genet (2012) 90(6):1102-1107; Boeve et al., Brain (2006) 129(Pt 11):3103-3114; and Wauters et al., Neurobiol Aging (2018) 67:84-94). Furthermore, decreased plasma progranulin levels are associated with increased severity of Parkinson's disease (Yao et al., Neurosci Lett (2020) 725:134873). Progranulin deficiency also worsens outcomes in rodent models of Parkinson's disease (Martens et al., J Clin Invest (2012) 122(11):3955-3959), whereas progranulin gene delivery improves these outcomes (Van Kampen et al., PLoS One (2014) 7;9(5):e97032).
[0008] Furthermore, mutant progranulin alleles have been identified in patients with Alzheimer's disease (Seelaar, H et al., (2011). Journal of neurology, neurosurgery, and psychiatry 82, 476-486). Importantly, progranulin acts protectively in several disease models, with increased progranulin levels promoting behavioral recovery from ischemia (Tao, J et al., (2012) Brain Res 1436, 130-136; Egashira, Y. et al., (2013) J Neuroinflammation 10, 105), attenuating pathology in models of amyotrophic lateral sclerosis (Laird, AS et al., (2010). PLoS One 5, e13368) and arthritis (Tang, W et al., (2011). Science 332, 478-484), and preventing memory impairment in an Alzheimer's disease model (Minami, SS et al., (2014). Nat Med 20, 1157-1164).
[0009] Through various interactions with proteins such as progranulin, sortilin and its numerous ligands have been implicated in a variety of diseases, disorders, and conditions, including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis-frontotemporal dementia phenotype, Alzheimer's disease, Parkinson's disease, depression, neuropsychiatric disorders, vascular dementia, stroke, retinal dystrophies, age-related macular degeneration, glaucoma, traumatic brain injury, aging, wound healing, stroke, arthritis, and atherosclerotic vascular disease.
[0010] Novel therapeutic antibodies targeting sortilin are one solution for treating diseases associated with sortilin or progranulin activity. However, administration of monoclonal antibodies can present challenges for such therapeutic use. For example, therapeutic antibodies are generally administered intravenously, subcutaneously, or intramuscularly due to limited oral bioavailability (Ovacik, M and Lin, L, (2018) Clin Transl Sci 11, 540-552). Among available administration options, subcutaneous administration is the most convenient because it can often be performed at home by the patient, whereas intravenous administration results in higher systemic exposure. Because delivery to the cerebrospinal fluid (CSF) requires a high systemic dose, intravenous administration is typically used because subcutaneous administration may not deliver a sufficiently high dose. However, intravenous administration can be challenging for patients with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, or FTD, where treatment is typically administered over many years, potentially posing challenges to patient compliance.
[0011] Thus, there is a need for therapeutic antibodies that specifically bind to a Sortilin protein to treat one or more diseases, disorders, and conditions associated with Sortilin activity. Additionally, there is a need to identify methods for treating patients with precise dosages and for administering those dosages in a manner that facilitates patient compliance.
[0012] All references cited herein, including patents, patent applications, and publications, are incorporated herein by reference in their entirety. Summary of the Invention
[0013] overview In one aspect, provided herein is a method of treating or delaying the progression of a disease, disorder, or injury in an individual, comprising administering to said individual an anti-Sortilin antibody at a dose of at least about 6 mg / kg, wherein said antibody comprises a light chain variable domain and a heavy chain variable domain, wherein said heavy chain variable domain comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 6, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 8, and wherein the light chain variable domain comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 9, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 11.
[0014] In another aspect, provided herein is a method of increasing Progranulin levels in an individual having a disease, disorder, or injury, comprising administering to the individual an anti-Sortilin antibody at a dose of at least about 6 mg / kg, wherein the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 6, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 8, and the light chain variable domain comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 9, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 11. In some embodiments, increasing Progranulin levels comprises increasing Progranulin levels in the cerebrospinal fluid of the individual, the plasma of the individual, or both.
[0015] In another aspect, provided herein is a method of treating or delaying the progression of a disease, disorder, or injury in an individual, comprising administering to the individual an anti-Sortilin antibody by subcutaneous injection at a dose of about 150 mg to about 600 mg, wherein the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 6, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 8, and the light chain variable domain comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 9, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 11.
[0016] In another aspect, provided herein is a method of increasing progranulin levels in an individual having a disease, disorder, or injury, comprising administering to the individual an anti-Sortilin antibody by subcutaneous injection at a dose of about 150 mg to about 600 mg, wherein the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 6, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 8, and the light chain variable domain comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 9, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 11.
[0017] In some embodiments that may be combined with any of the preceding embodiments, the method comprises administering an anti-Sortilin antibody by intravenous infusion or subcutaneous injection. In some embodiments, the method comprises administering an anti-Sortilin antibody by intravenous infusion at a dose of at least about 6 mg / kg, at least about 15 mg / kg, at least about 30 mg / kg, or at least about 60 mg / kg. In some embodiments, the method comprises administering an anti-Sortilin antibody by intravenous infusion at a dose of about 6 mg / kg and about 30 mg / kg. In some embodiments, the method comprises administering an anti-Sortilin antibody by intravenous infusion at a dose of about 6 mg / kg, about 15 mg / kg, about 30 mg / kg, or about 60 mg / kg.
[0018] In some embodiments, the method comprises: (a) administering an anti-Sortilin antibody by intravenous infusion at an initial dose of about 60 mg / kg, followed by one or more lower doses of the anti-Sortilin antibody of about 6 mg / kg to about 59 mg / kg, or about 6 mg / kg to about 30 mg / kg, or about 6 mg / kg to about 15 mg / kg; (b) administering an anti-Sortilin antibody by intravenous infusion at an initial dose of about 30 mg / kg, followed by one or more lower doses of the anti-Sortilin antibody of about 6 mg / kg to about 29 mg / kg, or about 6 mg / kg to about 15 mg / kg; (c) administering an anti-Sortilin antibody by intravenous infusion at an initial dose of about 15 mg / kg, followed by one or more lower doses of the anti-Sortilin antibody of about 6 mg / kg to about 14 mg / kg. (d) administering an anti-Sortilin antibody by intravenous infusion at an initial dose of about 6 mg / kg, followed by one or more higher doses of the anti-Sortilin antibody of about 7 mg / kg to about 30 mg / kg, about 15 mg / kg to about 30 mg / kg, or about 30 mg / kg to about 60 mg / kg; (e) administering an anti-Sortilin antibody by intravenous infusion at an initial dose of about 15 mg / kg, followed by one or more higher doses of the anti-Sortilin antibody of about 16 mg / kg to about 30 mg / kg, or about 30 mg / kg to about 60 mg / kg; or (f) administering an anti-Sortilin antibody by intravenous infusion at an initial dose of about 30 mg / kg, followed by one or more higher doses of the anti-Sortilin antibody of about 31 mg / kg to about 60 mg / kg.
[0019] In some embodiments, the method comprises administering the anti-Sortilin antibody about once every 4 weeks or less frequently. In some embodiments, the method comprises administering the anti-Sortilin antibody about once every 4 weeks, about once every 5 weeks, about once every 6 weeks, about once every 7 weeks, about once every 8 weeks, about once every 9 weeks, or about once every 10 weeks. In some embodiments, the method comprises administering the anti-Sortilin antibody by intravenous infusion at a dose of about 15 mg / kg about once every 4 weeks, about once every 6 weeks, or about once every 8 weeks. In some embodiments, the method comprises administering the anti-Sortilin antibody by intravenous infusion at a dose of about 15 mg / kg about once every 6 weeks or about once every 8 weeks. In some embodiments, the method comprises administering the anti-Sortilin antibody by intravenous infusion at a dose of about 30 mg / kg about once every 4 weeks, about once every 6 weeks, or about once every 8 weeks. In some embodiments, the method comprises administering an anti-Sortilin antibody by intravenous infusion at a dose of about 30 mg / kg about once every 6 weeks or about once every 8 weeks. In some embodiments, the method comprises administering an anti-Sortilin antibody by intravenous infusion at a dose of about 60 mg / kg about once every 4 weeks, about once every 6 weeks, or about once every 8 weeks. In some embodiments, the method comprises administering an anti-Sortilin antibody by intravenous infusion at a dose of about 60 mg / kg about once every 6 weeks or about once every 8 weeks. In some embodiments, the method comprises administering an anti-Sortilin antibody by subcutaneous injection at a dose of at least about 270 mg. In some embodiments, the method comprises administering an anti-Sortilin antibody by subcutaneous injection at a dose of about 150 mg to about 600 mg. In some embodiments, the method comprises administering an anti-Sortilin antibody by subcutaneous injection at a dose of any of about 150 mg, about 270 mg, about 300 mg, or about 600 mg. In some embodiments, the methods comprise administering the anti-Sortilin antibody at a dose of about 150 mg by subcutaneous injection, hi some embodiments, the methods comprise administering the anti-Sortilin antibody at a dose of about 270 mg by subcutaneous injection.In some embodiments, the method comprises administering the anti-Sortilin antibody by subcutaneous injection at a dose of about 300 mg. In some embodiments, the method comprises administering the anti-Sortilin antibody by subcutaneous injection at a dose of about 600 mg. In some embodiments, the method comprises administering the anti-Sortilin antibody by subcutaneous injection about every 2 weeks, about every 4 weeks, about every 6 weeks, or about every 8 weeks. In some embodiments, the method comprises administering the anti-Sortilin antibody by subcutaneous injection about once every 4 weeks. In some embodiments that may be combined with any of the preceding embodiments, the anti-Sortilin antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 20 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 21. In some embodiments, the anti-Sortilin antibody has a human IgG1 isotype. In some embodiments, the anti-Sortilin antibody comprises an Fc region comprising amino acid substitutions L234A, L235A, and P331S, where the numbering of residue positions is according to EU numbering. In some embodiments, the anti-Sortilin antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 25 or 26. In some embodiments, the anti-Sortilin antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 30, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 or 32. In some embodiments, the anti-Sortilin antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 30, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 32. In some embodiments, the anti-Sortilin antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 30, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 31.
[0020] In some embodiments that may be combined with any of the preceding embodiments, the method further includes measuring progranulin levels in blood or cerebrospinal fluid samples obtained from the individual before and after the individual receives one or more doses of an anti-Sortilin antibody.
[0021] In some embodiments that may be combined with any of the preceding embodiments, the method further includes measuring sortilin levels in leukocytes in blood samples obtained from the individual before and after the individual receives one or more doses of anti-sortilin antibody.
[0022] In some embodiments that may be combined with any of the preceding embodiments, the method further includes measuring levels of neurofilament light chain (NF-L), tau, one or more biomarkers of neuroinflammation, one or more biomarkers of inflammation, one or more biomarkers of complement function, and / or one or more biomarkers of microglial activity in blood or cerebrospinal fluid samples obtained from the individual before and after the individual receives one or more doses of anti-Sortilin antibody. In some embodiments, (a) the one or more biomarkers of neuroinflammation are selected from the group consisting of IL-6, SPP1, IFI2712A, CHIT1, YKL-40, GFAP, YWHAE, CSF1, AIF1, LY86, CD86, and TOP2A; (b) the one or more biomarkers of inflammation are selected from the group consisting of osteopontin (SPP1), YWHAE (14-3-3 protein ε), allograft inflammatory factor 1 (AIF1), colony-stimulating factor 1 (CSF1), chitinase 1 (CHIT1), lymphocyte antigen 86 (LY86), and CD86; (c) the one or more biomarkers of complement function are selected from the group consisting of C1qb and C1qc; and / or (d) the one or more biomarkers of microglial activity are selected from the group consisting of YKL-40, GFAP, and interleukin-6.
[0023] In some embodiments that may be combined with any of the preceding embodiments, administering a 6 mg / kg or 15 mg / kg dose of anti-Sortilin antibody to an individual by intravenous infusion results in an increase in the individual's plasma progranulin level of at least about 1.4-fold, at least about 1.8-fold, at least about 2-fold, at least about 2.2-fold, at least about 2.4-fold, at least about 2.6-fold, at least about 2.8-fold, or at least about 3-fold the individual's plasma progranulin level prior to administration of the anti-Sortilin antibody. In some embodiments, the increase in the individual's plasma progranulin level is present within about 1 day after administration of the anti-Sortilin antibody. In some embodiments, the dose of the anti-Sortilin antibody is 6 mg / kg, and the increase in the individual's plasma progranulin level is present about 1 day, about 2 days, about 5 days, about 7 days, about 12 days, about 17 days, about 24 days, about 29 days, or about 42 days after administration of the anti-Sortilin antibody. In some embodiments, the dose of the anti-Sortilin antibody is 15 mg / kg, and the increase in Progranulin levels in the individual's plasma is present at about 1 day, about 2 days, about 5 days, about 7 days, about 12 days, about 17 days, about 24 days, about 29 days, about 42 days, or about 56 days after administration of the anti-Sortilin antibody.
[0024] In some embodiments that may be combined with any of the preceding embodiments, administration of a 6 mg / kg, 15 mg / kg, 30 mg / kg, or 60 mg / kg dose of an anti-Sortilin antibody to an individual by intravenous infusion increases the level of Progranulin in the individual's plasma by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or In some embodiments, the dose of the anti-Sortilin antibody is 6 mg / kg, and the increase in Progranulin levels in the individual's plasma is present at about 1 day, about 7 days, about 14 days, about 21 days, or about 28 days after administration of the anti-Sortilin antibody. In some embodiments, the dose of the anti-Sortilin antibody is 15 mg / kg and the increase in the plasma level of Progranulin of the individual is present about 1 day, about 7 days, about 14 days, about 21 days, about 28 days, about 35 days, or about 42 days after administration of the anti-Sortilin antibody. In some embodiments, the dose of the anti-Sortilin antibody is 30 mg / kg and the increase in the plasma level of Progranulin of the individual is present about 1 day, about 7 days, about 14 days, about 21 days, about 28 days, about 35 days, about 42 days, about 49 days, or about 56 days after administration of the anti-Sortilin antibody. In some embodiments, the dose of the anti-Sortilin antibody is 60 mg / kg, and the increase in Progranulin levels in the individual's plasma is present at about 1 day, about 7 days, about 14 days, about 21 days, about 28 days, about 35 days, about 42 days, about 49 days, about 56 days, about 63 days, about 70 days, about 77 days, or about 84 days after administration of the anti-Sortilin antibody.
[0025] In some embodiments that may be combined with any of the preceding embodiments, administering a dose of about 150 mg of anti-Sortilin antibody to an individual by subcutaneous injection results in an increase in the level of Progranulin in the individual's plasma by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 110%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 160%, at least about 170%, at least about 180%, at least about 190%, or at least about 200% compared to the level of Progranulin in the individual's plasma before administration of the anti-Sortilin antibody. In some embodiments that may be combined with any of the preceding embodiments, administering a dose of about 300 mg of anti-Sortilin antibody to an individual by subcutaneous injection results in an increase in the level of Progranulin in the individual's plasma by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 110%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 160%, at least about 170%, at least about 180%, at least about 190%, or at least about 200% compared to the level of Progranulin in the individual's plasma before administration of the anti-Sortilin antibody.In some embodiments that may be combined with any of the preceding embodiments, administering a dose of about 600 mg of anti-Sortilin antibody to an individual by subcutaneous injection results in an increase in the level of Progranulin in the individual's plasma by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 110%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 160%, at least about 170%, at least about 180%, at least about 190%, or at least about 200% compared to the level of Progranulin in the individual's plasma before administration of the anti-Sortilin antibody. In some embodiments, the increase in progranulin levels in the individual's plasma is present at about 1 day, about 7 days, about 14 days, about 21 days, or about 28 days after administration of the anti-sortilin antibody.
[0026] In some embodiments that may be combined with any of the preceding embodiments, administering a 6 mg / kg dose of anti-Sortilin antibody to an individual by intravenous infusion results in an increase in Progranulin levels in the cerebrospinal fluid of the individual of at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, or at least about 20% compared to the Progranulin levels in the cerebrospinal fluid of the individual before administration of the anti-Sortilin antibody. In some embodiments, the increase in Progranulin levels in the cerebrospinal fluid of the individual is present at about 1 day, about 2 days, about 5 days, about 7 days, about 12 days, about 14 days, about 17 days, about 21 days, about 24 days, about 28 days, about 29 days, about 35 days, about 42 days, about 49 days, or about 56 days after administration of the anti-Sortilin antibody.
[0027] In some embodiments that may be combined with any of the preceding embodiments, administering a 15 mg / kg dose of an anti-Sortilin antibody to an individual by intravenous infusion results in an increase in Progranulin levels in the cerebrospinal fluid of the individual by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% compared to the Progranulin levels in the cerebrospinal fluid of the individual before administration of the anti-Sortilin antibody. In some embodiments, the increase in Progranulin levels in the cerebrospinal fluid of the individual is present at about 1 day, about 2 days, about 5 days, about 7 days, about 12 days, about 14 days, about 17 days, about 21 days, about 24 days, about 28 days, about 29 days, about 35 days, about 42 days, about 49 days, or about 56 days after administration of the anti-Sortilin antibody.
[0028] In some embodiments that may be combined with any of the preceding embodiments, administering a 30 mg / kg dose of an anti-Sortilin antibody to an individual by intravenous infusion results in an increase in Progranulin levels in the cerebrospinal fluid of the individual by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, or at least about 70% compared to the Progranulin levels in the cerebrospinal fluid of the individual before administration of the anti-Sortilin antibody. In some embodiments, the increase in Progranulin levels in the cerebrospinal fluid of the individual is present at about 1 day, about 2 days, about 5 days, about 7 days, about 12 days, about 14 days, about 17 days, about 21 days, about 24 days, about 28 days, about 29 days, about 35 days, about 42 days, about 49 days, or about 56 days after administration of the anti-Sortilin antibody.
[0029] In some embodiments that may be combined with any of the preceding embodiments, administering a 60 mg / kg dose of an anti-Sortilin antibody to an individual by intravenous infusion results in an increase in Progranulin levels in the cerebrospinal fluid of the individual by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, or at least about 70% compared to the Progranulin levels in the cerebrospinal fluid of the individual before administration of the anti-Sortilin antibody. In some embodiments, the increase in Progranulin levels in the cerebrospinal fluid of the individual is present at about 1 day, about 7 days, about 14 days, about 21 days, about 28 days, about 35 days, about 42 days, about 49 days, about 56 days, about 63 days, about 70 days, about 77 days, or about 84 days after administration of the anti-Sortilin antibody.
[0030] In some embodiments that may be combined with any of the preceding embodiments, administering a dose of about 150 mg of an anti-Sortilin antibody to an individual by subcutaneous injection results in an increase in progranulin levels in the cerebrospinal fluid of the individual by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, or at least about 70%, compared to the progranulin levels in the cerebrospinal fluid of the individual before administration of the anti-Sortilin antibody. In some embodiments that may be combined with any of the preceding embodiments, administering a dose of about 300 mg of an anti-Sortilin antibody to an individual by subcutaneous injection results in an increase in progranulin levels in the cerebrospinal fluid of the individual by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, or at least about 70%, compared to the progranulin levels in the cerebrospinal fluid of the individual before administration of the anti-Sortilin antibody. In some embodiments that may be combined with any of the preceding embodiments, administering a dose of about 600 mg of an anti-Sortilin antibody to an individual by subcutaneous injection results in an increase in Progranulin levels in the cerebrospinal fluid of the individual by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, or at least about 70% compared to the Progranulin levels in the cerebrospinal fluid of the individual before administration of the anti-Sortilin antibody. In some embodiments, the increase in Progranulin levels in the cerebrospinal fluid of the individual is present about 1 day, about 7 days, about 14 days, or about 21 days after administration of the anti-Sortilin antibody.
[0031] In some embodiments that may be combined with any of the preceding embodiments, the disease, disorder, or injury is selected from frontotemporal dementia, progressive supranuclear palsy, Alzheimer's disease, vascular dementia, stroke, retinal dystrophy, amyotrophic lateral sclerosis (ALS), traumatic brain injury, spinal cord injury, dementia, stroke, Parkinson's disease, acute disseminated encephalomyelitis, retinal degeneration, age-related macular degeneration, glaucoma, multiple sclerosis, septic shock, bacterial infection, arthritis, or osteoarthritis. In some embodiments, the individual is at risk for the disease, disorder, or injury. In some embodiments, the disease, disorder, or injury is Parkinson's disease. In some embodiments, the individual is at risk for Parkinson's disease. In some embodiments, the disease, disorder, or injury is sporadic Parkinson's disease. In some embodiments, the individual has at least one pathogenic mutation in the GBA1 gene. In some embodiments, the individual is homozygous or heterozygous for at least one pathogenic mutation in the GBA1 gene. In some embodiments, the at least one pathogenic mutation in the GBA1 gene is selected from the group consisting of 1226A>G, c.1448T>C, IVS2+1G>A, RecNciI, 84insGG, and any combination thereof; or the at least one pathogenic mutation in the GBA1 gene is a mutation in the GBA1 gene resulting in an amino acid substitution in the GBA1 gene product selected from the group consisting of N370S, L444P, R120W, H255Q, D409H, E326K, T369M, R496H, and any combination thereof. In some embodiments, the Parkinson's disease is classified as grade I to III based on the Hoehn-Yarr diagnostic criteria. In some embodiments, the individual has received one or more therapies for Parkinson's disease before administration of the anti-sortilin antibody. In some embodiments, the individual continues to receive one or more therapies for Parkinson's disease after initiation of treatment with the anti-sortilin antibody. In some embodiments, the methods involve administering an anti-Sortilin antibody in combination with one or more treatments for Parkinson's disease.In some embodiments, the one or more treatments for Parkinson's disease are selected from glutamate antagonists, anticholinergics, dopaminergics, levodopa (L-DOPA and decarboxylase [DDC] inhibitors), monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, beta-blockers, selective serotonin uptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), or indomethacin. In some embodiments, the method further comprises measuring the levels of progranulin, GCase, and / or alpha-synuclein in plasma or cerebrospinal fluid samples obtained from the individual before and after the individual receives one or more doses of an anti-sortilin antibody. In some embodiments, the method further comprises measuring the levels of one or more biomarkers of lysosomal function in plasma or cerebrospinal fluid samples obtained from the individual before and after the individual receives one or more doses of an anti-sortilin antibody. In some embodiments, the one or more biomarkers of lysosomal function are selected from GCase protein, GCase activity, lyso-Gb1, one or more cathepsins, LAMP1, N-acetyl-D-glucosamine kinase (NAGK), and glucosylceramide; optionally, the one or more cathepsins are selected from cathepsin B (CTSB) and cathepsin D (CTSD). In some embodiments, the method further comprises assessing the cognitive function of the individual before and after the individual receives one or more doses of an anti-Sortilin antibody. In some embodiments, the cognitive function is assessed using the Montreal Cognitive Assessment (MoCA). In some embodiments, the method further comprises assessing the motor function of the individual before and after the individual receives one or more doses of an anti-Sortilin antibody. In some embodiments, motor function is assessed using the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (MDS-UPDRS Part III), or the UPDRS Total Scale.In some embodiments, the method comprises administering to the individual an anti-Sortilin antibody for at least about 6 months or at least about 24 weeks.
[0032] In some embodiments, the disease, disorder, or injury is frontotemporal dementia (FTD). In some embodiments, the individual (a) is optionally heterozygous for one or more mutations in the GRN gene, and the one or more mutations are loss-of-function mutations; (b) is heterozygous for a C9orf72 hexanucleotide repeat expansion; (c) has symptoms of FTD, such as no symptoms of FTD or pre-symptomatic FTD; and / or (d) has FTD-GRN, or FTD caused by one or more mutations in the GRN gene. In some embodiments, (a) the individual has pre-symptomatic FTD and (i) has increased levels of one or more biomarkers selected from the group consisting of Nfl, SPP1, YWHAE, AIF1, CSF1, CHIT1, and LY86, and / or (ii) has decreased levels of one or more biomarkers selected from the group consisting of NAGK and CTSB; or (b) the individual does not have symptoms of FTD and (i) is heterozygous for one or more mutations in the GRN gene and / or (ii) has decreased PGRN levels or function.
[0033] In some embodiments, the disease, disorder, or injury is Alzheimer's disease.
[0034] In some embodiments, the disease, disorder, or injury is ALS.
[0035] In some embodiments that may be combined with any of the preceding embodiments, the method further comprises measuring the levels of progranulin, GCase, and / or alpha-synuclein in plasma or cerebrospinal fluid samples obtained from the individual before and after the individual receives one or more doses of an anti-Sortilin antibody. In some embodiments that may be combined with any of the preceding embodiments, the method further comprises measuring the levels of one or more biomarkers of lysosomal function in plasma or cerebrospinal fluid samples obtained from the individual before and after the individual receives one or more doses of an anti-Sortilin antibody. In some embodiments, the one or more biomarkers of lysosomal function are selected from GCase protein, GCase activity, lyso-Gb1, one or more cathepsins, LAMP1, N-acetyl-D-glucosamine kinase (NAGK), and glucosylceramide; optionally, the one or more cathepsins are selected from cathepsin B (CTSB) and cathepsin D (CTSD). In some embodiments that may be combined with any of the preceding embodiments, the method further includes assessing the individual's cognitive function before and after the individual receives one or more doses of an anti-Sortilin antibody. In some embodiments that may be combined with any of the preceding embodiments, the individual is a human.
[0036] In another aspect, provided herein is a method of monitoring treatment of an individual being administered an anti-Sortilin antibody, comprising measuring the level of one or more biomarkers, wherein the one or more biomarkers are selected from progranulin, GCase, neurofilament light chain (NF-L), tau, one or more markers of neuroinflammation, one or more inflammatory biomarkers, one or more biomarkers of complement function, one or more biomarkers of microglial activity, or alpha-synuclein, wherein the level of the one or more biomarkers is measured in plasma or cerebrospinal fluid samples obtained from the individual before and after the individual receives one or more doses of the anti-Sortilin antibody.
[0037] In another aspect, provided herein is a method for monitoring treatment of an individual being administered an anti-Sortilin antibody, the method comprising measuring the level of one or more biomarkers of lysosomal function in plasma or cerebrospinal fluid samples obtained from the individual before and after the individual receives one or more doses of the anti-Sortilin antibody.
[0038] In some embodiments that may be combined with any of the preceding embodiments, the one or more biomarkers of lysosomal function are selected from GCase protein, GCase activity, lyso-Gb1, one or more cathepsins, LAMP1, N-acetyl-D-glucosamine kinase (NAGK), and glucosylceramide; optionally, the one or more cathepsins are selected from cathepsin B (CTSB) and cathepsin D (CTSD). In some embodiments, the method further comprises assessing anti-Sortilin antibody activity in the individual based on the level of the one or more biomarkers in the sample.
[0039] In some embodiments that may be combined with any of the preceding embodiments, (a) the one or more markers of neuroinflammation are selected from IL-6, SPP1, IFI2712A, CHIT1, YKL-40, GFAP, YWHAE, CSF1, AIF1, LY86, CD86, and TOP2A; (b) the one or more inflammatory biomarkers are selected from osteopontin (SPP1), YWHAE (14-3-3 protein ε), allograft inflammatory factor 1 (AIF1), colony-stimulating factor 1 (CSF1), chitinase 1 (CHIT1), lymphocyte antigen 86 (LY86), and CD86; (c) the one or more biomarkers of complement function are selected from C1qb and C1qc; and / or (d) the one or more biomarkers of microglial activity are selected from YKL-40, GFAP, and interleukin-6.
[0040]
[0014] In another aspect, provided herein is an antibody that binds to a Sortilin protein, wherein the antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 20 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 21, wherein the antibody has a human IgG1 isotype and comprises an Fc region comprising amino acid substitutions L234A, L235A, and P331S, wherein the numbering of residue positions is according to EU numbering.
[0041] In another aspect, provided herein is an antibody that binds to a sortilin protein, wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 30, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 or 32.
[0042]
[0014] In another aspect, provided herein is an anti-Sortilin antibody at a dose of at least about 6 mg / kg for use in a method of treating or delaying the progression of a disease, disorder, or injury in an individual, wherein the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO:6, HVR-H2 comprising the amino acid sequence of SEQ ID NO:7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:8, and the light chain variable domain comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO:9, HVR-L2 comprising the amino acid sequence of SEQ ID NO:10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:11.
[0043] In another aspect, provided herein is an anti-Sortilin antibody at a dose of at least about 6 mg / kg for use in a method for increasing progranulin levels in an individual having a disease, disorder, or injury, wherein the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 6, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 8, and the light chain variable domain comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 9, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 11.
[0044]
[0014] In another aspect, provided herein is an antibody that binds to a Sortilin protein for use in a method of treating or delaying the progression of a disease, disorder, or injury in an individual, wherein the antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 20 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 21, wherein the antibody has a human IgG1 isotype and comprises an Fc region comprising amino acid substitutions L234A, L235A, and P331S, wherein the numbering of residue positions is according to EU numbering.
[0045] In another aspect, provided herein is an antibody that binds to Sortilin protein for use in a method for increasing progranulin levels in an individual having a disease, disorder, or injury, wherein the antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 20 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 21, wherein the antibody has a human IgG1 isotype and comprises an Fc region comprising amino acid substitutions L234A, L235A, and P331S, wherein the numbering of residue positions is according to EU numbering.
[0046] In another aspect, provided herein is an antibody that binds to a Sortilin protein for use in a method of treating or delaying the progression of a disease, disorder, or injury in an individual, the antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO: 30, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 or 32.
[0047] In another aspect, provided herein is an antibody that binds to a Sortilin protein for use in a method for increasing progranulin levels in an individual having a disease, disorder, or injury, wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 30, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 or 32.
[0048] In another aspect, provided herein is the use of an anti-Sortilin antibody at a dose of at least about 6 mg / kg in the manufacture of a medicament for treating or delaying the progression of a disease, disorder, or injury in an individual, wherein the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 6, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 8, and the light chain variable domain comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 9, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 11.
[0049] In another aspect, provided herein is the use of an anti-Sortilin antibody at a dose of at least about 6 mg / kg in the manufacture of a medicament for increasing progranulin levels in an individual having a disease, disorder, or injury, wherein the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 6, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 8, and the light chain variable domain comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 9, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 11.
[0050]
[0013] In another aspect, provided herein is the use of an antibody that binds to a Sortilin protein in the manufacture of a medicament for treating or delaying the progression of a disease, disorder, or injury in an individual, wherein the antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 20 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 21, wherein the antibody has a human IgG1 isotype and comprises an Fc region comprising amino acid substitutions L234A, L235A, and P331S, wherein the numbering of residue positions is according to EU numbering.
[0051] In another aspect, provided herein is the use of an antibody that binds to a Sortilin protein in the manufacture of a medicament for increasing Progranulin levels in an individual having a disease, disorder, or injury, wherein the antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 20 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 21, wherein the antibody has a human IgG1 isotype and comprises an Fc region comprising amino acid substitutions L234A, L235A, and P331S, and wherein the numbering of residue positions is according to EU numbering.
[0052] In another aspect, provided herein is the use of an antibody that binds to a Sortilin protein in the manufacture of a medicament for treating or delaying the progression of a disease, disorder, or injury in an individual, wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 30, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 or 32.
[0053] In another aspect, provided herein is the use of an antibody that binds to a Sortilin protein in the manufacture of a medicament for increasing progranulin levels in an individual having a disease, disorder, or injury, wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 30 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 or 32. [Brief explanation of the drawings]
[0054] [Figure 1] Figure 1 is a diagram of the design of the study described in Example 1. CSF = cerebrospinal fluid; D = study day; IV = intravenous; SC = subcutaneous. Study days on which CSF samples were collected during the study are indicated. [Figure 2A]Figures 2A-2C show plasma progranulin levels for subjects in Cohort 1 of the study described in Examples 1-2. Figure 2A shows plasma progranulin levels at the indicated times (pre-dose, EOI, 4HR, 8HR, 12HR) on Study Day 1 for each of Cohort 1 Subjects 1-8, who received the anti-Sortilin antibody ALX at a dose of 6 mg / kg. The y-axis is labeled 100, 150, and 200 ng / ml. Figure 2B shows plasma progranulin levels at the indicated times (pre-dose, EOI, 4HR, 8HR, 12HR) on Study Day 1 for each of Cohort 1 Subjects 1-3, who received placebo. The y-axis is labeled 100, 150, and 200 ng / ml. Figure 2C shows mean plasma progranulin levels on the indicated study days for subjects in Cohort 1 who received placebo or antibody ALX. [Figure 2B] Continuation of Figure 2A. [Figure 2C] Continuation of Figure 2B. [Figure 3A] Figures 3A-3C show plasma progranulin levels for subjects in Cohort 2 of the study described in Examples 1-2. Figure 3A shows plasma progranulin levels at the indicated time points on study day 1 for each of Cohort 2 subjects 1-6, who received the anti-sortilin antibody ALX at a dose of 15 mg / kg. Figure 3B shows plasma progranulin levels at the indicated time points on study day 1 for each of Cohort 2 subjects 1-2, who received a placebo. Figure 3C shows mean plasma progranulin levels on the indicated study days for subjects in Cohort 2 who received a placebo or antibody ALX. [Figure 3B] This is a continuation of Figure 3A. [Figure 3C] This is a continuation of Figure 3B. [Figure 4] Figure 4 shows the mean progranulin levels in plasma on designated study days for subjects in Cohorts 1 and 2 who received the anti-sortilin antibody ALX or placebo. [Figure 5A]Figures 5A-5D show plasma progranulin levels for subjects in Cohorts 1 and 2 of the study described in Examples 1-2. Figure 5A shows plasma progranulin levels for each subject in Cohorts 1 and 2 of the study who received a placebo on the indicated days after placebo administration. Each line represents one subject. Figure 5B shows plasma progranulin levels for each subject in Cohort 1 who received antibody ALX (6 mg / kg) on the indicated days after antibody administration. Each line represents one subject. Figure 5C shows plasma progranulin levels for each subject in Cohort 2 who received antibody ALX (15 mg / kg) on the indicated days after antibody administration. Each line represents one subject. Figure 5D shows mean plasma progranulin levels for subjects in Cohorts 1 and 2 who received antibody ALX or placebo on the indicated days after antibody or placebo administration. All subjects who received placebo from Cohorts 1 and 2 were pooled ("pooled placebo"). SD = single dose; IV = intravenous. [Figure 5B] This is a continuation of Figure 5A. [Figure 5C] This is a continuation of Figure 5B. [Figure 5D] This is a continuation of Figure 5C. [Figure 6] 6 shows the change in CSF progranulin levels for subjects in Cohorts 1 and 2 of the study described in Examples 1-2. CSF progranulin levels are shown as the mean percentage change on the indicated study day compared to baseline CSF progranulin levels. The number of subjects included in the analysis of progranulin CSF levels for each cohort on each study day is indicated below the graph. [Figure 7A]7A-7B show the mean concentrations (ng / ml) of anti-Sortilin antibody ALX in serum from cynomolgus monkeys administered antibody intravenously at doses of 20 mg / kg, 60 mg / kg, and 200 mg / kg once weekly for 4 weeks, as described in Example 4. Figure 7A shows the mean concentrations of anti-Sortilin antibody ALX in serum at the indicated times (hours) after administration of each dose of antibody on study days 1, 8, and 15. Figure 7B shows the mean concentrations of anti-Sortilin antibody ALX in serum at the indicated times (hours) after administration of each dose of antibody on study days 22 and 29. [Figure 7B] This is a continuation of Figure 7A. [Figure 8A] Figures 8A-8C show white blood cell (WBC) sortilin expression, serum progranulin, and CSF progranulin levels in cynomolgus monkeys administered antibody ALX intravenously at doses of 0 mg / kg (control), 20 mg / kg, 60 mg / kg, and 200 mg / kg once weekly for four weeks, as described in Example 4. Figure 8A shows the level of sortilin (SORT1) expression in leukocytes as a percentage of baseline levels at the indicated times after administration of the first dose of antibody ALX. Figure 8B shows the level of progranulin in serum as a percentage of baseline levels at the indicated times after administration of the first dose of antibody ALX. Figure 8C shows the level of progranulin in CSF as a percentage of baseline levels at the indicated times after administration of the first dose of antibody ALX. In Figures 8A-8C, arrows indicate the time of administration of antibody ALX doses. [Figure 8B] This is a continuation of Figure 8A. [Figure 8C] This is a continuation of Figure 8B. [Figure 9] Figure 9 is a diagram of the participant breakdown of the enrolled population at various time points during the study. IV = intravenous; SD = single dose; SC = subcutaneous. a Subject-initiated withdrawal (n=2); b Subject-initiated withdrawal; c Physician's decision; d Physician's decision (n=1) and subject-initiated withdrawal (n=3); e Adverse event. [Figure 10A]Figures 10A-10B show the mean concentrations (ng / ml) of anti-sortilin antibody ALX in serum and CSF of subjects from cohorts receiving a single intravenous dose of antibody ALX at doses of 6 mg / kg (Cohort 1), 15 mg / kg (Cohort 2), 30 mg / kg (Cohort 3), or 60 mg / kg (Cohort 4), or a single subcutaneous dose of ALX antibody at 600 mg (SD SC cohort), as described in Example 5. Figure 10A shows serum ALX concentrations at the indicated times (days) after a single intravenous or subcutaneous administration of ALX. Figure 10B shows mean CSF ALX concentrations at the indicated times (days) after a single intravenous or subcutaneous administration of ALX. [Figure 10B] This is a continuation of Figure 10A. [Figure 11A] Figures 11A-11B show the mean percentage change from baseline in plasma and CSF progranulin concentrations following a single intravenous administration of antibody ALX at doses of 6 mg / kg (Cohort 1), 15 mg / kg (Cohort 2), 30 mg / kg (Cohort 3), or 60 mg / kg (Cohort 4), or a single subcutaneous administration of ALX antibody at 600 mg (SD SC cohort), as described in Example 5. Figure 11A shows the mean percentage change from baseline in plasma progranulin concentrations at the indicated times (days) after a single administration of antibody ALX. Figure 11B shows the mean percentage change from baseline in CSF progranulin concentrations at the indicated times (days) after a single administration of antibody ALX. [Figure 11B] This is a continuation of Figure 11A. [Figure 12] Figure 12 shows a diagram of the single subcutaneous dose cohort design. Subjects receive a single subcutaneous dose of 150 mg antibody ALX. As indicated by the arrow, the single dose is administered on day 1. Study days on which CSF samples are collected are indicated by boxes. LP = lumbar puncture; BL = baseline; SC = subcutaneous; EoS = end of study. [Figure 13]Figure 13 shows a diagram of the multiple subcutaneous dosing cohort design. As indicated by the arrows, subjects (n=10) receive seven doses of 300 mg of antibody ALX on days 1, 15, 29, 43, 57, 71, and 85. Study days on which CSF samples were collected are indicated by boxes. LP = lumbar puncture; BL = baseline; SC = subcutaneous; HV = healthy volunteer; EoS = end of study. [Figure 14] Figure 14 shows a diagram of the multiple intravenous dosing cohort design. Subjects (n=10) received four doses of 30 mg / kg antibody ALX or placebo in an 8:2 ratio (antibody ALX:placebo) on days 1, 29, 57, and 85, as indicated by the arrows. Study days on which CSF samples were collected are indicated by boxes. LP = lumbar puncture; BL = baseline; IV = intravenous; HV = healthy volunteer; EoS = end of study. [Figure 15] Figure 15 shows a diagram of the design of the study described in Example 1. CSF = cerebrospinal fluid; DLAE = dose-limiting adverse events; IV = intravenous; PD = pharmacodynamics; PK = pharmacokinetics; SC = subcutaneous; SD = single dose. aPost-dose CSF sampling was performed at two time points, on days 25, 43, or 57; bPost-dose CSF sampling was performed at two time points, on days 25, 43, 57, or 85; cPost-dose CSF sampling was performed at two time points, on days 43, 57, or 85; dPost-dose CSF sampling was performed at two time points, on days 25, 43, 57, or 85; eParticipants in the 6-mg / kg, 15-mg / kg, and 30-mg / kg dose groups were followed for 12 weeks; fParticipants in the 60-mg / kg dose group were followed for 16 weeks; gFinal study visit for participants in the 6-mg / kg, 15-mg / kg, and 30-mg / kg dose groups; hFinal study visit for participants in the 60-mg / kg dose group; iPost-dose CSF sampling was performed at two time points, on days 8, 13, 18, 25, or 43. DETAILED DESCRIPTION OF THE INVENTION
[0055] Detailed Description definition As used herein, the term "preventing" includes providing prophylaxis against the occurrence or recurrence of a particular disease, disorder, or condition in an individual who may be predisposed to or susceptible to a particular disease, disorder, or condition, or who may be at risk of developing such a disease, disorder, or condition, but who has not yet been diagnosed with the disease, disorder, or condition.
[0056] As used herein, an individual "at risk" of developing a particular disease, disorder, or condition may or may not have detectable disease or disease symptoms, and may or may not exhibit detectable disease or disease symptoms prior to the treatment methods described herein. "At risk" means that an individual has one or more risk factors, which are measurable parameters known in the art that correlate with the development of a particular disease, disorder, or condition. Individuals who have one or more of these risk factors have a higher probability of developing a particular disease, disorder, or condition than individuals who do not have one or more of these risk factors.
[0057] As used herein, the term "treatment" or "treating" refers to a clinical intervention designed to alter the natural course of a clinical pathology in a treated individual. Desirable effects of treatment include slowing the rate of progression, delaying progression, ameliorating or alleviating a pathological condition, and improving the remission or prognosis of a particular disease, disorder, or condition. For example, an individual is successfully "treated" if one or more symptoms associated with a particular disease, disorder, or condition are reduced or eliminated.
[0058] An "effective amount" refers to at least an amount effective, at a dosage and for a period of time necessary, to achieve the desired therapeutic or prophylactic result. An effective amount may be provided in one or more administrations. The effective amount herein may vary depending on factors such as the individual's condition, age, sex, and weight, as well as the ability of the treatment to elicit a desired response in the individual. An effective amount is also an amount in which the therapeutically beneficial effects outweigh the toxic or detrimental effects of the treatment. For prophylactic use, beneficial or desired results include results such as elimination or reduction of the risk, reduction in severity, or delay in the onset of disease, including biochemical, histological, and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes exhibited during disease development. For therapeutic use, beneficial or desired results include clinical results such as alleviation of one or more symptoms caused by the disease, improvement in the quality of life of a person suffering from the disease, reduction in the dose of other medications required to treat the disease, or enhancement of the effect of another medication by targeting the disease, delaying progression, and / or prolonging survival. An effective amount of a drug, compound, or pharmaceutical composition is an amount sufficient to directly or indirectly achieve prophylactic or therapeutic treatment. As understood in a clinical context, an effective amount of a drug, compound, or pharmaceutical composition may or may not be achieved in combination with another drug, compound, or pharmaceutical composition. Thus, an "effective amount" can be considered in the context of administering one or more therapeutic agents, and a single agent can be considered to be administered in an effective amount if a desired result is obtained or achieved in combination with one or more other agents.
[0059] As used herein, administration "in conjunction with" or "in combination with" another compound or composition includes simultaneous administration and / or administration at different times. Concurrent or combined administration also encompasses administration as a co-formulation or as separate compositions, and includes different dosing frequencies or intervals, using the same or different routes of administration.
[0060] An "individual" for purposes of treatment, prevention, or risk reduction refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sport, or pet animals, such as dogs, horses, rabbits, cows, pigs, hamsters, gerbils, mice, ferrets, rats, cats, etc. In some embodiments, the individual is a human.
[0061] The terms "Sortilin," "Sortilin protein," and "Sortilin polypeptide" are used interchangeably herein and refer to any native Sortilin of any mammalian origin, including primates (e.g., humans and cynomolgus monkeys) and rodents (e.g., mice and rats), unless otherwise specified. In some embodiments, the term encompasses both wild-type sequences and naturally occurring variant sequences, e.g., splice variants or allelic variants. In some embodiments, the term encompasses unprocessed "full-length" Sortilin, as well as any form of Sortilin that results from processing in the cell. In some embodiments, the Sortilin is human Sortilin. In some embodiments, the amino acid sequence of an exemplary human Sortilin is SEQ ID NO: 1.
[0062] The terms "anti-Sortilin antibody," "antibody that binds to Sortilin," and "antibody that specifically binds to Sortilin" refer to an antibody that can bind to Sortilin with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent that targets Sortilin. In one embodiment, the extent of binding of the anti-Sortilin antibody to an unrelated non-Sortilin polypeptide is less than about 10% of the binding of the antibody to Sortilin, as measured, for example, by a radioimmunoassay (RIA), a biolayer interference assay (e.g., using a ForteBio system), or a surface plasmon resonance (SPR) assay (see, e.g., Hearty et al., Methods Mol Biol (2012) 907:411-42; Vishal and Rafique, Analytical Biochemistry (2017) 536, pp. 16-31; Estep et al., MAbs (2013) 5(2):270-8; and Friguet et al., Analytical Biochemistry (1993) 210(2): 344-350). In certain embodiments, antibodies that bind to sortilin have a specific binding affinity of <1 μM, <100 nM, <10 nM, <1 nM, <0.1 nM, <0.01 nM, or <0.001 nM (e.g., 10 -8 M or less, e.g., 10 -8 M~10 -13 M, e.g., 10 -9 M~10 -13 M) In certain embodiments, the anti-Sortilin antibody binds to an epitope of Sortilin that is conserved among Sortilins of different species.
[0063] The term "immunoglobulin" (Ig) is used interchangeably herein with "antibody." The term "antibody" is used herein in the broadest sense and specifically encompasses monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), including those formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity.
[0064] "Native antibodies" are typically heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light ("L") chains and two identical heavy ("H") chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain contains at one end a variable domain (V H ) followed by multiple constant domains. Each light chain has a variable domain (V) at one end. L ) at one end and a constant domain at the other end, with the light-chain constant domain aligned with the first constant domain of the heavy chain and the light-chain variable domain aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light-chain variable domain and the heavy-chain variable domain.
[0065] For the structure and properties of different classes of antibodies, see, e.g., Basic and Clinical Immunology, 8th ed., Daniel P. Stites, Abba I. Terr and Tristram G. Parslow (eds.), Appleton & Lange, Norwalk, CT, 1994, page 71 and chapter 6.
[0066] The light chains of any vertebrate species can be assigned to one of two clearly distinct types, called kappa ("κ") and lambda ("λ"), based on the amino acid sequence of their constant domains. Immunoglobulins can be assigned to different classes or isotypes depending on the amino acid sequence of the constant domains (CH) of their heavy chains. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, each with heavy chains called alpha ("α"), delta ("δ"), epsilon ("ε"), gamma ("γ"), and mu ("μ"). The gamma and alpha classes are further divided into subclasses (isotypes) based on relatively minor differences in CH sequence and function; for example, humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known and are described generally in, for example, Abbas et al., Cellular and Molecular Immunology, 4th ed. (WB Saunders Co., 2000).
[0067] A "variable region" or "variable domain" of an antibody, e.g., an anti-Sortilin antibody of the present disclosure, refers to the amino-terminal domains of the heavy or light chain of the antibody. The variable domains of the heavy and light chains, respectively, are referred to as "V H " and "V L These domains are generally the most variable parts of an antibody (relative to other antibodies of the same class) and contain the antigen-binding sites.
[0068] The term "variable" refers to the fact that certain segments of variable domains vary widely in sequence among antibodies, e.g., the anti-sortilin antibodies of the present disclosure. Variable domains mediate antigen binding and define the specificity of a particular antibody for a particular antigen. However, variability is not evenly distributed throughout the variable domains. Rather, it is concentrated in three segments called hypervariable regions (HVRs) in both the light-chain and heavy-chain variable domains. The more highly conserved portions of the variable domains are called framework regions (FRs). Naturally occurring heavy-chain and light-chain variable domains each contain four FR regions, largely adopting a β-sheet configuration, connected by three HVRs, which form loops that connect and, in some cases, form part of the β-sheet structure. The HVRs of each chain are held together in close proximity by the FR regions and, together with the HVRs of the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Immunological Interest, 5th ed., National Institutes of Health, Bethesda, MD (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.
[0069] An "isolated" antibody, e.g., an anti-Sortilin antibody of the present disclosure, is one that has been identified, separated, and / or recovered (e.g., naturally or recombinantly) from components of its production environment. Preferably, an isolated polypeptide is free of association with all other contaminating components from its production environment. Contaminating components from the production environment, such as those resulting from recombinantly transfected cells, are generally substances that would interfere with the research, diagnostic, or therapeutic use of the antibody and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide is purified (1) to greater than 95% by weight, and in some embodiments, greater than 99% by weight, of the antibody, as determined, e.g., by the Lowry method; (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence using a spinning cup sequencer; or (3) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue staining or, preferably, silver staining. Isolated antibody includes the antibody in situ within recombinant T cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated polypeptide or antibody will be prepared by at least one purification step.
[0070] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, e.g., a monoclonal anti-Sortilin antibody of the present disclosure, i.e., the individual antibodies comprising the population are identical except for naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation, etc.), which may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In contrast to polyclonal antibody preparations, which generally include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they are synthesized by hybridoma culture, uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous antibody population and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies for use in accordance with the present invention can be produced by a variety of techniques, including, but not limited to, one or more of the following methods: immunization of animals, including, but not limited to, rats, mice, rabbits, guinea pigs, hamsters, and / or chickens, with one or more of DNA, virus-like particles, polypeptides, and / or cells; hybridoma methods; B-cell cloning methods; recombinant DNA methods; and techniques for producing human or human-like antibodies in animals having some or all of the human immunoglobulin loci or genes encoding human immunoglobulin sequences.
[0071] The terms "full length antibody," "intact antibody," or "whole antibody" are used interchangeably and refer to an antibody in substantially intact form, e.g., an anti-Sortilin antibody of the present disclosure, rather than an antibody fragment. Specifically, whole antibodies include those having heavy and light chains, including an Fc region. The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof. In some cases, intact antibodies may have one or more effector functions.
[0072] An "antibody fragment" comprises a portion of an intact antibody, preferably the antigen-binding and / or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies (see U.S. Pat. No. 5,641,870, Example 2; Zapata et al., Protein Eng. 8(10):1057-1062 (1995)); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
[0073] Papain digestion of an antibody, such as the anti-Sortilin antibody of the present disclosure, produces two identical antigen-binding fragments called "Fab" fragments and one residual "Fc" fragment, a name reflecting its ability to crystallize readily. The Fab fragment contains the entire light chain and the variable region domain (V) of the heavy chain. H ) and the first constant domain of one heavy chain (C H 1). Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin treatment of an antibody yields a single large F(ab')2 fragment, which roughly corresponds to two disulfide-linked Fab fragments with different antigen-binding activities and is still capable of cross-linking antigen. Fab' fragments contain one or more cysteines from the antibody hinge region, C H F(ab')2 antibody fragments differ from Fab fragments by having a few additional residues at the carboxy terminus of one domain. Fab'-SH is the designation used herein for Fab' in which the cysteine residues of the constant domains bear a free thiol group. F(ab')2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
[0074] The Fc fragment contains the carboxy-terminal portions of both H chains held together by disulfides. The effector functions of the antibody are determined by the sequences in the Fc region, which is also recognized by Fc receptors (FcRs) found on certain cell types.
[0075] An "Fv" is the minimum antibody fragment that contains a complete antigen-recognition and binding site. This fragment consists of a dimer of one heavy-chain variable domain and one light-chain variable domain in tight, noncovalent association. The folding of these two domains generates six hypervariable loops (three loops from each H and L chain), which contribute amino acid residues for antigen binding and confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing only three antigen-specific HVRs) has the ability to recognize and bind antigen, albeit with lower affinity than the entire binding site.
[0076] A "single-chain Fv," also abbreviated as "sFv" or "scFv," is an antibody fragment comprising the VH and VL antibody domains linked in a single polypeptide chain. Preferably, the sFv polypeptide comprises a VH domain and a VL domain. H Domains and V L The sFv further comprises a polypeptide linker between the domains that enables the sFv to form the desired structure for antigen binding. For a review of sFvs, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
[0077] A "functional fragment" of an antibody, e.g., an anti-Sortilin antibody of the present disclosure, generally comprises a portion of the intact antibody, including the antigen-binding or variable region of the intact antibody, or the F region of the antibody that retains FcR binding ability or has altered FcR binding ability. Examples of antibody fragments include linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments.
[0078] The term "diabody" refers to a V diabody in which inter-chain but not intra-chain variable domain pairing is achieved, thereby resulting in a bivalent fragment, i.e., a fragment with two antigen-binding sites. H Domains and V L This refers to small antibody fragments prepared by constructing sFv fragments (see previous paragraph) with a short linker (approximately 5-10 residues) between the domains. Bispecific diabodies are small antibody fragments prepared by combining the V domains of these two antibodies. H Domains and V L It is a heterodimer of two "crossover" sFv fragments in which the domains are present on different polypeptide chains.
[0079] As used herein, a "chimeric antibody" refers to an antibody (immunoglobulin) in which a portion of the heavy and / or light chain is identical to or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, and the remainder of the chain is identical to or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, e.g., the chimeric anti-Sortilin antibodies of the present disclosure, as well as fragments of such antibodies, so long as they exhibit the desired biological activity. Chimeric antibodies of interest herein include PRIMATIZED® antibodies, in which the antigen-binding region of the antibody is derived from, for example, an antibody produced by immunizing macaque monkeys with an antigen of interest. As used herein, "humanized antibody" is used as a subset of "chimeric antibody."
[0080] "Humanized" forms of non-human (e.g., murine) antibodies, e.g., humanized forms of the anti-Sortilin antibodies of the present disclosure, are chimeric antibodies comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody comprises substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.
[0081] A "human antibody" is an antibody produced by a human and / or made using any of the techniques for making human antibodies as disclosed herein, e.g., an antibody having an amino acid sequence corresponding to an anti-Sortilin antibody of the present disclosure. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues. Human antibodies can be produced using a variety of techniques known in the art, including phage display libraries and yeast-based platform technologies. Human antibodies can be prepared by administering antigen to transgenic animals, e.g., immunized xenomice, that have been engineered to produce such antibodies in response to antigen challenge but whose endogenous loci have been disabled, and can also be generated through human B-cell hybridoma technology.
[0082] As used herein, the terms "hypervariable region," "HVR," or "HV" refer to the regions of an antibody variable domain, e.g., the regions of an anti-Sortilin antibody of the disclosure, that are hypervariable in sequence and / or form structurally defined loops. Generally, antibodies contain six HVRs; H Three in (H1, H2, H3), V LThere are three HVRs (L1, L2, and L3) in the nucleus. In native antibodies, H3 and L3 are the most diverse of the six HVRs, and H3 in particular is thought to play a unique role in conferring superior specificity to antibodies. Native camelid antibodies, consisting only of heavy chains, are functional and stable even in the absence of light chains.
[0083] Multiple HVR descriptions are in use and are encompassed herein. In some embodiments, the HVR may be a Kabat complementarity-determining region (CDR), which is based on sequence variability and is the most commonly used (Kabat et al., supra). In some embodiments, the HVR may be a Chothia CDR. Chothia refers more to the location of structural loops (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)). In some embodiments, the HVR may be an AbM HVR. AbM HVRs represent a compromise between Kabat CDRs and Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software. In some embodiments, the HVR may be a "contacting" HVR. "Contacting" HVRs are based on analysis of available complex crystal structures. The residues of each of these HVRs are described below. TIFF2023553399000002.tif46155
[0084] HVRs may include the following "extended HVRs": 24-36 or 24-34 (L1), 46-56 or 50-56 (L2), and 89-97 or 89v96 (L3) in the VL, and 26-35 (H1), 50-65 or 49-65 (preferred embodiment) (H2), and 93-102, 94-102, or 95-102 (H3) in the VH. The variable domain residues are numbered according to Kabat et al., supra, for each of these extended HVR definitions.
[0085] "Framework" or "FR" residues are those variable domain residues other than the HVR residues as herein defined.
[0086] As used herein, an "acceptor human framework" refers to a V-framework derived from a human immunoglobulin framework or a human consensus framework. L or V H The acceptor human framework "derived" from a human immunoglobulin framework or a human consensus framework may contain the same amino acid sequence or may contain changes to the existing amino acid sequence. In some embodiments, the number of existing amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. When existing amino acid changes are present in the VH, it is preferred that those changes occur at only three, two, or one of positions 71H, 73H, and 78H; for example, the amino acid residues at those positions may be 71A, 73T, and / or 78A. In one embodiment, the VL acceptor human framework is a VL acceptor human framework. L The sequence is identical to a human immunoglobulin framework sequence or a human consensus framework sequence.
[0087] The "human consensus framework" is based on human immunoglobulin V L or V H The framework represents the most frequently occurring amino acid residue in the framework sequence selection. Generally, human immunoglobulin V L or V H The selection of sequences is made from a subgroup of variable domain sequences. Typically, the subgroup of sequences is a subgroup such as those in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991). Examples include the V Land the subgroup can be subgroup kappa I, kappa II, kappa III, or kappa IV as in Kabat et al., supra. H For example, the subgroup can be subgroup I, subgroup II, or subgroup III as in Kabat et al., supra.
[0088] For example, an "amino acid modification" at a specified position of an anti-Sortilin antibody of the present disclosure refers to a substitution or deletion of the specified residue, or an insertion of at least one amino acid residue adjacent to the specified residue. An insertion "adjacent to" a specified residue means an insertion within 1 to 2 residues thereof. The insertion may be N-terminal or C-terminal to the specified residue. A preferred amino acid modification herein is a substitution.
[0089] An "affinity matured" antibody, e.g., an anti-Sortilin antibody of the disclosure, comprises one or more changes in one or more HVRs thereof, which changes result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody that does not comprise the changes. In one embodiment, the affinity matured antibody has nanomolar or picomolar affinity for the target antigen. Affinity matured antibodies are generated by techniques known in the art. For example, Marks et al., Bio / Technology 10:779-783 (1992) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of HVR and / or framework residues is described, for example, in: Barbas et al. Proc Nat. Acad. Sci. USA 91:3809-3813 (1994); Schier et al. Gene 169:147-155 (1995); Yelton et al. J. Immunol. 155:1994-2004 (1995); Jackson et al., J. Immunol. 154(7):3310-9 (1995); and Hawkins et al., J. Mol. Biol. 226:889-896 (1992).
[0090] As used herein, the terms "specifically recognize" or "specifically bind" refer to a measurable and reproducible interaction, such as attraction or binding, between a target and an antibody, e.g., an anti-Sortilin antibody of the present disclosure, that determines the presence of the target in the presence of a heterogeneous population of molecules, including biomolecules. For example, an antibody that specifically or preferentially binds to a target or epitope, e.g., an anti-Sortilin antibody of the present disclosure, is an antibody that binds to that target or epitope with higher affinity, avidity, more readily, and / or with longer duration than it binds to other targets or other epitopes of that target. By reading this definition, it is also understood that, for example, an antibody (or moiety) that specifically or preferentially binds to a first target may or may not specifically or preferentially bind to a second target. Thus, "specific binding" or "preferential binding" does not necessarily require (although it may include) exclusive binding. An antibody that specifically binds to a target has at least about 10 3 M -1 or 10 4 M -1 , possibly about 10 5 M -1 or 10 6 M -1 , and in other cases about 10 6 M -1 or 10 7 M -1 , about 10 8 M -1 ~10 9 M -1 , or about 10 10 M -1 ~10 11 M -1The antibody may have an association constant equal to or greater than 100 kJ / min. A variety of immunoassay formats can be used to select antibodies that specifically immunoreact with a particular protein. For example, solid-phase ELISA immunoassays are commonly used to select monoclonal antibodies that specifically immunoreact with a protein. See, for example, Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York, for a description of formats and conditions that can be used to determine specific immunoreactivity.
[0091] As used herein, an "interaction" between a sortilin protein and a second protein includes, but is not limited to, protein-protein interactions, physical interactions, chemical interactions, bonds, covalent bonds, and ionic bonds. As used herein, an antibody "inhibits the interaction" between two proteins if the antibody prevents, reduces, or completely eliminates the interaction between the two proteins. An antibody of the present disclosure, or a fragment thereof, "inhibits the interaction" between two proteins if the antibody or a fragment thereof binds to one of the two proteins.
[0092] Antibody "effector functions" refer to the biological activities attributable to the Fc region (native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary depending on the antibody isotype.
[0093] The term "Fc region" herein is used to define the C-terminal region of an immunoglobulin heavy chain, including native-sequence Fc regions and variant Fc regions. Although the boundaries of the Fc region of an immunoglobulin heavy chain can vary, the human IgG heavy chain Fc region is usually defined as extending from the amino acid residue at position Cys226 or from Pro230 to its carboxyl terminus. The C-terminal lysine of the Fc region (residue 447, according to the EU numbering system) can be removed, for example, during antibody production or purification, or by recombinantly modifying the nucleic acid encoding the antibody heavy chain. Thus, an intact antibody composition can include antibody populations in which all K447 residues have been removed, antibody populations in which the K447 residue has not been removed, and antibody populations having a mixture of antibodies containing and excluding the K447 residue. Native-sequence Fc regions suitable for use in the antibodies of the present disclosure include IgG1, IgG2, IgG3, and IgG4.
[0094] A "native-sequence Fc region" comprises an amino acid sequence identical to that of an Fc region found in nature. Native-sequence human Fc regions include native-sequence human IgG1 Fc regions (non-A and A allotypes), native-sequence human IgG2 Fc regions, native-sequence human IgG3 Fc regions, and native-sequence human IgG4 Fc regions, as well as naturally occurring variants thereof.
[0095] A "variant Fc region" comprises an amino acid sequence that differs from that of a native-sequence Fc region by at least one amino acid modification, preferably one or more amino acid substitutions. Preferably, the variant Fc region has at least one amino acid substitution compared to the native-sequence Fc region or the Fc region of a parent polypeptide, e.g., about one to about ten amino acid substitutions, preferably about one to about five amino acid substitutions, in the native-sequence Fc region or the Fc region of a parent polypeptide. A variant Fc region herein preferably has at least about 80% homology with the native-sequence Fc region and / or the Fc region of the parent polypeptide, most preferably at least about 90% homology thereto, and more preferably at least about 95% homology thereto.
[0096] "Fc receptor" or "FcR" refers to a receptor that binds to the Fc region of an antibody. A preferred FcR is a native-sequence human FcR. Furthermore, a preferred FcR is one that binds IgG antibodies (gamma receptors), including receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA ("activating receptors") and FcγRIIB ("inhibiting receptors"), which have similar amino acid sequences that differ primarily in their cytoplasmic domains. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif ("ITAM") in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif ("ITIM") in its cytoplasmic domain. Other FcRs, including those identified in the future, are encompassed by the term "FcR" herein. FcRs may also extend the serum half-life of antibodies. As used herein, "percent (%) amino acid sequence identity" and "homology" with respect to a peptide, polypeptide, or antibody sequence refer to the percentage of amino acid residues in a candidate sequence that are identical to those in a specified peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, without considering conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in a variety of ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN™ (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms known in the art necessary to achieve maximum alignment over the entire length of the sequences being compared.
[0097] An "isolated" cell is a molecule or cell that has been identified and separated from at least one contaminating cell with which it is normally associated in the environment in which it was produced. In some embodiments, an isolated cell is free from association with all components associated with the production environment. An isolated cell exists in a form or setting that is different from that in which it is found in nature. An isolated cell is distinguished from cells that naturally occur in a tissue, organ, or individual. In some embodiments, an isolated cell is a host cell of the present disclosure.
[0098] An "isolated" nucleic acid molecule encoding an antibody, e.g., an anti-Sortilin antibody of the present disclosure, is a nucleic acid molecule that has been identified and separated from at least one contaminant nucleic acid molecule with which it is normally associated in the environment in which it is produced. Preferably, an isolated nucleic acid is free from association with all components associated with the production environment. Isolated nucleic acid molecules encoding the polypeptides and antibodies of the present disclosure are present in a form that is different from the form or setting in which it is found in nature. Thus, isolated nucleic acid molecules are distinguished from nucleic acids encoding the polypeptides and antibodies of the present disclosure that are naturally present in a cell.
[0099] As used herein, the term "vector" is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it is linked. One type of vector is a "plasmid," which refers to a circular double-stranded DNA to which additional DNA segments can be ligated. Another type of vector is a phage vector. Another type of vector is a viral vector, in which additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and are thus replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operably linked. Such vectors are referred to herein as "recombinant expression vectors" or simply "expression vectors." In general, expression vectors useful in recombinant DNA techniques are often in the form of plasmids. As used herein, "plasmid" and "vector" can be used interchangeably, as the plasmid is the most commonly used form of vector.
[0100] "Polynucleotide" or "nucleic acid," as used interchangeably herein, refer to a polymer of nucleotides of any length, including DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase or by a synthetic reaction.
[0101] A "host cell" includes an individual cell or cell culture that can be or has been the recipient of a vector for incorporating a polynucleotide insert. A host cell includes the progeny of a single host cell, which progeny may not necessarily be completely identical (in morphology or genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. A host cell includes cells transfected in vivo with a polynucleotide of this disclosure.
[0102] As used herein, a "carrier" includes a pharmaceutically acceptable carrier, excipient, or stabilizer that is nontoxic to cells or mammals exposed to the carrier at the dosages and concentrations employed.
[0103] As used herein, the term "about" refers to the normal error range for the respective value, which is readily known to one of ordinary skill in the art. Reference herein to "about" a value or parameter includes (describes) embodiments that are directed to the value or parameter itself.
[0104] As used herein and in the appended claims, the singular forms "a," "an," and "the" include the plural forms unless the context clearly dictates otherwise. For example, a reference to an "antibody" is a reference to one to many antibodies, such as molar amounts, and includes equivalents thereof known to those skilled in the art.
[0105] It is understood that the aspects and embodiments of the present disclosure described herein include "comprising," "consisting of," and "consisting essentially of" aspects and embodiments.
[0106] overview The present disclosure relates to methods for treating and / or delaying the progression of a disease, disorder, or injury in an individual by administering an anti-Sortilin antibody to the individual. Non-limiting examples of diseases, disorders, or injuries that can be treated or delayed include frontotemporal dementia, progressive supranuclear palsy, Alzheimer's disease, vascular dementia, stroke, retinal dystrophy, amyotrophic lateral sclerosis (ALS), traumatic brain injury, spinal cord injury, dementia, stroke, Parkinson's disease, acute disseminated encephalomyelitis, retinal degeneration, age-related macular degeneration, glaucoma, multiple sclerosis, septic shock, bacterial infection, arthritis, and osteoarthritis. In some embodiments, the disease or disorder that can be treated or delayed according to the methods provided herein is a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, or frontotemporal dementia. In some embodiments, the disease or disorder that can be treated or delayed according to the methods provided herein is Alzheimer's disease. In some embodiments, the disease or disorder that can be treated or delayed according to the methods provided herein is Parkinson's disease. In some embodiments, the disease or disorder that can be treated or delayed according to the methods provided herein is frontotemporal dementia. In some embodiments, the disease or disorder that can be treated or delayed according to the methods provided herein is ALS. In any of the above embodiments, the individual is at risk for the disease or disorder. As described below, the methods of the present disclosure fulfill a need in the art aimed at identifying methods for treating patients with an appropriate dose of an anti-Sortilin antibody of the present disclosure and / or methods for administering a dose that increases patient compliance.
[0107] Patients with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, ALS, and frontotemporal dementia generally suffer from these diseases for a long period of time and require regular treatment for many years. Intravenous administration of therapeutic drugs cannot be performed at home and requires patients to be transported to an infusion facility, which can be a burden to both patients and caregivers. Furthermore, memory loss, mood swings, aggression, and other behavioral symptoms that may be associated with these diseases can make patient compliance difficult. Therefore, fewer intravenous administration procedures for patients with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, ALS, and frontotemporal dementia are advantageous for patients suffering from such diseases. Furthermore, subcutaneous administration, e.g., administration by subcutaneous injection, can be performed at home, for example, by a caregiver or the patient themselves, making it a convenient form of administration of treatment for patients with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, ALS, and frontotemporal dementia.
[0108] Advantageously, intravenous administration to humans of a single dose of an anti-Sortilin antibody of the present disclosure according to the methods provided herein results in a pharmacodynamic (PD) effect, e.g., increased levels of Progranulin in plasma and cerebrospinal fluid, that persists for an extended period of time (e.g., up to about 57 days or longer after administration of a single dose of the anti-Sortilin antibody). See, e.g., Examples 1-2.
[0109] Moreover, advantageously, administration of multiple doses of the anti-Sortilin antibodies of the present disclosure to cynomolgus monkeys results in a decrease in leukocyte Sortilin expression along with increased serum and cerebrospinal fluid Progranulin levels that persists for several weeks (e.g., up to about 6 weeks or longer) after the last dose of the anti-Sortilin antibody, demonstrating a long-lasting pharmacodynamic effect of the anti-Sortilin antibodies of the present disclosure (see, e.g., Example 4).
[0110] Thus, the methods provided herein allow for relatively infrequent administration of the anti-Sortilin antibodies of the present disclosure by intravenous infusion (see, e.g., Examples 1-3) or subcutaneous administration (see, e.g., Example 1), which is particularly beneficial for patients with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, ALS, and frontotemporal dementia.
[0111] Thus, in some embodiments, the present disclosure relates to methods of treating and / or delaying the progression of a disease, disorder, or injury in an individual by administering to the individual an anti-Sortilin antibody of the present disclosure at a dose of at least about 6 mg / kg. In some embodiments, administration of the antibody is by intravenous infusion or subcutaneous injection. In some embodiments, the methods provided herein comprise administering the anti-Sortilin antibody about once every four weeks or less frequently. In some embodiments, the disease, disorder, or injury is Alzheimer's disease. In some embodiments, the disease, disorder, or injury is Parkinson's disease. In some embodiments, the disease, disorder, or injury is ALS. In some embodiments, the disease, disorder, or injury is frontotemporal dementia.
[0112] All references cited herein, including patents, patent applications, and publications, are incorporated herein by reference in their entirety.
[0113] therapeutic use The present disclosure provides a method for treating and / or slowing the progression of a disease, disorder, or injury in an individual, the method comprising administering an anti-Sortilin antibody to the individual. As disclosed herein, the anti-Sortilin antibody of the present disclosure can be used to treat and / or slow the progression of frontotemporal dementia, progressive supranuclear palsy, Alzheimer's disease, vascular dementia, stroke, retinal dystrophy, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, dementia, stroke, Parkinson's disease, acute disseminated encephalomyelitis, retinal degeneration, age-related macular degeneration, glaucoma, multiple sclerosis, septic shock, bacterial infection, arthritis, or osteoarthritis. In some embodiments, the disease or disorder is frontotemporal dementia. In some embodiments, the disease or disorder is Alzheimer's disease. In some embodiments, the disease or disorder is Parkinson's disease.
[0114] Parkinson's disease Parkinson's disease, sometimes called idiopathic or primary parkinsonism, hypokinetic stiffness syndrome (HRS), or paralytic agitation, is a neurodegenerative brain disorder that affects the control of the motor system. The progressive death of dopamine-producing cells in the brain leads to the primary symptoms of Parkinson's disease. Most cases of Parkinson's disease are diagnosed in people over the age of 50. Symptoms of Parkinson's disease include, but are not limited to, tremors (e.g., in the hands, arms, legs, jaw, and face), muscle rigidity of the limbs and trunk, slowness of movement (bradykinesia), postural instability, difficulty walking, neuropsychiatric problems, changes in speech and behavior, depression, anxiety, pain, psychosis, dementia, hallucinations, and sleep disorders.
[0115] Parkinson's disease is idiopathic (of unknown cause) in most people. Most cases of Parkinson's disease occur in people with no apparent family history of Parkinson's disease and are thought to result from a complex interaction of environmental and genetic factors. These cases of Parkinson's disease are called "sporadic" Parkinson's disease.
[0116] Additionally, approximately 15% of Parkinson's disease patients have a known family history of Parkinson's disease, and certain familial cases are associated with mutations in genes such as PARK2, LRRK2, PARK7, PINK1, PRKN, or SNCA.
[0117] Mutations in the GBA1 and / or UCHL1 genes are also associated with Parkinson's disease and are thought to alter the risk of developing the disease. For example, approximately 5% of Parkinson's disease patients have mutations in the GBA1 gene, which encodes the lysosomal enzyme β-glucocerebrosidase (GBA). Heterozygous or homozygous GBA1 mutations have been shown to increase the risk of Parkinson's disease by approximately 20- to 30-fold. Furthermore, GBA1 mutations in Parkinson's disease have been associated with an earlier age of onset and more rapid cognitive and motor decline. See, e.g., Stoker et al., Pathological Mechanisms and Clinical Aspects of GBA1 Mutation-Associated Parkinson's Disease, Parkinson's Disease: Pathogenesis and Clinical Aspects, Codon Publications; 2018, Chapter 3; medlineplus[dot]gov / genetics / condition / parkinson-disease / #resources; and www[dot]ninds[dot]nih[dot]gov / Disorders / All-Disorders / Parkinsons-Disease-Challenges-Progress-and-Promise.
[0118] Progranulin (PGRN), encoded by the GRN gene, has also been implicated in Parkinson's disease. The GRN Parkinson's disease risk allele is associated with reduced progranulin levels in plasma, cerebrospinal fluid, and the brain, whereas homozygous loss-of-function forms of progranulin cause neuronal ceroid lipofuscinosis, and heterozygous loss-of-function forms of progranulin cause frontotemporal dementia (FTD), sometimes presenting with parkinsonism (Smith et al., Am J Hum Genet (2012) 90(6):1102-1107; Boeve et al., Brain (2006) 129(Pt 11):3103-3114; and Wauters et al., Neurobiol Aging (2018) 67:84-94). Furthermore, reduced plasma progranulin levels are associated with increased severity of Parkinson's disease (Yao et al., Neurosci Lett (2020) 725:134873). Progranulin deficiency worsens outcomes in rodent models of Parkinson's disease (Martens et al., J Clin Invest (2012) 122(11):3955-3959), whereas progranulin gene delivery improves these outcomes (Van Kampen et al., PLoS One (2014) 7;9(5):e97032).
[0119] Progranulin is a ~88 kDa precursor protein of granulin. It is a highly conserved, multifunctional secreted glycoprotein with a unique "chain-of-beads" structure. Its activities include modulating neuroinflammation in the central nervous system (CNS), affecting cell signaling pathways by regulating excitotoxicity, oxidative stress, synaptogenesis, inflammation, and amyloidogenesis (Hsiung et al., GeneReviews. University of Washington, Seattle). It also acts as an autocrine neuronal growth factor, promoting neurite outgrowth in the brain (Gass et al., Mol Neurodegener (2012) 10(7):33), and promoting and enhancing the survival of motor and cortical neurons (De Muynck et al., Neurobiol Aging (2013) 34(11):2541-2547).
[0120] A recent genome-wide association study (GWAS) revealed that genetic determinants of Parkinson's disease risk are enriched in lysosomal genes, such as GBA, GPNMB, GALC, CTSB, and GRN (Nalls et al., Lancet Neurol (2019) 18(2):1091-1102). Furthermore, it is known that progranulin is transported to lysosomes after receptor-mediated uptake, and its complete absence in humans results in early-onset lysosomal storage disorders (Paushter et al., Acta Neuropathol (2018) 136(1):1-17). These findings suggest that progranulin plays a role in lysosomal function. Emerging evidence also suggests that progranulin interacts with lysosomal enzymes, such as cathepsin D and glucocerebrosidase (GCase). Furthermore, progranulin, together with its binding partner prosaposin (PSAP), is thought to regulate the activity of these enzymes (Arrant et al., Acta Neuropathologica Comm (2019) 7(1):218; Valdez et al., Hum Mol Genet (2020) 29(5):716-726; Zhou et al., PLoS One (2019) 14(7):e0212382; Valdez et al., Hum Mol Genet (2017) 26(24):4861-4872; Zhou et al., J Cell Biol (2015) 210(6):991-1002; and Zhou et al., Mol Neurodegener (2017) 23;12(1):62).
[0121] Thus, for example, increasing progranulin levels in the cerebrospinal fluid and / or plasma of individuals with or at risk of having Parkinson's disease may treat and / or slow the progression of Parkinson's disease by increasing GCase activity, reducing inflammation, and / or improving lysosomal function.
[0122] In some embodiments, administration of an anti-Sortilin antibody of the present disclosure can treat and / or slow the progression of Parkinson's disease in an individual. In some embodiments, administration of an anti-Sortilin antibody of the present disclosure to an individual having or at risk of having Parkinson's disease can increase Progranulin levels in the individual, e.g., in plasma and / or cerebrospinal fluid; and / or decrease Sortilin levels; and / or inhibit the interaction between Sortilin and one or more proteins; and / or inhibit the interaction between Sortilin and Progranulin, thereby treating Parkinson's disease and / or slowing its progression.
[0123] In some embodiments, the disease or disorder treated according to the methods provided herein is Parkinson's disease, such as sporadic Parkinson's disease or Parkinson's disease in an individual with at least one pathogenic mutation in the GBA1 gene or GBA1 gene product. In some embodiments, the Parkinson's disease treated according to the methods provided herein is sporadic Parkinson's disease. In some embodiments, the Parkinson's disease treated according to the methods provided herein is Parkinson's disease in an individual with at least one pathogenic mutation in the GBA1 gene or GBA1 gene product. In some embodiments, the individual is homozygous or heterozygous for one or more mutations in the GBA1 gene or GBA1 gene product. Pathogenic mutations in the GBA1 gene or GBA1 gene product are known in the art. See, for example, Avenali et al., Front Aging Neurosci, 2020; O'Reagan et al., J. Parkinsons Dis, 7:411-422 (2017); Zhang et al., Front. Mol. Neurosci, 11:43 (2018); and Zhang et al., Parkisons Dis, 3136415 (2018). Exemplary pathogenic mutations in the GBA1 gene or GBA1 gene product include, but are not limited to, N370S (c.1226A>G), L444P (c.1448T>C), R120W, IVS2+1G>A, H255Q, D409H, RecNciI, E326K, T369M, R496H, and 84insGG. The presence of mutations in the GBA1 gene or GBA1 gene product may be assessed using any method known in the art, such as sequencing, polymerase chain reaction, hybridization methods such as fluorescent in situ hybridization, mass spectrometry, and immunoblotting.
[0124] In some embodiments, the individual treated according to the methods provided herein has Parkinson's disease classified as grade I-III based on the Hoehn-Yahr diagnostic criteria, e.g., as described in Hoehn and Yahr, Neurology (1967) 17:427-42 and Goetz et al., Mov Disord (2004) 19:1020-8.
[0125] In some embodiments, the individual being treated according to the methods provided herein has received one or more therapies for Parkinson's disease, such as a glutamate antagonist, an anticholinergic, a dopaminergic, a levodopa (L-DOPA and decarboxylase [DDC] inhibitor), a monoamine oxidase B (MAO-B) inhibitor, a catechol-O-methyltransferase (COMT) inhibitor, a beta-blocker, a selective serotonin uptake inhibitor (SSRI), a tricyclic antidepressant (TCA), or indomethacin, prior to administration of an anti-Sortilin antibody of the present disclosure. In some embodiments, the individual continues to receive one or more therapies for Parkinson's disease after initiation of treatment with an anti-Sortilin antibody of the present disclosure. In some embodiments, the methods provided herein include administering an anti-Sortilin antibody of the disclosure in combination with one or more treatments for Parkinson's disease, such as glutamate antagonists, anticholinergics, dopaminergics, levodopa (L-DOPA and decarboxylase [DDC] inhibitors), monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, beta-blockers, selective serotonin uptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and indomethacin.
[0126] Treatment or delay of Parkinson's disease may be assessed using any method known in the art.
[0127] In some embodiments, the treatment or delay of Parkinson's disease in an individual treated according to the methods provided herein is assessed based on the individual's cognitive function before and after the individual receives one or more doses of an anti-sortilin antibody. Cognitive function may be assessed using any method known in the art, such as the Montreal Cognitive Assessment (MoCA). See, for example, Nareddine et al., J American Geriatrics Soc (2005) 53(4):695-9. In some embodiments, the treatment or delay of Parkinson's disease is assessed based on one or more clinical assessments related to Parkinson's disease. Examples of clinical assessments of Parkinson's disease that can be used to assess the treatment or delay of Parkinson's disease in an individual treated according to the methods provided herein include, but are not limited to, the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (MDS-UPDRS Part III) or the UPDRS Total Scale. See, e.g., Goetz et al., (2008) Movement Disorders 23(15):2129-2170.
[0128] In some embodiments, the treatment or delay of Parkinson's disease in an individual treated according to the methods provided herein is assessed based on the level of one or more biomarkers for Parkinson's disease, such as progranulin, GCase protein or activity, and / or alpha-synuclein protein. In some embodiments, the level of one or more biomarkers for Parkinson's disease is assessed in plasma or cerebrospinal fluid samples obtained from the individual before and after the individual receives one or more doses of an anti-Sortilin antibody. Non-limiting examples of methods that can be used to assess the level of one or more biomarkers in a sample obtained from an individual include the SOMASCAN assay (see, e.g., Candia et al. (2017) Sci Rep 7, 14248), Western blot, mass spectrometry, flow cytometry, and enzyme-linked immunosorbent assay (ELISA).
[0129] In some embodiments, the treatment or delay of Parkinson's disease in an individual treated according to the methods provided herein is assessed based on the level of one or more biomarkers of lysosomal function. In some embodiments, the level of one or more biomarkers of lysosomal function is assessed in plasma or cerebrospinal fluid samples obtained from the individual before and after the individual receives one or more doses of an anti-sortilin antibody. In some embodiments, the one or more biomarkers of lysosomal function are GCase protein, GCase activity, glucosylsphingosine (lyso-Gb1), and / or glucosylceramide. Non-limiting examples of methods that can be used to assess the level of one or more biomarkers in a sample obtained from an individual include SOMASCAN assay (see, e.g., Candia et al. (2017) Sci Rep 7, 14248), Western blot, mass spectrometry, flow cytometry, and enzyme-linked immunosorbent assay (ELISA). In some embodiments, the levels of lyso-Gb1 or glucosylceramide may be measured using any method known in the art, such as mass spectrometry, for example, high performance liquid chromatography tandem mass spectrometry.
[0130] In some embodiments, treatment with an anti-Sortilin antibody of the present disclosure according to the methods provided herein results in an increase in Progranulin protein levels in the plasma or cerebrospinal fluid of an individual by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%, compared to the Progranulin protein levels in the plasma or cerebrospinal fluid of the individual before administration of the anti-Sortilin antibody. In some embodiments, treatment with an anti-Sortilin antibody of the present disclosure according to the methods provided herein results in an increase in Progranulin protein levels in the plasma or cerebrospinal fluid of an individual of at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 225%, at least about 250%, at least about 275%, at least about 300%, or more, compared to the Progranulin protein levels in the plasma or cerebrospinal fluid of the individual before administration of the anti-Sortilin antibody.
[0131] In some embodiments, treatment with an anti-Sortilin antibody of the disclosure according to the methods provided herein results in an increase in GCase protein levels in the individual's plasma or cerebrospinal fluid of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to the GCase protein levels in the individual's plasma or cerebrospinal fluid before administration of the anti-Sortilin antibody. In some embodiments, treatment with an anti-Sortilin antibody of the present disclosure according to the methods provided herein results in an increase in GCase protein levels in the individual's plasma or cerebrospinal fluid of at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 225%, at least about 250%, at least about 275%, at least about 300%, or more, compared to the GCase protein levels in the individual's plasma or cerebrospinal fluid before administration of the anti-Sortilin antibody.
[0132] In some embodiments, treatment with an anti-Sortilin antibody of the disclosure according to the methods provided herein results in an increase in the level of GCase activity in the individual's plasma or cerebrospinal fluid by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%, compared to the level of GCase activity in the individual's plasma or cerebrospinal fluid before administration of the anti-Sortilin antibody. In some embodiments, treatment with an anti-Sortilin antibody of the present disclosure according to the methods provided herein results in an increase in the level of GCase activity in the individual's plasma or cerebrospinal fluid of at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 225%, at least about 250%, at least about 275%, at least about 300%, or more, compared to the individual's GCase activity level before administration of the plasma or cerebrospinal fluid anti-Sortilin antibody.
[0133] In some embodiments, treatment with an anti-Sortilin antibody of the disclosure according to the methods provided herein results in a reduction in alpha-synuclein protein levels in the individual's plasma or cerebrospinal fluid by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or about 100% compared to the individual's alpha-synuclein protein levels before administration of the plasma or cerebrospinal fluid anti-Sortilin antibody.
[0134] In some embodiments, treatment with an anti-Sortilin antibody of the disclosure according to the methods provided herein results in a reduction in glucosylsphingosine (lyso-Gb1) levels in the individual's plasma or cerebrospinal fluid by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or about 100% compared to the individual's lyso-Gb1 levels before administration of the plasma or cerebrospinal fluid anti-Sortilin antibody.
[0135] In some embodiments, treatment with an anti-Sortilin antibody of the disclosure according to the methods provided herein results in a reduction in glucosylceramide levels in the individual's plasma or cerebrospinal fluid by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or about 100% compared to the individual's glucosylceramide levels before administration of the plasma or cerebrospinal fluid anti-Sortilin antibody.
[0136] In some embodiments, the treatment or delay of Parkinson's disease in an individual treated according to the methods provided herein is assessed based on the level of one or more proteins in the cerebrospinal fluid proteome. In some embodiments, the level of one or more proteins in the cerebrospinal fluid proteome is assessed in a cerebrospinal fluid sample obtained from the individual before and after the individual receives one or more doses of an anti-Sortilin antibody. Non-limiting examples of methods that can be used to measure the level of one or more proteins in the cerebrospinal fluid proteome in a sample obtained from an individual include the SOMASCAN assay (see, e.g., Candia et al. (2017) Sci Rep 7, 14248), mass spectrometry, and Western blot.
[0137] frontotemporal dementia Frontotemporal dementia (FTD) is a condition resulting from progressive degeneration of the frontal lobes of the brain. Over time, this degeneration can also progress to the temporal lobes. Second only to Alzheimer's disease (AD), FTD accounts for 20% of presenile dementia cases. Clinical features of FTD include memory impairment, behavioral abnormalities, personality changes, and language impairment (Cruts, M. & Van Broeckhoven, C., Trends Genet. 24:186-194 (2008); Neary, D., et al., Neurology 51:1546-1554 (1998); Ratnavalli, E., Brayne, C., Dawson, K. & Hodges, JR, Neurology 58:1615-1621 (2002)).
[0138] Although a significant proportion of FTD cases are inherited in an autosomal dominant manner, even within a single family, symptoms can span a spectrum ranging from FTD with behavioral disturbances to primary progressive aphasia and corticobasal degeneration. Like most neurodegenerative disorders, FTD can be characterized by the pathological presence of specific protein aggregates in the discosed brain. Historically, the first description of FTD recognized the presence of intraneuronal accumulations of hyperphosphorylated tau protein in neurofibrillary tangles or Pick bodies. Identification of mutations in the gene encoding tau protein in several families supported the causative role of the microtubule-associated protein tau (Hutton, M., et al., Nature 393:702-705 (1998)). However, the majority of FTD brains do not show accumulation of hyperphosphorylated tau but do show immunoreactivity for ubiquitin (Ub) and the TAR DNA-binding protein (TDP43) (Neumann, M., et al., Arch. Neurol. 64:1388-1394 (2007)). Most of these FTD cases with Ub inclusions (FTD-U) have been shown to have mutations in the progranulin gene.
[0139] Progranulin mutations result in haploinsufficiency and are known to be present in nearly 50% of familial FTD cases, making them the major genetic cause of FTD. Without wishing to be bound by theory, the characteristics of loss-of-function heterozygotes of progranulin mutations suggest that progranulin expression plays an important role in protecting healthy individuals from the development of FTD in a dose-dependent manner. Therefore, increasing progranulin levels by inhibiting the interaction between sortilin and progranulin could potentially treat and / or delay the progression of FTD.
[0140] In some embodiments, administration of an anti-Sortilin antibody of the disclosure can treat and / or slow the progression of FTD in an individual. In some embodiments, administration of an anti-Sortilin antibody of the disclosure to an individual having or at risk of FTD can increase Progranulin levels, e.g., in the plasma and / or cerebrospinal fluid of the individual; and / or decrease Sortilin levels; and / or inhibit the interaction of Sortilin with one or more proteins; and / or inhibit the interaction of Sortilin with Progranulin, thereby treating and / or slowing the progression of FTD.
[0141] In some embodiments, treatment of FTD and / or delay of its progression can be determined by a change from baseline in a neurocognitive and / or functional test or assessment (i.e., a clinical outcome assessment). Non-limiting examples of neurocognitive and functional tests that can be used to assess treatment and / or delay of FTD progression include the Frontotemporal Dementia Clinical Rating Scale (FCRS), the Frontotemporal Dementia Rating Scale (FRS), the Clinical Global Impression-Improvement (CGI-I) assessment, the Neuropsychiatric Inventory (NPI) assessment, the Color Trails Test (CTT) Part 2, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Delis-Kaplan Executive Function System Color-Word Interference Test, the Interpersonal Reactivity Index, the Winterlight Labs Speech Assessment (WLA), and the Summerlight Labs Speech Assessment (SLA). In some embodiments, treatment of FTD and / or delay of its progression can be determined by a change from baseline in one neurocognitive and / or functional test or assessment. In some embodiments, treatment and / or delay of FTD progression may be determined by change from baseline in two or more neurocognitive and / or functional tests or assessments (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or more neurocognitive and / or functional tests or assessments).
[0142] In some embodiments, treating FTD and / or delaying its progression is determined by changes from baseline in global and / or regional brain volume, white matter hyperintensity volume, cerebral perfusion, fractional anisotropy, mean diffusivity, axial diffusivity, and radial diffusivity, and / or functional brain activity. In certain embodiments, cerebral perfusion is measured by arterial spin-labeling MRI. In certain embodiments, radial diffusivity is measured by diffusion tensor imaging. In certain embodiments, functional brain activity is measured by functional MRI.
[0143] In some embodiments, treatment of FTD and / or delay in its progression is determined by a change from baseline in markers of neurodegeneration in whole blood, plasma, and CSF. Markers of neurodegeneration include, but are not limited to, neurofilament light chain (Nfl), tau, and / or p-tau. Neurofilament light chain can be measured by methods including, but not limited to, assays from Quanterix and / or Roche Diagnostics. In some embodiments, treatment of FTD and / or delay in its progression is determined by a change from baseline in markers of lysosomal function. Markers of lysosomal function can be, but are not limited to, cathepsins such as cathepsin B (CTSB), NAGK (N-acetyl-D-glucosamine kinase), GCase protein, GCase activity, glucosylsphingosine (lyso-Gb1), and / or glucosylceramide. In some embodiments, treatment of FTD and / or delay of its progression is determined by changes from baseline in levels of inflammatory markers such as osteopontin (SPP1), YWHAE (14-3-3 protein ε), allograft inflammatory factor 1 (AIF1), colony-stimulating factor 1 (CSF1), chitinase 1 (CHIT1), lymphocyte antigen 86 (LY86), and CD86. Certain biomarkers of lysosomal function may be overexpressed when PGRN is deficient. For example, cathepsin D (CTSD) and Lamp1 are overexpressed in PGRN-deficient mice (GRN knockout mice). See Huang et al. (2020) Acta Neuropath Comm 8:163; Goetzl et al., (2014) Acta Neuropathol 127(6):845-60; and Lui et al., (2016) Cell 165:921-935. Thus, restoring PGRN function can reduce the expression of biomarkers of lysosomal function that are increased when PGRN is deficient. Certain biomarkers of complement function are overexpressed when PGRN is deficient.For example, C1qb and C1qc (subunits that form the complement protein C1q) show increased levels in PGRN-dependent (GRN knockout) mice. See Huang et al. (2020) Acta Neuropath Comm 8:163; Gotzl et al., (2014) Acta Neuropathol 127(6):845-60; and Lui et al., (2016) Cell 165:921-935. Thus, restoring PGRN function can reduce the expression of biomarkers of complement function that are increased when PGRN is deficient. In some embodiments, treating FTD and / or delaying its progression is determined by a change from baseline in a marker of microglial activity. Markers of microglial activity can be, but are not limited to, YKL-40 and / or interleukin-6. In some embodiments, treating FTD and / or delaying its progression is determined by a change from baseline in messenger ribonucleic acid (mRNA) expression in peripheral cells. In some embodiments, treating FTD and / or delaying its progression is determined by changes from baseline in analytes related to FTD disease biology and / or response to an anti-sortilin antibody. In some embodiments, the level of one or more proteins, such as any of the above markers, can be measured in a sample obtained from an individual, such as a whole blood, plasma, and / or CSF sample. Non-limiting examples of methods that can be used to measure the level of one or more proteins in a sample obtained from an individual include the SOMASCAN assay (see, e.g., Candia et al. (2017) Sci Rep 7, 14248), Western blot, mass spectrometry, flow cytometry, and enzyme-linked immunosorbent assay (ELISA).
[0144] In some embodiments, the treatment of FTD and / or its slowing of progression is determined by the change from baseline of neuroinflammation and / or microglial activation.Neuroinflammation and / or microglial activation can be measured by any method known in the art.In certain embodiments, neuroinflammation and / or microglial activation can be measured using translocator protein positron emission tomography (TSPO-PET) imaging.
[0145] In some embodiments, the individual treated according to the methods provided herein is heterozygous for a mutation in GRN (granulin gene). In some embodiments, the GRN mutation is a loss-of-function mutation. In some embodiments, the individual is heterozygous for a C9orf72 hexanucleotide repeat expansion. In some embodiments, the individual treated according to the methods provided herein exhibits symptoms of FTD. In some embodiments, the individual treated according to the methods provided herein does not exhibit symptoms of FTD. In some such embodiments, the individual is presymptomatic. In some such embodiments, the individual is identified as being heterozygous for a mutation in the GRN gene or as exhibiting reduced PGRN levels or function, but does not exhibit symptoms of FTD. In some such embodiments, the subject has FTD-GRN, or FTD caused by a mutation in the GRN gene. In some embodiments of a pre-symptomatic individual, the individual may exhibit an increased level of one or more biomarkers relative to normal levels, e.g., an increased level of Nfl, SPP1, YWHAE, AIF1, CSF1, CHIT1, or LY86, and / or a decreased level of one or more biomarkers relative to normal levels, e.g., a decreased level of NAGK or CTSB.
[0146] Alzheimer's disease Alzheimer's disease (AD) is the most common form of dementia. There is no cure for the disease, and it worsens as it progresses, eventually leading to death. AD is often diagnosed in people over the age of 65. However, early-onset Alzheimer's disease, which is less prevalent, can occur much earlier.
[0147] Common symptoms of Alzheimer's disease include behavioral symptoms such as difficulty remembering recent events, cognitive symptoms, confusion, irritability and aggression, mood swings, language impairment, and long-term memory loss. As the disease progresses, bodily functions are lost and death ultimately follows. Alzheimer's disease takes an unknown and variable amount of time to become fully apparent and can go undiagnosed for years.
[0148] Sortilin has been shown to bind to amyloid protein precursor (APP) and the APP-processing enzyme BACE1. Without wishing to be bound by theory, it is believed that these interactions are involved in Alzheimer's disease. Thus, without wishing to be bound by any particular theory, it is believed that the anti-Sortilin antibodies of the present disclosure can inhibit such interactions and be used to prevent, reduce the risk of, or treat Alzheimer's disease in individuals in need thereof.
[0149] In some embodiments, administration of an anti-Sortilin antibody of the present disclosure treats and / or slows the progression of Alzheimer's disease in an individual. In some embodiments, administration of an anti-Sortilin antibody of the present disclosure to an individual having or at risk of having Alzheimer's disease can increase Progranulin levels in the individual, e.g., in plasma and / or cerebrospinal fluid; and / or decrease Sortilin levels; and / or inhibit the interaction of Sortilin with one or more proteins; and / or inhibit the interaction of Sortilin with Progranulin, thereby treating and / or slowing the progression of Alzheimer's disease. In some embodiments, without wishing to be bound by theory, it is believed that anti-Sortilin antibodies of the disclosure that inhibit the interaction of Sortilin with a neurotrophin of the disclosure (e.g., proneurotrophin, proneurotrophin-3, proneurotrophin-4 / 5, proNGF, proBDNF, neurotrophin-3, neurotrophin-4 / 5, NGF, BDNF, etc.), p75, amyloid protein precursor (APP), and / or β peptide, or that inhibit one or more activities of Sortilin, can be used to treat and / or slow the progression of Alzheimer's disease in an individual in need thereof.
[0150] vascular dementia Vascular dementia (VaD) is an insidious, progressive deterioration of memory and other cognitive functions thought to be due to cerebrovascular disease (vascular disease in the brain). Cerebrovascular disease is a progressive change in the blood vessels (vasculature) of the brain (cerebrum). The most common vascular change associated with aging is the accumulation of cholesterol and other substances in the blood vessel walls. This results in thickening and hardening of the vessel walls and narrowing of the blood vessels, which can reduce or even completely stop blood flow to the brain areas supplied by the affected arteries. Patients with vascular dementia often exhibit symptoms similar to those of patients with Alzheimer's disease (AD). However, the associated brain changes are not due to AD pathology but rather to a chronic reduction in blood flow in the brain, ultimately leading to dementia. VaD is considered one of the most common types of dementia in older adults. Symptoms of VaD include memory problems, difficulty organizing and solving complex problems, slowed thinking, inattention or "spaceiness," difficulty retrieving words from memory, mood or behavior changes such as depression, irritability, or lethargy, and hallucinations or delusions.
[0151] Without wishing to be bound by theory, it is believed that one or more activities of sortilin, or the interaction of sortilin with progranulin, a neurotrophin of the disclosure (e.g., proneurotrophin, proneurotrophin-3, proneurotrophin-4 / 5, proNGF, proBDNF, neurotrophin-3, neurotrophin-4 / 5, NGF, BDNF, etc.), neurotensin, lipoprotein lipase, apolipoprotein AV, and / or receptor-associated proteins, is involved in vascular dementia. Thus, without wishing to be bound by theory, it is believed that anti-Sortilin antibodies of the disclosure that inhibit the interaction of Sortilin with a neurotrophin of the disclosure (e.g., proneurotrophin, proneurotrophin-3, proneurotrophin-4 / 5, proNGF, proBDNF, neurotrophin-3, neurotrophin-4 / 5, NGF, BDNF, etc.), neurotensin, p75, Sortilin propeptide (Sort-pro), amyloid protein precursor (APP), B-peptide, lipoprotein lipase (LpL), apolipoprotein AV (APOA5), apolipoprotein E (APOE), and / or receptor-associated protein (RAP); or that inhibit one or more activities of Sortilin, can be used to prevent, reduce the risk of, or treat vascular dementia in an individual in need thereof.
[0152] In some embodiments, administration of an anti-Sortilin antibody of the present disclosure can treat and / or slow the progression of vascular dementia in an individual. In some embodiments, administration of an anti-Sortilin antibody of the present disclosure to an individual having or at risk of having vascular dementia can increase Progranulin levels in the individual, e.g., in the plasma and / or cerebrospinal fluid; and / or decrease Sortilin levels; and / or inhibit the interaction of Sortilin with one or more proteins; and / or inhibit the interaction of Sortilin with Progranulin, thereby treating and / or slowing the progression of vascular dementia.
[0153] Dementia Dementia is a nonspecific syndrome (i.e., a set of signs and symptoms) that manifests as a profound loss of global cognitive ability in a previously unimpaired individual beyond that expected from normal aging. Dementia can be static, for example, as a result of specific global brain damage. Dementia can also be progressive, resulting in long-term decline due to physical injury or disease. Dementia is far more prevalent in the elderly population, but can also develop by age 65. Cognitive domains affected by dementia include, but are not limited to, memory, attention, language, and problem-solving. Generally, symptoms must persist for at least six months for a dementia diagnosis to be made. Exemplary forms of dementia include, but are not limited to, frontotemporal dementia, Alzheimer's disease, vascular dementia, semantic dementia, and dementia with Lewy bodies.
[0154] Without wishing to be bound by theory, it is believed that administration of an anti-Sortilin antibody of the present disclosure can treat dementia and / or slow its progression. In some embodiments, administration of an anti-Sortilin antibody of the present disclosure can treat dementia and / or slow its progression in an individual. In some embodiments, administration of an anti-Sortilin antibody of the present disclosure to an individual having or at risk of having dementia can increase Progranulin levels in the individual, for example, in the plasma and / or cerebrospinal fluid; and / or decrease Sortilin levels; and / or inhibit the interaction of Sortilin with one or more proteins; and / or inhibit the interaction of Sortilin with Progranulin, thereby treating dementia and / or slowing its progression.
[0155] Stroke, retinal dystrophy, traumatic brain injury, and spinal cord injury As used herein, retinal dystrophy refers to any disease or condition involving degeneration of the retina, which can lead to decreased vision or complete blindness.
[0156] As used herein, seizures, including epileptic seizures, refer to transient symptoms of abnormally excessive or synchronized neuronal activity in the brain. Seizures can be dramatic, such as violent movements, or mild, such as a brief loss of consciousness. Seizures can manifest as altered mental status, tonic or clonic movements, convulsions, and various other psychiatric symptoms.
[0157] Traumatic brain injury (TBI), sometimes called intracranial injury, occurs when the brain is traumatically injured by an external force. TBI can be classified based on severity, mechanism (closed or penetrating head injury), or other characteristics (e.g., whether it occurs in a specific location or is widespread).
[0158] Spinal cord injury (SCI) includes any spinal cord injury caused by trauma rather than disease. Depending on where the spinal cord and nerve roots are damaged, symptoms can vary widely, from pain to paralysis to incontinence. Spinal cord injuries are described on a range of levels, from "incomplete," meaning no effect on the patient, to "complete," meaning a complete loss of function.
[0159] Pro-neurotrophins (e.g., proneurotrophin-4 / 5, neurotrophin-4 / 5, proNGF, proBDNF, etc.) have been shown to play a role in stroke, retinal dystrophy, traumatic brain injury, and spinal cord injury.
[0160] Thus, without wishing to be bound by theory, it is believed that anti-Sortilin antibodies of the disclosure that inhibit the interaction of Sortilin with a neurotrophin of the disclosure (e.g., proneurotrophin, proneurotrophin-3, proneurotrophin-4 / 5, proNGF, proBDNF, neurotrophin-3, neurotrophin-4 / 5, NGF, BDNF, etc.); or that inhibit one or more activities of Sortilin, can be used to prevent, reduce the risk of, or treat stroke, retinal dystrophy, traumatic brain injury, and / or spinal cord injury in an individual in need thereof.
[0161] In some embodiments, administration of an anti-Sortilin antibody of the present disclosure can treat and / or slow the progression of retinal dystrophy, traumatic brain injury, and / or spinal cord injury in an individual. In some embodiments, administration of an anti-Sortilin antibody of the present disclosure to an individual having or at risk of having retinal dystrophy, traumatic brain injury, and / or spinal cord injury can increase Progranulin levels in the individual, for example, in the plasma and / or cerebrospinal fluid; and / or decrease Sortilin levels; and / or inhibit the interaction of Sortilin with one or more proteins; and / or inhibit the interaction of Sortilin with Progranulin, thereby treating and / or slowing the progression of retinal dystrophy, traumatic brain injury, and / or spinal cord injury.
[0162] Undesirable symptoms of aging As used herein, undesirable symptoms of aging include, but are not limited to, memory loss, behavioral changes, dementia, Alzheimer's disease, retinal degeneration, atherosclerotic vascular disease, hearing loss, and cell destruction.
[0163] In some embodiments, without wishing to be bound by theory, it is believed that anti-Sortilin antibodies of the disclosure that inhibit the interaction of Sortilin with Progranulin, a neurotrophin of the disclosure (e.g., proneurotrophin, proneurotrophin-3, proneurotrophin-4 / 5, proNGF, proBDNF, neurotrophin-3, neurotrophin-4 / 5, NGF, BDNF, etc.), neurotensin, p75, lipoprotein lipase (LpL), apolipoprotein AV (APOA5), and / or receptor-associated protein (RAP); or that inhibit one or more activities of Sortilin, can be used to prevent, reduce the risk of, or treat one or more undesirable symptoms of aging.
[0164] In some embodiments, administration of an anti-Sortilin antibody of the present disclosure can treat and / or slow the progression of one or more undesirable symptoms of aging in an individual. In some embodiments, administration of an anti-Sortilin antibody of the present disclosure to an individual having or at risk of having one or more undesirable symptoms of aging can increase Progranulin levels in the individual, for example, in the plasma and / or cerebrospinal fluid; and / or decrease Sortilin levels; and / or inhibit the interaction of Sortilin with one or more proteins; and / or inhibit the interaction of Sortilin with Progranulin, thereby treating and / or slowing the progression of one or more undesirable symptoms of aging.
[0165] Amyotrophic lateral sclerosis (ALS) As used herein, amyotrophic lateral sclerosis (ALS), motor neuron disease, or Lou Gehrig's disease are used interchangeably to refer to a debilitating disease of various etiologies characterized by rapidly progressive weakness, muscle atrophy and contractions, muscle spasticity, speech problems (dysarthria), swallowing problems (pica), and breathing problems (dyspnea).
[0166] Haploinsufficiency of progranulin due to heterozygous loss-of-function mutations in the GRN gene results in reduced CSF progranulin levels and contributes to the development of frontotemporal dementia (FTD) with TDP-43 pathology (Sleegers et al., (2009) Ann Neurol 65:603; Smith et al., (2012) Am J Hum Genet 90:1102). TDP-43 has also been identified as a key pathological protein in ALS, suggesting similarities between ALS and FTD.
[0167] For example, more than 20 dominant mutations in TDP-43 have been identified in sporadic and familial ALS patients (Lagier-Tourenne et al., (2009) Cell 136:1001), and TDP-43-positive aggregates are found in approximately 95% of ALS cases (Prasad et al., (2019) Front Mol Neurosci 12:25). Furthermore, ALS risk genes such as MOBP, C9ORF72, MOBKL2B, NSF, and FUS can also cause FTD (Karch et al., (2018) JAMA Neurol 75:860). Furthermore, both progranulin and C9ORF72 mutations are associated with abnormal microglial activation, which appears to be another common pathology between FTD and ALS (Haukedal et al., (2019) J Mol Biol 431:1818). Other evidence suggests that ALS and FTD are closely related conditions with overlapping genetic, neuropathological, and clinical features (Weishaupt et al., (2016) Trends Mol Med 22:769; McCauley et al., (2018) Acta Neuropathol 137:715). Taken together, these results suggest that both diseases may benefit from common therapies and that progranulin mutations act as modifiers of the ALS course.
[0168] Furthermore, aside from demonstrating that loss of progranulin is deleterious in multiple models of acute and chronic neurodegeneration (Boddaert et al., (2018) Methods Mol Biol 1806:233), overexpression of progranulin has been found to be protective in many animal models of ALS (Laird et al., (2010) PLoS One 5:e13368; Tauffenberger et al., (2013) Hum Mol Genet 22:782; Beel et al., (2018) Mol Neurodegener 13:55; Chang et al., (2017) J Exp Med 214:2611). Furthermore, common GRN variants have been significantly associated with a lower age at onset and shorter survival time in ALS patients (Sleegers et al., (2008) Neurology 71:253).
[0169] Taken together, both human genetics and data from disease models support a protective role for progranulin in attenuating TDP-43 pathology and associated pathology in ALS cases.
[0170] In some embodiments, without wishing to be bound by theory, it is believed that anti-Sortilin antibodies of the disclosure that inhibit the interaction of Sortilin with Progranulin, a neurotrophin of the disclosure (e.g., proneurotrophin, proneurotrophin-3, proneurotrophin-4 / 5, proNGF, proBDNF, neurotrophin-3, neurotrophin-4 / 5, NGF, BDNF, etc.), neurotensin, p75, lipoprotein lipase (LpL), apolipoprotein AV (APOA5), and / or receptor-associated protein (RAP); or that inhibit one or more activities of Sortilin, can be used to prevent or treat one or more undesirable symptoms of ALS.
[0171] In some embodiments, administration of an anti-Sortilin antibody of the present disclosure can treat and / or slow the progression of ALS in an individual. In some embodiments, administration of an anti-Sortilin antibody of the present disclosure to an individual having or at risk of having ALS can increase Progranulin levels in the individual, e.g., in the plasma and / or cerebrospinal fluid; and / or decrease Sortilin levels; and / or inhibit the interaction of Sortilin with one or more proteins; and / or inhibit the interaction of Sortilin with Progranulin, thereby treating ALS and / or slowing its progression.
[0172] In some embodiments, the individual is heterozygous for the C9orf72 hexanucleotide repeat expansion.
[0173] In some embodiments, the treatment of ALS and / or its delay in progression is determined by the change from baseline in brain atrophy, brain connectivity, brain free water and / or brain inflammation.To measure brain atrophy, brain connectivity, brain free water and / or brain inflammation, any method known in the art can be used, including but not limited to MRI.In certain embodiments, brain atrophy is measured using structural MRI.In certain embodiments, brain free water and / or brain inflammation is measured using diffusion tensor imaging (DTI).
[0174] In some embodiments, treating ALS and / or slowing its progression is determined by changes from baseline in progranulin, a marker of neurodegeneration, a marker of glial activation, and / or a marker of TDP-43 pathology. In certain embodiments, progranulin is measured using an Adipogen immunoassay. In certain embodiments, markers of neurodegeneration include, but are not limited to, neurofilament light chain. Neurofilament light chain may be measured by any method known in the art, including, but not limited to, assays from Quanterix and / or Roche Diagnostics. In certain embodiments, markers of glial activation include, but are not limited to, YKL-40 (CHI3L), IL-6, and / or GFAP. GFAP may be measured using any method known in the art, including, but not limited to, assays from Roche Diagnostics.
[0175] Multiple sclerosis Multiple sclerosis (MS), sometimes called disseminated sclerosis or disseminated encephalomyelitis, is an inflammatory disease that damages the fatty myelin sheath surrounding axons in the brain and spinal cord, leading to demyelination and scarring, as well as a wide range of signs and symptoms. See, for example, www.ninds.nih.gov / Disorders / Patient-Caregiver-Education / Hope-Through-Research / Multiple-Sclerosis-Hope-Through-Research.
[0176] Symptoms of MS include, but are not limited to, changes in sensation such as decreased sensitivity or tingling; tingling or numbness such as hypoesthesia and paresthesia; muscle weakness; clonus; muscle spasms; difficulty moving; coordination and balance disorders such as ataxia; speech disorders such as dysarthria; or difficulty swallowing such as dysphagia; visual disturbances such as nystagmus, optic neuritis, including phosphenes and diplopia; fatigue; acute or chronic pain; bladder and bowel disorders; varying degrees of cognitive impairment; emotional symptoms such as depression or emotional lability; Uthoff's phenomenon, which is a worsening of existing symptoms due to exposure to temperatures higher than normal ambient temperature; and Lhermitte's sign, which is an electrical sensation down the back when the neck is bent.
[0177] In some embodiments, administration of an anti-Sortilin antibody of the present disclosure can treat MS and / or slow its progression in an individual. In some embodiments, administration of an anti-Sortilin antibody of the present disclosure to an individual who has or is at risk of having MS can increase Progranulin levels in the individual, e.g., in the plasma and / or cerebrospinal fluid; and / or decrease Sortilin levels; and / or inhibit the interaction of Sortilin with one or more proteins; and / or inhibit the interaction of Sortilin with Progranulin, thereby treating MS and / or slowing its progression.
[0178] Glaucoma and macular degeneration Glaucoma describes, but is not limited to, a group of diseases characterized by damage to the optic nerve, resulting in decreased vision and blindness. Glaucoma is usually caused by increased fluid pressure (e.g., intraocular pressure) in the anterior chamber beneath the cornea. Glaucoma results in the progressive loss of retinal ganglion cells, which are important for vision. Age-related macular degeneration typically affects older adults and causes decreased vision in the macula, primarily the central visual field. Macular degeneration can cause, but is not limited to, drusen, pigmentary changes, distortion of the visual field, ocular hemorrhage, atrophy, decreased visual acuity, blurred vision, central scotoma, decreased color vision, and decreased contrast sensitivity.
[0179] In some embodiments, administration of an anti-Sortilin antibody of the present disclosure can treat and / or slow the progression of glaucoma or macular degeneration in an individual. In some embodiments, administration of an anti-Sortilin antibody of the present disclosure to an individual who has or is at risk of having glaucoma or macular degeneration can increase Progranulin levels in the individual, e.g., in the plasma and / or cerebrospinal fluid; and / or decrease Sortilin levels; and / or inhibit the interaction of Sortilin with one or more proteins; and / or inhibit the interaction of Sortilin with Progranulin, thereby treating and / or slowing the progression of glaucoma or macular degeneration.
[0180] Administration and Pharmaceutical Dosage The anti-Sortilin antibodies (and any additional therapeutic agents) provided herein can be administered by any suitable means, including parenteral, intrapulmonary, intranasal, intralesional, intracerebrospinal, intracranial, intraspinal, intrasynovial, intrathecal, oral, topical, or inhalation routes. Parenteral administration includes intramuscular, intraarterial, intraarticular, intraperitoneal, subcutaneous, or intravenous administration. Intravenous administration includes administration as a bolus or by continuous infusion over a period of time. In some embodiments, the antibodies of the disclosure are administered intravenously. In some embodiments, the antibodies of the disclosure are administered by subcutaneous injection. Various administration schedules are contemplated herein, including, but not limited to, single or multiple administrations over various time points, bolus administration, and pulse infusion.
[0181] The anti-Sortilin antibodies provided herein are formulated, dosed, and administered in a manner consistent with good medical practice. Factors to consider in this context include the particular disease or disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of drug delivery, the method of administration, the schedule of administration, and other factors known to medical professionals. The antibody is optionally, but need not be, formulated with one or more agents currently used to prevent or treat the disease or disorder in question. In some embodiments, the anti-Sortilin antibodies of the present disclosure are formulated and / or administered in combination with one or more additional anti-Sortilin agents, e.g., one or more anti-Sortilin antibodies. The effective amount of such other agents will vary depending on the amount of antibody present in the formulation, the type of disease, disorder, or treatment, and other factors discussed above.
[0182] In some embodiments, the dose of a particular anti-Sortilin antibody of the present disclosure can be empirically determined in an individual who has been administered one or more doses of an anti-Sortilin antibody. In some embodiments, an individual is administered increasing doses of an anti-Sortilin antibody of the present disclosure. To assess the effectiveness of an anti-Sortilin antibody of the present disclosure, clinical symptoms of any of the diseases, disorders, or injuries of the present disclosure (e.g., frontotemporal dementia, progressive supranuclear palsy, Alzheimer's disease, vascular dementia, stroke, retinal dystrophy, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, dementia, stroke, Parkinson's disease, limbic-predominant senile TDP43 encephalopathy (LATE), acute disseminated encephalomyelitis, retinal degeneration, age-related macular degeneration, glaucoma, multiple sclerosis, septic shock, bacterial infection, arthritis, or osteoarthritis) can be monitored.
[0183] Intravenous administration In some embodiments, the methods provided herein comprise administering an anti-Sortilin antibody of the present disclosure by intravenous infusion to an individual having or at risk of having a disease, disorder, or injury. In some embodiments, the disease, disorder, or injury is frontotemporal dementia, progressive supranuclear palsy, Alzheimer's disease, vascular dementia, stroke, retinal dystrophy, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, dementia, stroke, Parkinson's disease, acute disseminated encephalomyelitis, retinal degeneration, age-related macular degeneration, glaucoma, multiple sclerosis, septic shock, bacterial infection, arthritis, or osteoarthritis. In some embodiments, the disease or disorder is Alzheimer's disease. In some embodiments, the disease or disorder is frontotemporal dementia. In some embodiments, the disease or disorder is Parkinson's disease.
[0184] In some embodiments, the anti-Sortilin antibody is administered intravenously at a dose of at least about 6 mg / kg. In some embodiments, the anti-Sortilin antibody is administered intravenously at a dose of about 6 mg / kg to about 60 mg / kg. In some embodiments, the anti-Sortilin antibody is administered intravenously at a dose of up to about 30 mg / kg. In some embodiments, the anti-Sortilin antibody is administered intravenously at a dose of about 15 mg / kg to about 30 mg / kg. In some embodiments, the anti-Sortilin antibody is administered intravenously at a dose of up to about 60 mg / kg. In some embodiments, the dose is about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 11 mg / kg, about 12 mg / kg, about 13 mg / kg, about 14 mg / kg, about 15 mg / kg, about 16 mg / kg, about 17 mg / kg, about 18 mg / kg, about 19 mg / kg, about 20 mg / kg, about 21 mg / kg, about 22 mg / kg, about 23 mg / kg, about 24 mg / kg, about 25 mg / kg, about 26 mg / kg, about 27 mg / kg, about 28 mg / kg, about 29 mg / kg, about 30 mg / kg, about 31 mg / kg, about 32 mg / kg, about In some embodiments, the anti-Sortilin antibody is administered intravenously at a dose of about 6 mg / kg. In some embodiments, the anti-Sortilin antibody is administered intravenously at a dose of about 15 mg / kg. In some embodiments, the anti-Sortilin antibody is administered intravenously at a dose of about 30 mg / kg. In some embodiments, the anti-Sortilin antibody is administered intravenously at a dose of about 60 mg / kg.
[0185] Such dosage can be administered intermittently.In certain embodiments, the administration frequency is 3 times a day, 2 times a day, once a day, once every other day, once every week, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, once every 6 weeks, once every 7 weeks, once every 8 weeks, once every 9 weeks, once every 10 weeks or less frequently.In certain embodiments, the administration frequency is once a year, once every 2 months, once every 3 months, once every 4 months, once every 5 months, once every 6 months or less frequently.
[0186] In some embodiments, the anti-Sortilin antibodies of the disclosure are administered intravenously at any of the doses above and using any of the dosing regimens below.
[0187] In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every four weeks or more frequently. In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every week (q1w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every two weeks (q2w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every three weeks (q3w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every four weeks (q4w).
[0188] In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every four weeks or less frequently. In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every four weeks (q4w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every five weeks (q5w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every six weeks (q6w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every seven weeks (q7w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every eight weeks (q8w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every nine weeks (q9w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every ten weeks (q10w).
[0189] In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once a month or less frequently. In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once a month. In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every two months. In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every three months. In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every four months. In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every five months. In some embodiments, an anti-Sortilin antibody of the present disclosure is administered intravenously about once every six months.
[0190] In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 6 mg / kg about once every four weeks (q4w), i.e., about once every 28 days. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 6 mg / kg about once a month. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 6 mg / kg about once every six weeks (q6w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 6 mg / kg about once every eight weeks (q8w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 6 mg / kg about once every four weeks (q4w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 6 mg / kg about once every six weeks (q6w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 6 mg / kg about once every eight weeks (q8w).
[0191] In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 15 mg / kg about once every four weeks (q4w), i.e., about once every 28 days. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 15 mg / kg about once a month. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 15 mg / kg about once every six weeks (q6w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 15 mg / kg about once every eight weeks (q8w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 15 mg / kg about once every four weeks (q4w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 15 mg / kg about once every six weeks (q6w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 15 mg / kg about once every eight weeks (q8w).
[0192] In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the disclosure intravenously at a dose of up to about 30 mg / kg about once every four weeks (q4w), i.e., about once every 28 days. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the disclosure intravenously at a dose of up to about 30 mg / kg about once a month.
[0193] In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 30 mg / kg about once every four weeks (q4w), i.e., once every 28 days. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 30 mg / kg about once a month. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 30 mg / kg about once every six weeks (q6w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 30 mg / kg about once every eight weeks (q8w).
[0194] In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 60 mg / kg about once every four weeks (q4w), i.e., once every 28 days. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 60 mg / kg about once a month. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 60 mg / kg about once every six weeks (q6w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 60 mg / kg about once every eight weeks (q8w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of at least about 60 mg / kg about once every four weeks (q4w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the disclosure intravenously at a dose of about 60 mg / kg about once every six weeks (q6w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the disclosure intravenously at a dose of about 60 mg / kg about once every eight weeks (q8w).
[0195] In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the disclosure intravenously at a dose of about 6 mg / kg to about 60 mg / kg about once every four weeks (q4w), i.e., about once every 28 days. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the disclosure intravenously at a dose of about 6 mg / kg to about 60 mg / kg once a month.
[0196] In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the disclosure intravenously at a dose of about 6 mg / kg to about 60 mg / kg about once every six weeks (q6w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the disclosure intravenously at a dose of about 6 mg / kg to about 60 mg / kg about once every eight weeks (q8w).
[0197] In some embodiments, the methods provided herein involve administering to an individual an anti-Sortilin antibody of the disclosure at about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 11 mg / kg, about 12 mg / kg, about 13 mg / kg, about 14 mg / kg, about 15 mg / kg, about 16 mg / kg, about 17 mg / kg, about 18 mg / kg, about 19 mg / kg, about 20 mg / kg, about 21 mg / kg, about 22 mg / kg, about 23 mg / kg, about 24 mg / kg, about 25 mg / kg, about 26 mg / kg, about 27 mg / kg, about 28 mg / kg, about 29 mg / kg, about 30 mg / kg, about 31 mg / kg, about 32 mg / kg, about 33 mg / kg, about 34 mg / kg, about 35 mg / kg, about 36 mg / kg, about 37 mg / kg, about 38 mg / kg, about 39 mg / kg, about 40 mg / kg, about 41 mg / kg, about 42 mg / kg, about 43 mg / kg, about 44 mg / kg, about 45 mg / kg, about 46 mg / kg, about 47 mg / kg, about 48 mg / kg, about 49 mg / kg, about 50 mg / kg, about 51 mg / kg, about 52 mg / kg, about 53 mg / kg, about 54 mg / kg, about 55 mg / kg, about 56 mg / kg, about 57 mg / kg, about 58 mg / kg, about 59 mg / kg, or about 60 mg / kg administered intravenously about once every four weeks (q4w), i.e., about once every 28 days.In some embodiments, the methods provided herein include administering to an individual an anti-Sortilin antibody of the disclosure at about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 11 mg / kg, about 12 mg / kg, about 13 mg / kg, about 14 mg / kg, about 15 mg / kg, about 16 mg / kg, about 17 mg / kg, about 18 mg / kg, about 19 mg / kg, about 20 mg / kg, about 21 mg / kg, about 22 mg / kg, about 23 mg / kg, about 24 mg / kg, about 25 mg / kg, about 26 mg / kg, about 27 mg / kg, about 28 mg / kg, about 29 mg / kg, about 30 mg / kg, about 31 mg / kg, about 32 mg / kg, about 33 mg / kg, about 34 mg / kg, about 35 mg / kg, about 36 mg / kg, about 37 mg / kg, about 38 mg / kg, about 39 mg / kg, about 40 mg / kg, about 41 mg / kg, about 42 mg / kg, about 43 mg / kg, about 44 mg / kg, about 45 mg / kg, about 46 mg / kg, about 47 mg / kg, about 48 mg / kg, about 49 mg / kg, about 50 mg / kg, about 51 mg / kg, about 52 mg / kg, about 53 mg / kg, about 54 mg / kg, about 55 mg / kg, about 56 mg / kg, about 57 mg / kg, about 58 mg / kg, about 59 mg / kg, about 60 mg / kg, about 61 mg / kg, about 62 mg / kg, about 63 mg / kg, about 64 mg / kg, about 65 mg / kg, about 66 mg / kg, about kg, about 33 mg / kg, about 34 mg / kg, about 35 mg / kg, about 36 mg / kg, about 37 mg / kg, about 38 mg / kg, about 39 mg / kg, about 40 mg / kg, about 41 mg / kg, about 42 mg / kg, about 43 mg / kg, about 44 mg / kg, about 45 mg / kg, about 46 mg / kg, about 47 mg / kg, about 48 mg / kg, about 49 mg / kg, about 50 mg / kg, about 51 mg / kg, about 52 mg / kg, about 53 mg / kg, about 54 mg / kg, about 55 mg / kg, about 56 mg / kg, about 57 mg / kg, about 58 mg / kg, about 59 mg / kg, or about 60 mg / kg administered intravenously about once a month.In some embodiments, the methods provided herein include administering to an individual an anti-Sortilin antibody of the disclosure at about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 11 mg / kg, about 12 mg / kg, about 13 mg / kg, about 14 mg / kg, about 15 mg / kg, about 16 mg / kg, about 17 mg / kg, about 18 mg / kg, about 19 mg / kg, about 20 mg / kg, about 21 mg / kg, about 22 mg / kg, about 23 mg / kg, about 24 mg / kg, about 25 mg / kg, about 26 mg / kg, about 27 mg / kg, about 28 mg / kg, about 29 mg / kg, about 30 mg / kg, about 31 mg / kg, about 32 mg / kg, about 33 mg / kg, about 34 mg / kg, about 35 mg / kg, about 36 mg / kg, about 37 mg / kg, about 38 mg / kg, about 39 mg / kg, about 40 mg / kg, about 41 mg / kg, about 42 mg / kg, about 43 mg / kg, about 44 mg / kg, about 45 mg / kg, about 46 mg / kg, about 47 mg / kg, about 48 mg / kg, about 49 mg / kg, about 50 mg / kg, about 51 mg / kg, about 52 mg / kg, about 53 mg / kg, about 54 mg / kg, about 55 mg / kg, about 56 mg / kg, about 57 mg / kg, about 58 mg / kg, about 59 mg / kg, about 60 mg / kg, about 61 mg / kg, about 62 mg / kg, about 63 mg / kg, about 64 mg / kg, about 65 mg / kg, about 66 mg / kg, about and administering intravenously once about every six weeks (q6w) at a dose of 3 mg / kg, about 34 mg / kg, about 35 mg / kg, about 36 mg / kg, about 37 mg / kg, about 38 mg / kg, about 39 mg / kg, about 40 mg / kg, about 41 mg / kg, about 42 mg / kg, about 43 mg / kg, about 44 mg / kg, about 45 mg / kg, about 46 mg / kg, about 47 mg / kg, about 48 mg / kg, about 49 mg / kg, about 50 mg / kg, about 51 mg / kg, about 52 mg / kg, about 53 mg / kg, about 54 mg / kg, about 55 mg / kg, about 56 mg / kg, about 57 mg / kg, about 58 mg / kg, about 59 mg / kg, or about 60 mg / kg.In some embodiments, the methods provided herein include administering to an individual an anti-Sortilin antibody of the disclosure at about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 11 mg / kg, about 12 mg / kg, about 13 mg / kg, about 14 mg / kg, about 15 mg / kg, about 16 mg / kg, about 17 mg / kg, about 18 mg / kg, about 19 mg / kg, about 20 mg / kg, about 21 mg / kg, about 22 mg / kg, about 23 mg / kg, about 24 mg / kg, about 25 mg / kg, about 26 mg / kg, about 27 mg / kg, about 28 mg / kg, about 29 mg / kg, about 30 mg / kg, about 31 mg / kg, about 32 mg / kg, about 33 mg / kg, about 34 mg / kg, about 35 mg / kg, about 36 mg / kg, about 37 mg / kg, about 38 mg / kg, about 39 mg / kg, about 40 mg / kg, about 41 mg / kg, about 42 mg / kg, about 43 mg / kg, about 44 mg / kg, about 45 mg / kg, about 46 mg / kg, about 47 mg / kg, about 48 mg / kg, about 49 mg / kg, about 50 mg / kg, about 51 mg / kg, about 52 mg / kg, about 53 mg / kg, about 54 mg / kg, about 55 mg / kg, about 56 mg / kg, about 57 mg / kg, about 58 mg / kg, about 59 mg / kg, about 60 mg / kg, about 61 mg / kg, about 62 mg / kg, about 63 mg / kg, about 64 mg / kg, about 65 mg / kg, about 66 mg / kg, about and administering intravenously once about every eight weeks (q8w) at a dose of 3 mg / kg, about 34 mg / kg, about 35 mg / kg, about 36 mg / kg, about 37 mg / kg, about 38 mg / kg, about 39 mg / kg, about 40 mg / kg, about 41 mg / kg, about 42 mg / kg, about 43 mg / kg, about 44 mg / kg, about 45 mg / kg, about 46 mg / kg, about 47 mg / kg, about 48 mg / kg, about 49 mg / kg, about 50 mg / kg, about 51 mg / kg, about 52 mg / kg, about 53 mg / kg, about 54 mg / kg, about 55 mg / kg, about 56 mg / kg, about 57 mg / kg, about 58 mg / kg, about 59 mg / kg, or about 60 mg / kg.
[0198] In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 6 mg / kg about once every four weeks (q4w), i.e., about once every 28 days. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 6 mg / kg about once a month. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 6 mg / kg about once every six weeks (q6w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 6 mg / kg about once every eight weeks (q8w).
[0199] In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 15 mg / kg about once every four weeks (q4w), i.e., about once every 28 days. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 15 mg / kg about once a month. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 15 mg / kg about once every six weeks (q6w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 15 mg / kg about once every eight weeks (q8w).
[0200] In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 30 mg / kg about once every four weeks (q4w), i.e., about once every 28 days. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 30 mg / kg about once a month. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 30 mg / kg about once every six weeks (q6w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 30 mg / kg about once every eight weeks (q8w).
[0201] In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 60 mg / kg about once every four weeks (q4w), i.e., about once every 28 days. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 60 mg / kg about once a month. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 60 mg / kg about once every six weeks (q6w). In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the present disclosure intravenously at a dose of about 60 mg / kg about once every eight weeks (q8w).
[0202] In certain embodiments, a dose of an anti-Sortilin antibody of the disclosure is administered to an individual intravenously, for example, over about 60 minutes using an infusion pump.
[0203] In certain embodiments, at least 1 dose, at least 2 doses, at least 3 doses, at least 4 doses, at least 5 doses, at least 6 doses, at least 7 doses, at least 8 doses, at least 9 doses, at least 10 doses, at least 11 doses, at least 12 doses, at least 13 doses, at least 14 doses, at least 15 doses, at least 16 doses, at least 17 doses, at least 18 doses, at least 19 doses, at least 20 doses, at least 21 doses, at least 22 doses, at least 23 doses, at least 24 doses, at least 25 doses, at least 26 doses, at least 27 doses, at least 28 doses, at least 29 doses, at least 30 doses, at least 31 doses, at least 32 doses, at least 33 doses, at least 34 doses, at least 35 doses, at least 36 doses, or more, of an anti-Sortilin antibody of the disclosure is administered intravenously to an individual. In certain embodiments, at least 6 doses of an anti-Sortilin antibody are administered to an individual.
[0204] In some embodiments, an initial dose of anti-Sortilin antibody is administered on the first day of the treatment period, and administration of the anti-Sortilin antibody continues about once every four weeks, or more frequently thereafter. In some embodiments, an initial dose of anti-Sortilin antibody is administered on the first day of the treatment period, and administration of the anti-Sortilin antibody continues about once every week (q1w), about once every two weeks (q2w), about once every three weeks (q3w), or about once every four weeks (q4w).
[0205] In some embodiments, an initial dose of anti-Sortilin antibody is administered on the first day of the treatment period, and administration of the anti-Sortilin antibody continues about once every four weeks, or less frequently thereafter. In some embodiments, an initial dose of anti-Sortilin antibody is administered on the first day of the treatment period, and administration of the anti-Sortilin antibody continues about once every four weeks (q4w), once every five weeks (q5w), once every six weeks (q6w), once every seven weeks (q7w), once every eight weeks (q8w), once every nine weeks (q9w), or once every ten weeks (q10w).
[0206] In some embodiments, an initial dose of anti-Sortilin antibody is administered on the first day of the treatment period, and administration of the anti-Sortilin antibody continues about once a month, or less frequently thereafter. In some embodiments, an initial dose of anti-Sortilin antibody is administered on the first day of the treatment period, and administration of the anti-Sortilin antibody continues about once a month, about once every two months, about once every three months, about once every four months, about once every five months, or about once every six months.
[0207] In some embodiments, an individual is treated with an anti-Sortilin antibody of the present disclosure for at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, or more. In some embodiments, an individual is treated with an anti-Sortilin antibody of the present disclosure for at least about 12 months, at least about 15 months, at least about 18 months, at least about 21 months, at least about 24 months, at least about 27 months, at least about 30 months, at least about 33 months, at least about 36 months, or more. In some embodiments, an individual is treated with an anti-Sortilin antibody of the present disclosure for at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, or more.
[0208] In some embodiments, an individual is administered a higher initial dose of an anti-Sortilin antibody, followed by one or more lower doses of the anti-Sortilin antibody. In some embodiments, an individual is administered an initial dose of about 60 mg / kg of an anti-Sortilin antibody, followed by one or more lower doses of the anti-Sortilin antibody, from about 6 mg / kg to about 59 mg / kg, or from about 6 mg / kg to about 30 mg / kg, or from about 6 mg / kg to about 15 mg / kg. In some embodiments, an individual is administered an initial dose of about 30 mg / kg of an anti-Sortilin antibody, followed by one or more lower doses of the anti-Sortilin antibody, from about 6 mg / kg to about 29 mg / kg, or from about 6 mg / kg to about 15 mg / kg. In some embodiments, an individual is administered an initial dose of about 60 mg / kg of an anti-Sortilin antibody, followed by one or more lower doses of the anti-Sortilin antibody, from about 6 mg / kg to about 59 mg / kg, from about 6 mg / kg to about 30 mg / kg, or from about 6 mg / kg to about 15 mg / kg. In some embodiments, an individual is administered a lower initial dose of an anti-Sortilin antibody, followed by one or more higher doses of the anti-Sortilin antibody. In some embodiments, an individual is administered an initial dose of about 6 mg / kg of an anti-Sortilin antibody, followed by one or more higher doses of the anti-Sortilin antibody, from about 7 mg / kg to about 30 mg / kg, from about 15 mg / kg to about 30 mg / kg, or from about 30 mg / kg to about 60 mg / kg. In some embodiments, an individual is administered an initial dose of about 15 mg / kg of anti-Sortilin antibody, followed by one or more higher doses of about 16 mg / kg to about 30 mg / kg, or about 30 mg / kg to about 60 mg / kg of anti-Sortilin antibody. In some embodiments, an individual is administered an initial dose of about 30 mg / kg of anti-Sortilin antibody, followed by one or more higher doses of about 31 mg / kg to about 60 mg / kg of anti-Sortilin antibody.
[0209] As will be understood by one of skill in the art, other dosing regimens can also be used in accordance with the methods provided herein, e.g., according to methods known in the art, e.g., based on monitoring of the individual and / or disease or disorder being treated as described herein.
[0210] Subcutaneous administration In some embodiments, the methods provided herein comprise administering an anti-Sortilin antibody of the present disclosure subcutaneously to an individual having or at risk of having a disease, disorder, or injury. In some embodiments, the disease, disorder, or injury is frontotemporal dementia, progressive supranuclear palsy, Alzheimer's disease, vascular dementia, stroke, retinal dystrophy, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, dementia, stroke, Parkinson's disease, acute disseminated encephalomyelitis, retinal degeneration, age-related macular degeneration, glaucoma, multiple sclerosis, septic shock, bacterial infection, arthritis, or osteoarthritis. In some embodiments, the disease or disorder is Alzheimer's disease. In some embodiments, the disease or disorder is frontotemporal dementia. In some embodiments, the disease or disorder is Parkinson's disease.
[0211] In some embodiments, the methods provided herein comprise subcutaneously administering to an individual an anti-Sortilin antibody of the present disclosure at a dose of at least about 150 mg. In some embodiments, the methods provided herein comprise subcutaneously administering to an individual an anti-Sortilin antibody of the present disclosure at a dose of at least about 260 mg. In some embodiments, the methods provided herein comprise subcutaneously administering to an individual an anti-Sortilin antibody of the present disclosure at a dose of about 260 mg to about 4000 mg. In some embodiments, the methods provided herein comprise administering to an individual an anti-Sortilin antibody of the disclosure at about 260 mg, about 280 mg, about 300 mg, about 320 mg, about 340 mg, about 360 mg, about 380 mg, about 400 mg, about 420 mg, about 440 mg, about 460 mg, about 480 mg, about 500 mg, about 520 mg, about 540 mg, about 560 mg, about 580 mg, about 600 mg, about 620 mg, about 640 mg, about 660 mg, about 680 mg, about 700mg, about 720mg, about 740mg, about 760mg, about 780mg, about 800mg, about 820mg, about 840mg, about 860mg, about 880mg, about 900mg, about 920mg, about 940mg, about 960mg, about 980mg, about 1000mg, about 1020mg, about 1040mg, about 1060mg, about 1080mg, about 1100mg, about 1120mg, about 1140mg, about 1160mg, about 1180mg, about 1200mg, about 1220 mg, about 1240mg, about 1260mg, about 1280mg, about 1300mg, about 1320mg, about 1340mg, about 1360mg, about 1380mg, about 1400mg, about 1420mg, about 1440mg, about 1460mg , about 1480mg, about 1500mg, about 1520mg, about 1540mg, about 1560mg, about 1580mg, about 1600mg, about 1620mg, about 1640mg, about 1660mg, about 1680mg, about 1700mg, about 1 720mg, about 1740mg, about 1760mg, about 1780mg, about 1800mg, about 1820mg, about 1840mg, about 1860mg, about 1880mg, about 1900mg, about 1920mg, about 1940mg, about 1960 mg, about 1980mg, about 2000mg, about 2020mg, about 2040mg, about 2060mg, about 2080mg, about 2100mg, about 2120mg, about 2140mg, about 2160mg, about 2180mg, about 2200mg,About 2220mg, about 2240mg, about 2260mg, about 2280mg, about 2300mg, about 2320mg, about 2340mg, about 2360mg, about 2380mg, about 2400mg, about 2420mg, about 244 0mg, about 2460mg, about 2480mg, about 2500mg, about 2520mg, about 2540mg, about 2560mg, about 2580mg, about 2600mg, about 2620mg, about 2640mg, about 2660mg, About 2680mg, about 2700mg, about 2720mg, about 2740mg, about 2760mg, about 2780mg, about 2800mg, about 2820mg, about 2840mg, about 2860mg, about 2880mg, about 290 0mg, about 2920mg, about 2940mg, about 2960mg, about 2980mg, about 3000mg, about 3020mg, about 3040mg, about 3060mg, about 3080mg, about 3100mg, about 3120mg, about 3140mg, about 3160mg, about 3180mg, about 3200mg, about 3220mg, about 3240mg, about 3260mg, about 3280mg, about 3300mg, about 3320mg, about 3340mg, about 3360 mg, about 3380mg, about 3400mg, about 3420mg, about 3440mg, about 3460mg, about 3480mg, about 3500mg, about 3520mg, about 3540mg, about 3560mg, about 3580mg, about and administering subcutaneously at a dose of about 3600 mg, about 3620 mg, about 3640 mg, about 3660 mg, about 3680 mg, about 3700 mg, about 3720 mg, about 3740 mg, about 3760 mg, about 3780 mg, about 3800 mg, about 3820 mg, about 3840 mg, about 3860 mg, about 3880 mg, about 3900 mg, about 3920 mg, about 3940 mg, about 3960 mg, about 3980 mg, or about 4000 mg.
[0212] In some embodiments, the methods provided herein comprise subcutaneously administering to an individual an anti-Sortilin antibody of the disclosure at a dose of about 270 mg to about 600 mg, about 600 mg to about 675 mg, about 675 mg to about 720 mg, about 720 mg to about 1350 mg, about 1350 mg to about 1600 mg, about 1600 mg to about 1800 mg, or about 1800 mg to about 3600 mg. In some embodiments, the methods provided herein comprise subcutaneously administering to an individual an anti-Sortilin antibody of the disclosure at a dose of about 270 mg, about 675 mg, about 720 mg, about 1350 mg, about 1800 mg, or about 3600 mg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 150 mg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 270 mg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 300 mg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 600 mg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 675 mg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 720 mg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 1350 mg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 1600 mg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 1800 mg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 3600 mg.
[0213] In some embodiments, the methods provided herein comprise subcutaneously administering to an individual an anti-Sortilin antibody of the disclosure at a dose of about 6 mg / kg to about 60 mg / kg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of up to about 30 mg / kg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of up to about 60 mg / kg. In some embodiments, the dose is about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 11 mg / kg, about 12 mg / kg, about 13 mg / kg, about 13.3 mg / kg, about 14 mg / kg, about 15 mg / kg, about 16 mg / kg, about 17 mg / kg, about 18 mg / kg, about 19 mg / kg, about 20 mg / kg, about 21 mg / kg, about 22 mg / kg, about 23 mg / kg, about 24 mg / kg, about 25 mg / kg, about 26 mg / kg, about 27 mg / kg, about 28 mg / kg, about 29 mg / kg, about 30 mg / kg, about 31 mg / kg, about 32 mg / kg, about 33 mg / kg, about 34 mg / kg, about 35 mg / kg, about 36 mg / kg, about 37 mg / kg, about 38 mg / kg, about 39 mg / kg, about 40 mg / kg, about 41 mg / kg, about 42 mg / kg, about 43 mg / kg, about 44 mg / kg, about 45 mg / kg, about 46 mg / kg, about 47 mg / kg, about 48 mg / kg, about 49 mg / kg, about 50 mg / kg, about 51 mg / kg, about 52 mg / kg, about 53 mg / kg, about 54 mg / kg, about 55 mg / kg, about 56 mg / kg, about 57 mg / kg, about 58 mg / kg, about 59 mg / kg, or about 60 mg / kg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 6 mg / kg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 13.3 mg / kg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 15 mg / kg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 30 mg / kg. In some embodiments, the anti-Sortilin antibody is administered subcutaneously at a dose of about 60 mg / kg.
[0214] Such dosage can be administered intermittently.In certain embodiments, the administration frequency is 3 times a day, 2 times a day, once a day, once every other day, once every week, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, once every 6 weeks, once every 7 weeks, once every 8 weeks, once every 9 weeks, once every 10 weeks or less frequently.In certain embodiments, the administration frequency is once a month, once every 2 months, once every 3 months, once every 4 months, once every 5 months, once every 6 months or less frequently.
[0215] In some embodiments, the anti-Sortilin antibodies of the disclosure are administered subcutaneously at any of the doses described above using any of the dosing regimens described below.
[0216] In some embodiments, an anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every four weeks (q4w) or more frequently. In some embodiments, an anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every week (q1w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every two weeks (q2w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every three weeks (q3w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every four weeks (q4w).
[0217] In some embodiments, an anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every four weeks (q4w) or less frequently. In some embodiments, an anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every four weeks (q4w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every five weeks (q5w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every six weeks (q6w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every seven weeks (q7w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every eight weeks (q8w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every nine weeks (q9w). In some embodiments, an anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every ten weeks (q10w).
[0218] In some embodiments, the anti-Sortilin antibody of the present disclosure is administered subcutaneously about once a month or less frequently. In some embodiments, the anti-Sortilin antibody of the present disclosure is administered subcutaneously about once a month. In some embodiments, the anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every two months. In some embodiments, the anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every three months. In some embodiments, the anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every four months. In some embodiments, the anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every five months. In some embodiments, the anti-Sortilin antibody of the present disclosure is administered subcutaneously about once every six months.
[0219] In certain embodiments, a dose of an anti-Sortilin antibody is administered subcutaneously to an individual as a subcutaneous injection. In certain embodiments, a dose of an anti-Sortilin antibody is administered subcutaneously to an individual as a slow subcutaneous injection over about 15 minutes.
[0220] In certain embodiments, at least 1 dose, at least 2 doses, at least 3 doses, at least 4 doses, at least 5 doses, at least 6 doses, at least 7 doses, at least 8 doses, at least 9 doses, at least 10 doses, at least 11 doses, at least 12 doses, at least 13 doses, at least 14 doses, at least 15 doses, at least 16 doses, at least 17 doses, at least 18 doses, at least 19 doses, at least 20 doses, at least 21 doses, at least 22 doses, at least 23 doses, at least 24 doses, at least 25 doses, at least 26 doses, at least 27 doses, at least 28 doses, at least 29 doses, at least 30 doses, at least 31 doses, at least 32 doses, at least 33 doses, at least 34 doses, at least 35 doses, at least 36 doses, or more, of an anti-Sortilin antibody are administered subcutaneously to an individual. In certain embodiments, at least 6 doses of an anti-Sortilin antibody are administered to an individual.
[0221] In some embodiments, the first dose of anti-Sortilin antibody is administered on the first day of the treatment period, and administration of the anti-Sortilin antibody continues about once every four weeks (q4w) or more frequently thereafter. In some embodiments, the first dose of anti-Sortilin antibody is administered on the first day of the treatment period, and administration of the anti-Sortilin antibody continues about once every week (q1w), about once every two weeks (q2w), about once every three weeks (q3w), or about once every four weeks (q4w).
[0222] In some embodiments, the first dose of anti-Sortilin antibody is administered on the first day of the treatment period, and administration of the anti-Sortilin antibody continues about once every four weeks (q4w), or less frequently thereafter. In some embodiments, the first dose of anti-Sortilin antibody is administered on the first day of the treatment period, and administration of the anti-Sortilin antibody continues about once every four weeks (q4w), once every five weeks (q5w), once every six weeks (q6w), once every seven weeks (q7w), once every eight weeks (q8w), once every nine weeks (q9w), or once every ten weeks (q10w).
[0223] In some embodiments, an initial dose of anti-Sortilin antibody is administered on the first day of the treatment period, and administration of the anti-Sortilin antibody continues about once a month, or less frequently thereafter. In some embodiments, an initial dose of anti-Sortilin antibody is administered on the first day of the treatment period, and administration of the anti-Sortilin antibody continues about once a month, about once every two months, about once every three months, about once every four months, about once every five months, or about once every six months.
[0224] In some embodiments, an individual is treated with an anti-Sortilin antibody of the present disclosure for at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, or more. In some embodiments, an individual is treated with an anti-Sortilin antibody of the present disclosure for at least about 12 months, at least about 15 months, at least about 18 months, at least about 21 months, at least about 24 months, at least about 27 months, at least about 30 months, at least about 33 months, at least about 36 months, or more. In some embodiments, an individual is treated with an anti-Sortilin antibody of the present disclosure for at least about 1 year, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, or more.
[0225] In some embodiments, an individual is administered a higher initial dose of an anti-Sortilin antibody, followed by one or more lower doses of the anti-Sortilin antibody. In some embodiments, an individual is administered an initial dose of about 60 mg / kg of an anti-Sortilin antibody, followed by one or more lower doses of the anti-Sortilin antibody, from about 6 mg / kg to about 59 mg / kg, or from about 6 mg / kg to about 30 mg / kg, or from about 6 mg / kg to about 15 mg / kg. In some embodiments, an individual is administered an initial dose of about 30 mg / kg of an anti-Sortilin antibody, followed by one or more lower doses of the anti-Sortilin antibody, from about 6 mg / kg to about 29 mg / kg, or from about 6 mg / kg to about 15 mg / kg. In some embodiments, an individual is administered an initial dose of about 60 mg / kg of an anti-Sortilin antibody, followed by one or more lower doses of the anti-Sortilin antibody, from about 6 mg / kg to about 59 mg / kg, from about 6 mg / kg to about 30 mg / kg, or from about 6 mg / kg to about 15 mg / kg. In some embodiments, an individual is administered a lower initial dose of an anti-Sortilin antibody, followed by one or more higher doses of the anti-Sortilin antibody. In some embodiments, an individual is administered an initial dose of about 6 mg / kg of an anti-Sortilin antibody, followed by one or more higher doses of the anti-Sortilin antibody, from about 7 mg / kg to about 30 mg / kg, from about 15 mg / kg to about 30 mg / kg, or from about 30 mg / kg to about 60 mg / kg.
[0226] As will be understood by one of skill in the art, other dosing regimens can also be used in accordance with the methods provided herein, e.g., according to methods known in the art, e.g., based on monitoring of the individual and / or disease or disorder being treated as described herein.
[0227] Sortilin antibodies In some aspects, the disclosure provides anti-Sortilin antibodies that bind to Sortilin, e.g., human Sortilin protein or mammalian Sortilin protein.
[0228] Sortilin protein In some aspects, the present disclosure provides anti-Sortilin antibodies that bind to the Sortilin protein. Sortilin is variously referred to as Sortilin 1, sort1, SORT1, 100kDa NT receptor, glycoprotein 95 (GP95), progranulin receptor (PGRN-R), and neurotensin receptor 3 (NT-3 or NTR-3). Sortilin is an 831-amino acid protein that encodes a type I membrane receptor. Various Sortilin homologs are known, including, but not limited to, human Sortilin, rat Sortilin, cynomolgus monkey Sortilin, and mouse Sortilin. The amino acid sequence of human Sortilin is shown below as SEQ ID NO: 1 (key amino acid residues predicted to be involved in Progranulin binding are shown in bold, and the predicted proNGF binding region is underlined). TIFF2023553399000003.tif147152
[0229] Furthermore, the amino acid sequence of mouse sortilin is shown in SEQ ID NO:2. TIFF2023553399000004.tif14153TIFF2023553399000005.tif48153
[0230] Furthermore, the amino acid sequence of rat sortilin is shown in SEQ ID NO:3. TIFF2023553399000006.tif62153
[0231] Furthermore, the amino acid sequence of cynomolgus monkey sortilin is shown in SEQ ID NO:27. TIFF2023553399000007.tif54164
[0232] In some embodiments, antibodies of the present disclosure bind to mammalian Sortilin protein, human Sortilin protein, primate Sortilin protein (e.g., cynomolgus monkey Sortilin), mouse Sortilin protein, and / or rat Sortilin protein. In some embodiments, antibodies of the present disclosure may bind to an epitope within one or more of mammalian Sortilin protein, human Sortilin protein, primate Sortilin protein (e.g., cynomolgus monkey Sortilin), mouse Sortilin protein, and rat Sortilin protein. In some embodiments, antibodies of the present disclosure bind to human Sortilin. In some embodiments, antibodies of the present disclosure bind to mouse Sortilin. In some embodiments, antibodies of the present disclosure bind to cynomolgus monkey Sortilin. In some embodiments, antibodies of the present disclosure bind to human Sortilin and mouse Sortilin. In some embodiments, antibodies of the present disclosure bind to human Sortilin, mouse Sortilin, and cynomolgus monkey.
[0233] In some embodiments, the Sortilin protein is a preprotein that includes a signal sequence. In some embodiments, the Sortilin protein is a mature protein. In some embodiments, the mature Sortilin protein does not include a signal sequence. In some embodiments, the mature Sortilin protein is expressed in the cell.
[0234] The sortilin protein of the present disclosure includes several domains, including, but not limited to, a signal sequence, a propeptide, a luminal domain, and a Vps10p domain, including, for example, an Asp box motif, a 10-bladed β-propeller structure, a hydrophobic loop, a 10CC domain, a transmembrane domain, and a cytoplasmic domain. Furthermore, the sortilin protein of the present disclosure is expressed at high levels in multiple tissues, including, but not limited to, the brain, spinal cord, heart and skeletal muscle, thyroid, placenta, and testis. Sortilin is a member of the Vps10p family of sorting receptors, which also includes, but is not limited to, sorting protein-associated receptor with A-type repeats (SorLA), sortilin-related receptor CNS expression 1 (SorCS1), sortilin-related receptor CNS expression 2 (SorCS2), and sortilin-related receptor CNS expression 3 (SorCS3). In yeast Vps10p (Vps10p domain), the luminal region of sortilin is aligned with each of the two luminal domains. The Vps10p domain is characterized by an amino-terminal propeptide and a carboxy-terminal segment containing 10 conserved cysteine (10CC) residues. Other receptors in the Vps10p family share the amino-terminally located Vps10p domain and contain an additional ectodomain.
[0235] Sorting receptors of the Vps10p family have diverse functions both within the nervous system and elsewhere. These receptors bind several different ligands, including, but not limited to, progranulin (PGRN), pro-nerve growth factor (proNGF), nerve growth factor (NGF), PCSK9, proneurotrophin, neurotrophin, proneurotrophin-3 (proNT3), proneurotrophin-4 / 5, pro-brain-derived neurotrophic factor (proBDNF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT3), neurotrophin-4 / 5, neurotensin, p75NTR, sortilin propeptide (Sort-pro), amyloid protein precursor (APP), lipoprotein lipase (LpL), apolipoproteins, apolipoprotein AV (apoA5), apolipoprotein E (apoE2, 3, 4), receptor-associated protein (RAP), and elements of the plasminogen activator system; and have been shown to be multifunctional, involved in intracellular sorting, endocytosis, and signal transduction. The sortilin protein of the present disclosure has been shown to mediate the rapid endocytosis of lipoprotein lipase, neurotensin, and pro-form of nerve growth factor, and to direct proteins to transport from the Golgi to late endosomes.Furthermore, the sortilin protein of the present disclosure has been shown to form a complex with p75 on the cell membrane and to be essential for pro-nerve growth factor (NGF)-induced neuronal cell death.Recently, members of the Vps10p receptor family have also been shown to interact with members of the neurotrophin family, including NGF, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 / 5, or pro-domain forms of neurotrophins (pro-neurotrophins).The sortilin protein of the present disclosure has also been shown to bind to and regulate the extracellular levels of PCSK9, which directs the low-density lipoprotein receptor for degradation in lysosomes, resulting in increased LDL cholesterol levels.
[0236] As disclosed herein, the interaction of a Sortilin protein of the disclosure with a proneurotrophin or neurotrophin is mediated by a Vps10p domain comprising a ten-bladed beta-propeller structure and an Asp-box motif. In certain embodiments, a Sortilin protein of the disclosure comprises a Vps10p domain that comprises a ten-bladed beta-propeller structure and is located within amino acid residues 78-611 of human Sortilin (SEQ ID NO: 1) or amino acid residues of a mammalian Sortilin that correspond to amino acid residues 78-611 of SEQ ID NO: 1. In certain embodiments, amino acid residues 190-220 of human Sortilin (SEQ ID NO: 1) or mammalian Sortilin that correspond to amino acid residues 190-220 of SEQ ID NO: 1 are located within the Vps10p domain.
[0237] The Vps10p domain of the present disclosure can comprise an Asp box motif. As used herein, the Asp box motif has the following sequence: (S / T)-X-(D / N)-XXXX-(W / F / Y) (SEQ ID NO: 22), or XX-(S / T)-X-(D / N)-XGX-(T / S)-(W / F / Y)-X (SEQ ID NO: 23), where X represents any amino acid. In human sortilin, the Asp box motif is located at amino acid residues 200-207 (SSDFAKNF (SEQ ID NO: 24)). Thus, in certain embodiments, the Asp box motif is located at amino acid residues 200-207 of human sortilin (SEQ ID NO: 1) or at amino acid residues in a mammalian sortilin that correspond to amino acid residues 200-207 of SEQ ID NO: 1.
[0238] As disclosed herein, the interaction of the disclosed sortilin proteins with p75 is mediated by the 10CC domain of the hydrophobic loop of the Vps10p domain.
[0239] In certain embodiments, a Sortilin protein of the disclosure comprises a 10CC domain located within amino acid residues 610-757 of human Sortilin (SEQ ID NO: 1) or amino acid residues of a mammalian Sortilin corresponding to amino acid residues 610-757 of SEQ ID NO: 1. In some embodiments, amino acid residues 592-593, 610-660, and / or 667-749 of human Sortilin (SEQ ID NO: 1) or amino acid residues of a mammalian Sortilin corresponding to amino acid residues 592-593, 610-660, and / or 667-749 of SEQ ID NO: 1 are located within the 10CC domain of Sortilin.
[0240] In other embodiments, a sortilin protein of the present disclosure comprises a hydrophobic loop within the Vps10p domain located within amino acid residues 130-141 of human sortilin (SEQ ID NO:1) or amino acid residues of a mammalian sortilin corresponding to amino acid residues 130-141 of SEQ ID NO:1.
[0241] As will be recognized by one of skill in the art, the beginning and ending residues of a domain of the present disclosure may vary depending on the computer modeling program used or the method used to determine the domain.
[0242] Exemplary Anti-Sortilin Antibodies In some embodiments, the anti-Sortilin antibodies used in the methods of the present disclosure are described in WO2016164637A1, which is incorporated herein by reference.
[0243] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises: (a) HVR-H1 comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 6; (b) HVR-H1 comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 6; HVR-H2 comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO:7; and (c) HVR-H3 comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO:8. and / or the light chain variable domain comprises one or more of: (a) an HVR-H3 comprising an amino acid sequence having at least 1%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 9; and / or the light chain variable domain comprises one or more of: (a) an HVR-H3 comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 9; (b) an HVR-L1 comprising an amino acid sequence having at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 10; (b) an HVR-L2 comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO: 10;and (c) one or more of HVR-L3 comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to SEQ ID NO:11;
[0244] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises HVR-H1, HVR-H2, and HVR-H3, and the light chain variable domain comprises HVR-L1, HVR-L2, and HVR-L3. In some embodiments, the anti-Sortilin antibody comprises HVR-H1 comprising an amino acid sequence that comprises substitutions (e.g., conservative substitutions, insertions, or deletions) relative to the amino acid sequence YTFTKYYMS (SEQ ID NO: 6), while retaining the ability to bind to Sortilin. In certain embodiments, up to 1, 2, 3, 4, 5, or 6 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence YTFTKYYMS (SEQ ID NO: 6). In some embodiments, an anti-Sortilin antibody comprises an HVR-H2 comprising an amino acid sequence that comprises a substitution (e.g., a conservative substitution, insertion, or deletion) relative to the amino acid sequence IINPIGGSTSYAQKFQG (SEQ ID NO: 7), but retains the ability to bind to Sortilin. In certain embodiments, up to 1, 2, 3, 4, 5, or 6 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence IINPIGGSTSYAQKFQG (SEQ ID NO: 7). In some embodiments, an anti-Sortilin antibody comprises an HVR-H3 comprising an amino acid sequence that comprises (e.g., a conservative substitution, insertion, or deletion) relative to the amino acid sequence ARDPSGIALAGPASRGYQGMDV (SEQ ID NO: 8), but retains the ability to bind to Sortilin. In certain embodiments, up to 1, 2, 3, 4, 5, or 6 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence ARDPSGIALAGPASRGYQGMDV (SEQ ID NO: 8). In some embodiments, the anti-Sortilin antibody comprises an HVR-L1 comprising an amino acid sequence that includes substitutions (e.g., conservative substitutions, insertions, or deletions) relative to the amino acid sequence RASQSVSSNLA (SEQ ID NO: 9), but retains the ability to bind to Sortilin. In particular embodiments, up to 1, up to 2, up to 3, up to 4, up to 5, or up to 6 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence RASQSVSSNLA (SEQ ID NO: 9).In some embodiments, the anti-Sortilin antibody comprises an HVR-L2 comprising an amino acid sequence that comprises a substitution (e.g., a conservative substitution, insertion, or deletion) relative to the amino acid sequence GASTRAT (SEQ ID NO: 10), yet retains the ability to bind to Sortilin. In certain embodiments, up to 1, 2, 3, 4, 5, or 6 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence GASTRAT (SEQ ID NO: 10). In some embodiments, the anti-Sortilin antibody comprises an HVR-L3 comprising an amino acid sequence that comprises a substitution (e.g., a conservative substitution, insertion, or deletion) relative to the amino acid sequence QQARLGPWT (SEQ ID NO: 11), yet retains the ability to bind to Sortilin. In certain embodiments, up to 1, 2, 3, 4, 5, or 6 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence QQARLGPWT (SEQ ID NO: 11).
[0245] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises HVR-H1 comprising the amino acid sequence YTFTKYYMS (SEQ ID NO: 6), HVR-H2 comprising the amino acid sequence IINPIGGSTSYAQKFQG (SEQ ID NO: 7), and HVR-H3 comprising the amino acid sequence ARDPSGIALAGPASRGYQGMDV (SEQ ID NO: 8), and the light chain variable domain comprises HVR-L1 comprising the amino acid sequence RASQSVSSNLA (SEQ ID NO: 9), HVR-L2 comprising the amino acid sequence GAST rat (SEQ ID NO: 10), and HVR-L3 comprising the amino acid sequence QQARLGPWT (SEQ ID NO: 11).
[0246] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain (a) matches at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least (b) an HVR-H2 amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the HVR-H2 amino acid sequence of antibody S-15-10-7. and (c) an HVR-H3 comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the HVR-H3 amino acid sequence of antibody S-15-10-7. and / or the light chain variable domain comprises: (a) an HVR-L1 comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the HVR-L1 amino acid sequence of antibody S-15-10-7;(b) an HVR-L2 comprising an amino acid sequence at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the HVR-L2 amino acid sequence of antibody S-15-10-7; and (c) an HVR-L3 comprising an amino acid sequence at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the HVR-L3 amino acid sequence of antibody S-15-10-7;
[0247] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises HVR-H1, HVR-H2, and HVR-H3, and the light chain variable domain comprises HVR-L1, HVR-L2, and HVR-L3. In some embodiments, an anti-Sortilin antibody comprises an HVR-H1 that comprises an amino acid sequence that comprises substitutions (e.g., conservative substitutions, insertions, or deletions) relative to the HVR-H1 amino acid sequence of antibody S-15-10-7, while retaining the ability to bind to Sortilin. In certain embodiments, up to 1, 2, 3, 4, 5, or 6 amino acids have been substituted, inserted, and / or deleted in the HVR-H1 amino acid sequence of antibody S-15-10-7. In some embodiments, the anti-Sortilin antibody comprises an HVR-H2 comprising an amino acid sequence that comprises substitutions (e.g., conservative substitutions, insertions, or deletions) relative to the HVR-H2 amino acid sequence of antibody S-15-10-7, yet retains the ability to bind to Sortilin. In certain embodiments, up to 1, 2, 3, 4, 5, or 6 amino acids have been substituted, inserted, and / or deleted in the HVR-H2 amino acid sequence of antibody S-15-10-7. In some embodiments, the anti-Sortilin antibody comprises an HVR-H3 comprising an amino acid sequence that comprises substitutions (e.g., conservative substitutions, insertions, or deletions) relative to the HVR-H3 amino acid sequence of antibody S-15-10-7, yet retains the ability to bind to Sortilin. In certain embodiments, up to 1, 2, 3, 4, 5, or 6 amino acids have been substituted, inserted, and / or deleted in the HVR-H3 amino acid sequence of antibody S-15-10-7. In some embodiments, the anti-Sortilin antibody comprises an HVR-L1 that comprises an amino acid sequence that includes substitutions (e.g., conservative substitutions, insertions, or deletions) relative to the HVR-L1 amino acid sequence of antibody S-15-10-7, but retains the ability to bind to Sortilin. In certain embodiments, up to 1, 2, 3, 4, 5, or 6 amino acids have been substituted, inserted, and / or deleted in the HVR-L1 amino acid sequence of antibody S-15-10-7.In some embodiments, the anti-Sortilin antibody comprises an HVR-L2 comprising an amino acid sequence that comprises a substitution (e.g., a conservative substitution, insertion, or deletion) relative to the HVR-L2 amino acid sequence of antibody S-15-10-7, yet retains the ability to bind to Sortilin. In certain embodiments, up to 1, 2, 3, 4, 5, or 6 amino acids have been substituted, inserted, and / or deleted in the HVR-L2 amino acid sequence of antibody S-15-10-7. In some embodiments, the anti-Sortilin antibody comprises an HVR-L3 comprising an amino acid sequence that comprises a substitution (e.g., a conservative substitution, insertion, or deletion) relative to the HVR-L3 amino acid sequence of antibody S-15-10-7, yet retains the ability to bind to Sortilin. In certain embodiments, up to 1, up to 2, up to 3, up to 4, up to 5, or up to 6 amino acids have been substituted, inserted, and / or deleted in the HVR-L3 amino acid sequence of antibody S-15-10-7.
[0248] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises HVR-H1 comprising the HVR-H1 amino acid sequence of antibody S-15-10-7, HVR-H2 comprising the HVR-H2 amino acid sequence of antibody S-15-10-7, and HVR-H3 comprising the HVR-H3 amino acid sequence of antibody S-15-10-7; and the light chain variable domain comprises HVR-L1 comprising the HVR-L1 amino acid sequence of antibody S-15-10-7, HVR-L2 comprising the HVR-L2 amino acid sequence of antibody S-15-10-7, and HVR-L3 comprising the HVR-L3 amino acid sequence of antibody S-15-10-7.
[0249] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises one, two, three, or four framework regions (FR) selected from VH FR1, VH FR2, VH FR3, and VH FR4, wherein VH FR1 comprises the amino acid sequence of SEQ ID NO: 12, VH FR2 comprises the amino acid sequence of SEQ ID NO: 13, VH FR3 comprises the amino acid sequence of SEQ ID NO: 14, and VH FR4 comprises the amino acid sequence of SEQ ID NO: 15; and / or the light chain variable domain comprises one, two, three, or four framework regions selected from VL FR1, VL FR2, VL FR3, and VL FR4, wherein VL FR1 comprises the amino acid sequence of SEQ ID NO: 16, VL FR2 comprises the amino acid sequence of SEQ ID NO: 17, VL FR3 comprises the amino acid sequence of SEQ ID NO: 18, and VL FR4 comprises the amino acid sequence of SEQ ID NO: 19.
[0250] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:20; and / or the light chain variable domain comprises an amino acid sequence at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:21.
[0251] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 20, and the heavy chain variable domain comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 6, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 8. and / or the light chain variable domain comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 9, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 11; and / or the light chain variable domain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 21, and the light chain variable domain comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 9, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 11.
[0252] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 20, and the heavy chain variable domain comprises HVR-H1 comprising the HVR-H1 amino acid sequence of antibody S-15-10-7, HVR-H2 comprising the HVR-H2 amino acid sequence of antibody S-15-10-7, and HVR-H3 comprising the HVR-H4 amino acid sequence of antibody S-15-10-7. and / or the light chain variable domain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 21, and the light chain variable domain comprises an HVR-L1 comprising the HVR-L1 amino acid sequence of antibody S-15-10-7, an HVR-L2 comprising the HVR-L2 amino acid sequence of antibody S-15-10-7, and an HVR-L3 comprising the HVR-L3 amino acid sequence of antibody S-15-10-7.
[0253] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain matches at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or the heavy chain variable domain amino acid sequence of antibody S-15-10-7. and / or the light chain variable domain comprises an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the light chain variable domain amino acid sequence of antibody S-15-10-7.
[0254] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the heavy chain variable domain amino acid sequence of antibody S-15-10-7, and wherein the heavy chain variable domain comprises HVR-H1 comprising the HVR-H1 amino acid sequence of antibody S-15-10-7, HVR-H2 comprising the HVR-H2 amino acid sequence of antibody S-15-10-7, and HVR-H3 comprising the HVR-H4 amino acid sequence of antibody S-15-10-7. and / or the light chain variable domain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the light chain variable domain amino acid sequence of antibody S-15-10-7, wherein the light chain variable domain comprises HVR-L1 comprising the HVR-L1 amino acid sequence of antibody S-15-10-7, HVR-L2 comprising the HVR-L2 amino acid sequence of antibody S-15-10-7, and HVR-L3 comprising the HVR-L3 amino acid sequence of antibody S-15-10-7.
[0255] In some embodiments, an anti-Sortilin antibody of the present disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 20, and includes substitutions (e.g., conservative substitutions, insertions, or deletions relative to SEQ ID NO: 20), but wherein an anti-Sortilin antibody comprising that sequence retains the ability to bind to Sortilin. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence of SEQ ID NO: 20. In certain embodiments, a total of 1 to 6 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence of SEQ ID NO: 20. In certain embodiments, the substitutions, insertions, or deletions are found in regions outside of the HVRs (i.e., within the FR regions). In some embodiments, the substitutions, insertions, or deletions are found in one or more FR regions (i.e., VH FR1, VH FR2, VH FR3, and / or VH FR4). In certain embodiments, the substitutions, insertions, or deletions are found in one or more HVRs (i.e., HVR-H1, HVR-H2, and / or HVR-H3). In some embodiments, the anti-Sortilin antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 20, including post-translational modifications of that sequence.
[0256] In some embodiments, an anti-Sortilin antibody of the present disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 21, and contains substitutions (e.g., conservative substitutions, insertions, or deletions relative to SEQ ID NO: 21), but wherein an anti-Sortilin antibody comprising the sequence retains the ability to bind to Sortilin. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence of SEQ ID NO: 21. In certain embodiments, a total of 1 to 6 amino acids have been substituted, inserted, and / or deleted in the amino acid sequence of SEQ ID NO: 21. In certain embodiments, the substitutions, insertions, or deletions are found in regions outside of the HVRs (i.e., within the FR regions). In some embodiments, the substitutions, insertions, or deletions are found in one or more FR regions (i.e., VL FR1, VL FR2, VL FR3, and / or VL FR4). In certain embodiments, the substitutions, insertions, or deletions are found in one or more HVRs (i.e., HVR-L1, HVR-L2, and / or HVR-L3). In some embodiments, the anti-Sortilin antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 21, including post-translational modifications of that sequence.
[0257] In some embodiments, an anti-Sortilin antibody of the present disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the heavy chain variable domain amino acid sequence of antibody S-15-10-7, and contains substitutions (e.g., conservative substitutions, insertions, or deletions relative to the heavy chain variable domain amino acid sequence of antibody S-15-10-7), but wherein an anti-Sortilin antibody comprising that sequence retains the ability to bind to Sortilin. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in the heavy chain variable domain amino acid sequence of antibody S-15-10-7. In certain embodiments, a total of 1 to 6 amino acids are substituted, inserted, and / or deleted in the heavy chain variable domain amino acid sequence of antibody S-15-10-7. In certain embodiments, the substitutions, insertions, or deletions are found in regions outside of the HVRs (i.e., within the FR regions). In some embodiments, the substitutions, insertions, or deletions are found in one or more FR regions (i.e., VH FR1, VH FR2, VH FR3, and / or VH FR4). In certain embodiments, the substitutions, insertions, or deletions are found in one or more HVRs (i.e., HVR-H1, HVR-H2, and / or HVR-H3). In some embodiments, the anti-Sortilin antibody comprises a heavy chain variable domain comprising the heavy chain variable domain amino acid sequence of antibody S-15-10-7, including post-translational modifications of that sequence.
[0258] In some embodiments, an anti-Sortilin antibody of the present disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain comprises an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the light chain variable domain amino acid sequence of antibody S-15-10-7, and contains substitutions (e.g., conservative substitutions, insertions, or deletions relative to the light chain variable domain amino acid sequence of antibody S-15-10-7), but wherein an anti-Sortilin antibody comprising that sequence retains the ability to bind to Sortilin. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in the light chain variable domain amino acid sequence of antibody S-15-10-7. In certain embodiments, a total of 1 to 6 amino acids are substituted, inserted, and / or deleted in the light chain variable domain amino acid sequence of antibody S-15-10-7. In certain embodiments, the substitutions, insertions, or deletions are found in regions outside of the HVRs (i.e., within the FR regions). In some embodiments, the substitutions, insertions, or deletions are found in one or more FR regions (i.e., VL FR1, VL FR2, VL FR3, and / or VL FR4). In certain embodiments, the substitutions, insertions, or deletions are found in one or more HVRs (i.e., HVR-L1, HVR-L2, and / or HVR-L3). In some embodiments, the anti-Sortilin antibody comprises a light chain variable domain comprising the light chain variable domain amino acid sequence of antibody S-15-10-7, including post-translational modifications of that sequence.
[0259] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:20 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:21.
[0260] In some embodiments, an anti-Sortilin antibody of the disclosure comprises a heavy chain variable domain comprising the heavy chain variable domain amino acid sequence of antibody S-15-10-7 and a light chain variable domain comprising the light chain variable domain amino acid sequence of antibody S-15-10-7.
[0261] In some embodiments, an anti-Sortilin antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 or 32 and a light chain comprising the amino acid sequence of SEQ ID NO: 30. In some embodiments, an anti-Sortilin antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 and a light chain comprising the amino acid sequence of SEQ ID NO: 30. In some embodiments, an anti-Sortilin antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 32 and a light chain comprising the amino acid sequence of SEQ ID NO: 30.
[0262] In some embodiments, the anti-Sortilin antibody of the present disclosure is the anti-Sortilin antibody S-15-10-7, as described in, for example, WO2016164637A1, the entire contents of which are incorporated herein by reference.
[0263] [Table 1] TIFF2023553399000009.tif132162TIFF2023553399000010.tif131161
[0264] In some aspects, the present disclosure also provides antibodies that bind to Sortilin protein. In some embodiments, the antibody of the present disclosure is any of the anti-Sortilin antibodies described in the "Exemplary Anti-Sortilin Antibodies" section herein. In some embodiments, the antibody binds to human Sortilin and / or mammalian Sortilin protein. In some embodiments, the antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:20 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:21. In some embodiments, the antibody is of the human IgG1 isotype. In some embodiments, the antibody comprises an Fc region comprising amino acid substitutions L234A, L235A, and P331S, where the numbering of residue positions is according to EU numbering. In some embodiments, the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:30 and a heavy chain comprising the amino acid sequence of SEQ ID NO:31. In some embodiments, the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:30 and a heavy chain comprising the amino acid sequence of SEQ ID NO:32.
[0265] Anti-Sortilin antibody binding region In some embodiments, anti-Sortilin antibodies of the disclosure bind to one or more amino acids within amino acid residues 237-247 of human Sortilin, or amino acid residues on the Sortilin protein that correspond to amino acid residues 237-247 of human Sortilin. In some embodiments, anti-Sortilin antibodies of the disclosure bind to one or more amino acids within amino acid residues 237-247 of SEQ ID NO:1, or amino acid residues on the protein that correspond to amino acid residues 237-247 of SEQ ID NO:1.
[0266] In some embodiments, anti-Sortilin antibodies of the disclosure bind to amino acid residues 314-338 of human Sortilin, or one or more amino acids within the amino acid residues on the Sortilin protein that correspond to amino acid residues 314-338 of human Sortilin. In some embodiments, anti-Sortilin antibodies of the disclosure bind to one or more amino acids within amino acid residues 314-338 of SEQ ID NO:1, or the amino acid residues on the protein that correspond to amino acid residues 314-338 of SEQ ID NO:1.
[0267] In some embodiments, anti-Sortilin antibodies of the disclosure bind to one or more amino acids within amino acid residues 237-247 and 314-338 of human Sortilin, or amino acid residues on the Sortilin protein that correspond to amino acid residues 237-247 and 314-338 of human Sortilin. In some embodiments, anti-Sortilin antibodies of the disclosure bind to one or more amino acids within amino acid residues 237-247 and 314-338 of SEQ ID NO:1, or amino acid residues on the protein that correspond to amino acid residues 237-247 and 314-338 of SEQ ID NO:1.
[0268] In some embodiments, anti-Sortilin antibodies of the disclosure bind to one or more amino acids within the amino acid sequence NGLWVSKNFGG (SEQ ID NO: 4) of a Sortilin protein, such as human Sortilin. In some embodiments, anti-Sortilin antibodies of the disclosure bind to one or more amino acids within the amino acid sequence FASVMADKDTTRRIHVSTDQGDTWS (SEQ ID NO: 5) of a Sortilin protein, such as human Sortilin. In some embodiments, anti-Sortilin antibodies of the disclosure bind to one or more amino acids within the amino acid sequence NGLWVSKNFGG (SEQ ID NO: 4) and the amino acid sequence FASVMADKDTTRRIHVSTDQGDTWS (SEQ ID NO: 5) of a Sortilin protein, such as human Sortilin.
[0269] In some embodiments, the anti-Sortilin antibodies of the present disclosure bind to one or more amino acids within the beta propeller domain of a Sortilin protein, such as a human Sortilin protein.
[0270] Anti-Sortilin antibody binding affinity Anti-Sortilin antibodies of the disclosure can have micromolar, nanomolar, or picomolar affinities for a target antigen (e.g., human sortilin or mammalian sortilin).
[0271] In certain embodiments, the binding affinity of an anti-Sortilin antibody of the disclosure to a target antigen (e.g., human Sortilin or mammalian Sortilin) is greater than or equal to a dissociation constant K D The dissociation constant is measured by any analytical technique known in the art, including fluorescence-activated cell sorting (FACS), flow cytometry, enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), biolayer interferometry (e.g., Octet System by ForteBio), mesoscale discovery assays (e.g., MSD-SET), isothermal titration calorimetry (ITC), differential scanning calorimetry (DSC), circular dichroism (CD), stopped-flow assays, and colorimetric or fluorescent protein melting analysis; or a biochemical or biophysical technique such as a cell binding assay. In some embodiments, the dissociation constant (K) of sortilin (e.g., human sortilin or mammalian sortilin) is measured. D ) is determined at a temperature of approximately 25° C. In some embodiments, the dissociation constant (K D ) is determined at a temperature of approximately 4° C. In some embodiments, the dissociation constant (K D ) is measured, for example, at 4° C. or room temperature using FACS or a biolayer interference assay. In some embodiments, the dissociation constant (K) of sortilin (e.g., human sortilin or mammalian sortilin) is D ) is measured at 4° C. or room temperature using, for example, a cell binding assay, a ForteBio assay, or an MSD-SET assay.
[0272] In some embodiments of any of the antibodies provided herein, the antibody has an affinity for a target antigen (e.g., human sortilin or mammalian sortilin) of <1 μM, <100 nM, <10 nM, <1 nM, <0.1 nM, <0.01 nM, or <0.001 nM (e.g., 10 -8 M or less, e.g., 10 -8 M~10 -13 M, e.g., 10 -9 M~10 -13Dissociation constant (K D )
[0273] In certain embodiments, the K of the anti-Sortilin antibodies of the disclosure directed to human sortilin and / or mammalian sortilin, e.g., mouse sortilin or cynomolgus monkey sortilin, D is less than 100nM, less than 90nM, less than 80nM, less than 70nM, less than 60nM, less than 50nM, less than 40nM, less than 30nM, less than 20nM, less than 10nM, less than 9nM, less than 8nM, less than 7nM, less than 6nM, less than 5nM, less than 4nM, less than 3nM, less than 2nM, less than 1nM, less than 0.5nM, less than 0.1nM, less than 0.09nM, less than 0.08nM, less than 0.07nM nM, less than 0.06 nM, less than 0.05 nM, less than 0.04 nM, less than 0.03 nM, less than 0.02 nM, less than 0.01 nM, less than 0.009 nM, less than 0.008 nM, less than 0.007 nM, less than 0.006 nM, less than 0.005 nM, less than 0.004 nM, less than 0.003 nM, less than 0.002 nM, less than 0.001 nM, or less than 0.001 nM.
[0274] In some embodiments, antibodies of the disclosure bind to human sortilin with a dissociation constant ranging from about 0.005 nM to about 100 nM. In some embodiments, the antibodies of the disclosure have a dissociation constant (K) for human sortilin in the range of about 0.005 nM to about 1 nM, e.g., any of about 0.005 nM, about 0.006 nM, about 0.007 nM, about 0.008 nM, about 0.009 nM, about 0.01 nM, about 0.02 nM, about 0.03 nM, about 0.04 nM, about 0.05 nM, about 0.06 nM, about 0.07 nM, about 0.08 nM, about 0.09 nM, about 0.1 nM, about 0.2 nM, about 0.3 nM, about 0.4 nM, about 0.5 nM, about 0.6 nM, about 0.7 nM, about 0.8 nM, about 0.9 nM, or about 1 nM. DIn some embodiments, the antibodies of the present disclosure bind to human sortilin at a binding affinity in the range of about 1 nM to about 10 nM, e.g., about 1 nM, about 1.2 nM, about 1.4 nM, about 1.6 nM, about 1.8 nM, about 2 nM, about 2.2 nM, about 2.4 nM, about 2.6 nM, about 2.8 nM, about 3 nM, about 3.2 nM, about 3.4 nM, about 3.6 nM, about 3.8 nM, about 4 nM, about 4.2 nM, about 4.4 nM, about 4.6 nM, about 4.8 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, about 10 nM, about 11 nM, about 12 nM, about 13 nM, about 14 nM, about 15 nM, about 16 nM, about 17 nM, about 18 nM, about 19 nM, about 20 nM, about 21 nM, about 22 nM, about 23 nM, about 24 nM, about 25 nM, about 26 nM, about 27 nM, about 28 nM, about 29 nM, about 30 nM, about 31 nM, about 32 nM, about 33 nM, about 34 nM, about 35 nM, about 36 nM, about 37 nM, about 38 nM, about 39 nM, about 40 nM, about 41 nM, about 42 nM, about 43 nM, about 44 nM, about 45 nM, about 46 nM, about 47 nM, about 48 nM, about 49 nM, about 50 nM, a dissociation constant (K) of about 5.2 nM, about 5.4 nM, about 5.6 nM, about 5.8 nM, about 6 nM, about 6.2 nM, about 6.4 nM, about 6.6 nM, about 6.8 nM, about 7 nM, about 7.2 nM, about 7.4 nM, about 7.6 nM, about 7.8 nM, about 8 nM, about 8.2 nM, about 8.4 nM, about 8.6 nM, about 8.8 nM, about 9 nM, about 9.2 nM, about 9.4 nM, about 9.6 nM, about 9.8 nM, or about 10 nM D In some embodiments, the antibodies of the disclosure bind to human sortilin with a dissociation constant (K) of about 0.029 nM. D In some embodiments, the antibodies of the disclosure bind to human sortilin with a dissociation constant (K) of about 1.3 nM. D In some embodiments, the antibodies of the disclosure bind to human sortilin with a dissociation constant (K) of about 1.32 nM. D In some embodiments, the antibodies of the disclosure bind to human sortilin with a dissociation constant (K) of about 2.3 nM. D In some embodiments, the antibodies of the disclosure bind to human sortilin with a dissociation constant (K) of about 3.16 nM. D In some embodiments, the antibodies of the disclosure bind to human sortilin with a dissociation constant (K) of about 3.3 nM. D ) to join them.
[0275] In some embodiments, the antibodies of the disclosure have a dissociation constant (K) for mouse sortilin in the range of about 0.005 nM to about 100 nM. DIn some embodiments, the antibodies of the present disclosure bind to mouse sortilin at a binding affinity in the range of about 1 nM to about 10 nM, e.g., about 1 nM, about 1.2 nM, about 1.4 nM, about 1.6 nM, about 1.8 nM, about 2 nM, about 2.2 nM, about 2.4 nM, about 2.6 nM, about 2.8 nM, about 3 nM, about 3.2 nM, about 3.4 nM, about 3.6 nM, about 3.8 nM, about 4 nM, about 4.2 nM, about 4.4 nM, about 4.6 nM, about 4.8 nM, about a dissociation constant (K) of any of 5 nM, about 5.2 nM, about 5.4 nM, about 5.6 nM, about 5.8 nM, about 6 nM, about 6.2 nM, about 6.4 nM, about 6.6 nM, about 6.8 nM, about 7 nM, about 7.2 nM, about 7.4 nM, about 7.6 nM, about 7.8 nM, about 8 nM, about 8.2 nM, about 8.4 nM, about 8.6 nM, about 8.8 nM, about 9 nM, about 9.2 nM, about 9.4 nM, about 9.6 nM, about 9.8 nM, or about 10 nM D In some embodiments, the antibodies of the disclosure bind to mouse sortilin with a dissociation constant (K) of about 1.2 nM. D In some embodiments, the antibodies of the disclosure bind to mouse sortilin with a dissociation constant (K) of about 1.23 nM. D In some embodiments, the antibodies of the disclosure bind to mouse sortilin with a dissociation constant (K) of about 1.4 nM. D In some embodiments, the antibodies of the disclosure bind to mouse sortilin with a dissociation constant (K) of about 6.4 nM. D In some embodiments, the antibodies of the disclosure bind to mouse sortilin with a dissociation constant (K) of about 7.42 nM. D ) to join them.
[0276] In some embodiments, the dissociation constant (K) of an anti-Sortilin antibody of the disclosure to Sortilin (e.g., human Sortilin or mammalian Sortilin) is D) is determined using a ForteBio binding assay. In an exemplary ForteBio binding assay, affinity measurements are generally performed as previously described (Estep et al., MAbs. 2013 Mar-Apr;5(2):270-8). Briefly, ForteBio affinity measurements are performed by loading anti-Sortilin antibody onto an AHQ sensor online. The sensor is equilibrated offline with assay buffer for 30 minutes and then monitored online for 60 seconds to establish a baseline. For avidin binding measurements, the sensor with the loaded anti-Sortilin antibody is exposed to 100 nM of antigen (e.g., human sortilin or mammalian sortilin, e.g., human or mouse sortilin Fc fusion protein), and then transferred to assay buffer for dissociation rate measurements. Further avidin binding can be determined by loading biotinylated sortilin protein, e.g., human or mouse sortilin monomer, onto an SA sensor and exposing it to approximately 100 nM anti-Sortilin antibody in solution. Monovalent binding measurements can be obtained by loading Sortilin, e.g., human or mouse Sortilin Fc fusion protein, onto an AHQ sensor and then exposing it to about 100 nM of an anti-Sortilin antibody Fab. Further monovalent measurements can be obtained by loading biotinylated Sortilin protein, e.g., human or mouse Sortilin monomer, onto an SA sensor and then exposing it to about 100 nM of an anti-Sortilin antibody Fab in solution. Kinetic data can be fitted using 1:1 binding, for example, using a model in the data analysis software provided by ForteBio.
[0277] In some embodiments, the antibodies of the disclosure have a dissociation constant (K) for human sortilin of about 0.5 nM to about 2 nM, as measured, e.g., using a ForteBio assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind to human sortilin with a dissociation constant (K) of about 2 nM to about 4 nM, as measured, e.g., using a ForteBio assay, e.g., as described herein. DIn some embodiments, the antibodies of the disclosure bind to human sortilin with a dissociation constant (K) of about 0.9 nM, about 0.96 nM, about 0.98 nM, about 1 nM, about 1.18 nM, about 1.2 nM, or about 1.24 nM, as measured using, e.g., a ForteBio assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind with a dissociation constant (K) of about 2.3 nM or about 3.3 nM with respect to human sortilin, as measured, e.g., using a ForteBio assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind to mouse sortilin with a dissociation constant (K) of about 0.5 nM and about 2 nM, as measured, e.g., using a ForteBio assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind to mouse sortilin with a dissociation constant (K) of about 1 nM and about 8 nM, as measured using, e.g., a ForteBio assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind to mouse sortilin with a dissociation constant (K) of about 0.6 nM, about 0.68 nM, about 0.7 nM, about 0.76 nM, about 0.77 nM, about 0.8 nM, about 0.9 nM, about 1 nM, about 1.11 nM, or about 1.2 nM, as measured using, e.g., a ForteBio assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind to mouse sortilin with a dissociation constant (K) of about 1.4 nM or about 6.4 nM, as measured using, e.g., a ForteBio assay, e.g., as described herein. D ) to join them.
[0278] In some embodiments, the dissociation constant (K) of an anti-Sortilin antibody of the disclosure to Sortilin (e.g., human Sortilin or mammalian Sortilin) is D) is determined using a mesoscale discovery assay (see, e.g., MSD-SET). In an exemplary MSD-SET assay, equilibrium affinity measurements are performed as previously described (Estep et al., (2013) MAbs 5(2):270-8). Solution equilibrium titration (SET) was performed by holding the antigen (e.g., human sortilin or mammalian sortilin, e.g., biotinylated human sortilin or mouse sortilin) constant at 50 pM in PBS + 0.1% IgG-Free BSA (PBSF) and incubating with 3- to 5-fold serial dilutions of anti-sortilin antibody starting at 10 nM. Anti-sortilin antibody (20 nM in PBS) is coated onto a standard binding MSD-ECL plate overnight at 4°C or for 30 minutes at room temperature. The plate is then blocked for 30 minutes with shaking at 700 rpm, followed by three washes with wash buffer (PBSF + 0.05% Tween® 20). SET samples are applied to these plates and incubated for 150 seconds with shaking at 700 rpm, followed by one wash. Plate-captured antigen (e.g., human sortilin or mammalian sortilin, e.g., biotinylated human sortilin or mouse sortilin) is detected by incubating the plate with 250 ng / mL sulfo-tagged streptavidin in PBSF for 3 minutes. The plates are washed three times with wash buffer and then read on an MSD Sector Imager 2400 machine using 1× Read Buffer T with detergent. In Prism, the percent free antigen is plotted as a function of titered antibody and fitted to a quadratic equation to determine K D Extract.
[0279] In some embodiments, the antibodies of the disclosure have a dissociation constant (K) for human sortilin of about 0.02 nM to about 0.3 nM, as measured, e.g., using an MSD-SET assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind to human sortilin with a dissociation constant (K) of about 1 nM to about 5 nM, as measured, for example, using an MSD-SET assay, e.g., as described herein.D In some embodiments, the antibodies of the disclosure bind to human sortilin with a dissociation constant (K) of about 0.023 nM, about 0.032 nM, about 0.076 nM, about 0.19 nM, about 0.23 nM, or about 0.26 nM, as measured using, e.g., an MSD-SET assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind to human sortilin with a dissociation constant (K) of about 2.3 nM or about 3.3 nM, as measured, for example, using an MSD-SET assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind to mouse sortilin with a dissociation constant (K) of about 0.05 nM to about 0.2 nM, as measured using, e.g., an MSD-SET assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind to mouse sortilin with a dissociation constant (K) of about 1 nM to about 8 nM, as measured, e.g., using an MSD-SET assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind to mouse sortilin with a dissociation constant (K) of about 0.07 nM, about 0.1 nM, or about 0.11 nM, as measured using, e.g., an MSD-SET assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind to mouse sortilin with a dissociation constant (K) of about 1.4 nM, or about 6.4 nM, as measured using, e.g., an MSD-SET assay, e.g., as described herein. D ) to join them.
[0280] In some embodiments, the dissociation constant (K) of an anti-Sortilin antibody of the disclosure to Sortilin (e.g., human Sortilin or mammalian Sortilin) is D) is determined using a cellular assay, such as a cell binding assay. In an exemplary cell binding assay, cell binding affinity measurements are performed at 4°C using cells expressing human or mouse sortilin, such as HEK293T cells transiently transfected with mouse sortilin, or cells stably expressing human sortilin. Cells are harvested, washed with PBS, and the K of the antibody is measured. D The cells are incubated with an amount of antibody close to the K value. The antibody is diluted in FACS buffer (PBS + 2% FBS + 0.01% Na azide). After 1 hour of incubation on ice, the cells are washed three times with FACS buffer and incubated with an anti-human PE-conjugated secondary antibody (BD Biosciences, 1:100 dilution) on ice for 30 minutes. The cells are then washed twice with 200 μl FACS buffer and then analyzed on a FACS Canto or iQE FACS screening instrument (Intellicyt Corp). Binding to human and / or mouse sortilin is measured as the median fluorescence intensity (MFI) of PE. To determine the apparent affinity for cell-expressed sortilin, antibodies are added to the cells being titrated, for example, at 0.16-40 nM for human sortilin and 0.39-50 nM for mouse sortilin, and their binding K values are then calculated. D is determined by non-linear curve fitting (eg, using a modified OneSiteTotal, Graph Pad Prism).
[0281] In some embodiments, an antibody of the disclosure has a dissociation constant (K) of about 1 nM to about 10 nM (e.g., any of about 1 nM, about 2 nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, or about 10 nM) for human sortilin expressed on a cell, as measured, e.g., using a cell binding assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind to human sortilin expressed on cells with a dissociation constant (K) of about 2.17 nM, as measured, e.g., using a cell binding assay, e.g., as described herein. DIn some embodiments, the antibodies of the disclosure bind to human sortilin expressed on cells with a dissociation constant (K) of about 3.16 nM, as measured, e.g., using a cell binding assay, e.g., as described herein. D In some embodiments, an antibody of the disclosure binds to mouse sortilin expressed on a cell with a dissociation constant (K) of between about 1 nM and about 24 nM (e.g., any of about 1 nM, about 2 nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, about 10 nM, about 11 nM, about 12 nM, about 13 nM, about 14 nM, about 15 nM, about 16 nM, about 17 nM, about 18 nM, about 19 nM, about 20 nM, about 21 nM, about 22 nM, about 23 nM, or about 24 nM) when measured using, e.g., a cell binding assay, e.g., as described herein. D In some embodiments, the antibodies of the disclosure bind to mouse sortilin expressed on cells with a dissociation constant (K) of about 7.42 nM, as measured, e.g., using a cell binding assay, e.g., as described herein. D ) to join them.
[0282] In some embodiments, the K of the anti-Sortilin antibodies of the present disclosure directed to Sortilin D is determined, for example, using a monovalent antibody (e.g., a Fab) or a monovalent form of a full-length antibody as described herein. In some embodiments, K D is determined, for example, using a bivalent antibody and a monomeric recombinant sortilin protein as described herein.
[0283] Anti-sortilin antibody activity In certain aspects, anti-Sortilin antibodies of the present disclosure decrease cellular levels of Sortilin (e.g., cell surface levels of Sortilin, intracellular levels of Sortilin, and / or total levels of Sortilin); increase Progranulin levels (e.g., extracellular levels of Progranulin and / or cellular levels of Progranulin); and / or inhibit the interaction (e.g., binding) of Progranulin and Sortilin. In certain aspects, anti-Sortilin antibodies of the present disclosure increase extracellular levels of Progranulin and decrease cellular levels of Sortilin. In some embodiments, the decrease in cellular levels of Sortilin is a decrease in cell surface levels of Sortilin, a decrease in intracellular levels of Sortilin, a decrease in total levels of Sortilin, or any combination thereof. In some embodiments, the anti-Sortilin antibodies of the present disclosure (a) induce Sortilin degradation, Sortilin cleavage, Sortilin internalization, Sortilin downregulation, or any combination thereof; (b) inhibit the interaction of Sortilin with one or more proteins by reducing the effective level of Sortilin available for interaction with one or more proteins, by inducing Sortilin degradation, or both; (c) inhibit the interaction of Sortilin with Progranulin; (d) inhibit the interaction of Sortilin with pro-nerve growth factor (proNGF); (e) inhibit the interaction of Sortilin with pro-Nerve Growth Factor (proNGF) specifically against human Sortilin. (f) specifically bind to human Sortilin and mouse Sortilin, or specifically bind to human Sortilin, mouse Sortilin, and cynomolgus monkey Sortilin; (g) induce one or more Progranulin activities; (h) reduce endosomal internalization of Progranulin, or a fragment thereof; (i) increase the effective concentration of Progranulin; (j) inhibit the interaction of Sortilin and Progranulin expressed on cells; (k) reduce the expression of one or more pro-inflammatory mediators; and any combination thereof.
[0284] As contemplated herein, the anti-Sortilin antibodies of the present disclosure may also inhibit the interaction (e.g., binding) of Sortilin with one or more proteins, including, but not limited to, neurotrophins, such as proneurotrophin, proneurotrophin-3, neurotrophin-3, proneurotrophin-4 / 5, neurotrophin-4 / 5, pro-nerve growth factor (proNGF), nerve growth factor (NGF), pro-brain-derived neurotrophic factor (proBDNF), brain-derived neurotrophic factor (BDNF), and neurotrophin-4 (NT-4), neurotensin, low-affinity nerve growth factor (NGF) receptor (p75), lipoprotein lipase (LpL), apolipoprotein E (apoE), such as apolipoprotein AV (apoA5), apoE2, apoE3, and apoE4, amyloid protein precursor (APP), B-peptide, PCSK9, p75NTR, and receptor-associated protein (RAP).
[0285] Anti-Sortilin antibodies of the disclosure may also reduce expression of one or more pro-inflammatory mediators, including, but not limited to, cytokines, e.g., type I and II interferons, IL-6, IL12p70, IL12p40, IL-1β, TNF-α, IL-8, CRP, IL-20 family members, IL-33, LIF, OSM, CNTF, GM-CSF, IL-11, IL-12, IL-17, IL-18, CRP, and chemokines, e.g., CXCL1, CCL2, CCL3, CCL4, and CCL5.
[0286] Inhibition of the interaction between sortilin and progranulin Sortilin has been shown to directly interact with (e.g., bind to) Progranulin and mediate its degradation (e.g., Zheng, Y et al., (2011) PLoS ONE 6(6): e21023). In some embodiments, the antibodies of the present disclosure reduce, block, or inhibit the interaction between Sortilin and Progranulin.
[0287] In some embodiments, an anti-Sortilin antibody of the disclosure inhibits the interaction (e.g., binding) of Sortilin and Progranulin if it reduces the binding of Progranulin to Sortilin by 20% or more at a saturating antibody concentration as assessed using any method known in the art, such as any in vitro or cellular assay described herein or known in the art. In some embodiments, an anti-Sortilin antibody of the disclosure inhibits the interaction (e.g., binding) of Sortilin and Progranulin if it reduces the binding of Progranulin to Sortilin at a saturating antibody concentration as assessed using any in vitro or cellular assay described herein or known in the art compared to a control antibody.
[0288] In some embodiments, an anti-Sortilin antibody of the disclosure reduces binding of Progranulin to Sortilin by at least about 20%, at least about 21%, at least about 22%, at least about 23%, at least about 24%, at least about 25%, at least about 26%, at least about 27%, at least about 28%, at least about 29%, at least about 30%, at least about 31%, at least about 32%, at least about 33%, at least about 34%, at least about 35%, at least about 36%, at least about 37%, at least about 38%, at least about 39%, at least about 40%, at least about 41%, at least about 42%, at least about 43%, at least about 44%, at least about 45%, at least about 46%, at least about 47%, at least about 48%, at least about 49%, or at least about 50%. In some embodiments, the anti-Sortilin antibodies of the present disclosure reduce binding of Progranulin to Sortilin by at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100%. In some embodiments, the anti-Sortilin antibodies of the present disclosure reduce the binding of human Progranulin to human Sortilin by about 20% to about 50%, for example, by about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, or about 50%. In some embodiments, the anti-Sortilin antibodies of the present disclosure reduce the binding of human Progranulin to human Sortilin by about 21%. In some embodiments, the anti-Sortilin antibodies of the disclosure reduce the binding of human Progranulin to human Sortilin by about 36%.In some embodiments, an anti-Sortilin antibody of the present disclosure reduces binding of mouse Progranulin to mouse Sortilin by about 20% to about 50%, for example, by about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, or about 50%. In some embodiments, an anti-Sortilin antibody of the present disclosure reduces binding of mouse Progranulin to mouse Sortilin by about 21%. In some embodiments, the anti-Sortilin antibodies of the present disclosure reduce the binding of mouse Progranulin to mouse Sortilin by about 24%. In some embodiments, the binding of Progranulin to Sortilin, e.g., human Progranulin to human Sortilin or mouse Progranulin to mouse Sortilin, can be assessed using any method known in the art, such as any in vitro or cellular assay described herein or known in the art.
[0289] In some embodiments, the interaction, e.g., binding, between Sortilin and Progranulin can be evaluated using a cellular assay. In an exemplary cellular assay, recombinant human or mouse Progranulin (Adipogen) is biotinylated using the EZ-Link Micro NHS-PEG4 kit from ThermoScientific / Pierce according to the manufacturer's instructions. Cells expressing human or mouse Sortilin can be generated as known in the art. Sortilin-expressing cells or control cells are harvested and washed with PBS. Biotinylated human or mouse Progranulin is added to PBS+2% FBS with or without an anti-Sortilin antibody (10 μg / ml), e.g., an anti-Sortilin antibody of the present disclosure, or a control isotype antibody, and incubated on ice for 2 hours. After washing the cells three times with PBS+2% FBS, the cells are incubated in streptavidin-APC (BD Biosciences, 1:100) on ice for 30 minutes. The cells are then washed again, resuspended in PBS + 2% FBS, and analyzed by flow cytometry, for example, on a FACSCanto™ flow cytometer (BD Biosciences, Mississauga, ON). Progranulin binding is measured as the median fluorescence intensity of APCs in a Sortilin-expressing cell population. In some embodiments of the cellular assays described herein, human or mouse biotinylated Progranulin is used at increasing concentrations from 0 nM to about 100 nM. In some embodiments of the cellular assays described herein, human or mouse Sortilin-expressing cells are incubated with 15 nM biotinylated human or mouse Progranulin and 67 nM of an anti-Sortilin antibody, for example, an anti-Sortilin antibody of the present disclosure.
[0290] In some embodiments, the anti-Sortilin antibodies of the disclosure reduce the binding of human Progranulin to human Sortilin by between about 20% and about 50%, e.g., by any of about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, or about 50%, as assessed using a cellular assay, such as the cellular assays described herein. In some embodiments, the anti-Sortilin antibodies of the disclosure reduce the binding of human Progranulin to human Sortilin by about 21% as assessed using a cellular assay, such as the cellular assays described herein. In some embodiments, the anti-Sortilin antibodies of the disclosure reduce the binding of human Progranulin to human Sortilin by about 36% as assessed using a cellular assay, such as the cellular assays described herein. In some embodiments, an anti-Sortilin antibody of the disclosure reduces binding of mouse Progranulin to mouse Sortilin by about 20% to about 50%, e.g., by any of about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, or about 50%, as assessed using a cellular assay, such as the cellular assays described herein. In some embodiments, an anti-Sortilin antibody of the disclosure reduces the binding of mouse Progranulin to mouse Sortilin by about 21% as assessed using a cellular assay, such as the cellular assay described herein. In some embodiments, an anti-Sortilin antibody of the disclosure reduces the binding of mouse Progranulin to mouse Sortilin by about 24% as assessed using a cellular assay, such as the cellular assay described herein.
[0291] In some embodiments, the interaction between Sortilin and Progranulin can be evaluated using in vitro assay.For example, the interaction between Sortilin and Progranulin can be evaluated using ForteBio and surface plasmon resonance analysis (for example, Skeldal, S et al., (2012) J Biol Chem., 287:43798; and Andersen, OS et al., (2010) THE JOURNAL OF BIOLOGICAL CHEMISTRY, 285,12210-12222).In an exemplary assay, the interaction between Sortilin and Progranulin is characterized using surface plasmon resonance (SPR) analysis. Determination of the direct binding of human or mouse Progranulin to immobilized Sortilin, and the binding of human or mouse Sortilin to immobilized Progranulin in the presence or absence of the anti-Sortilin antibodies of the present disclosure, can be performed on a Biacore2000 instrument (Biacore, Sweden) using CaHBS as the standard running buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2 mM CaCl, 1 mM EGTA, and 0.005% Tween 20). Biosensor chips from Biacore (CM5, catalog number BR-1000-14) were activated using NHS / EDC, e.g., as described by the supplier, and then assayed to determine a protein density of 79 fmol / mm3. 2The flow cell can be coated with sortilin to a concentration of 0.01% and used for affinity measurements of native Progranulin protein. Regeneration of the flow cell after each cycle of the ligand binding experiment is performed with a single injection of two pulses of 10 μl regeneration buffer (10 mM glycine-HCl, pH 4.0, 500 mM NaCl, 20 mM EDTA, and 0.005% Tween 20) and 0.001% SDS. Fitting of the sensorgrams for affinity evaluation can be performed using BIAevaluation version 3.1. Following a similar protocol, immobilization of His-Progranulin was also performed on a CM5 biosensor chip using an NHS / EDC coupling kit (Biacore, Sweden) according to the manufacturer's instructions, resulting in a similar surface density of immobilized protein (approximately 300 fmol / mm). 2 ) can be obtained. The biosensor chip with immobilized Progranulin can also be used to examine the binding of Sortilin in the absence or presence of the anti-Sortilin antibodies of the present disclosure.
[0292] In some embodiments, the interaction between Sortilin and Progranulin can be evaluated using an immunoassay such as an ELISA assay. In an exemplary assay, human or mouse Sortilin (R&D Systems) is immobilized on an ELISA plate overnight (2 μg / ml in PBS). The plates are washed with washing buffer (PBS + 0.05% TWEEN 20) and blocked with binding buffer (PBS + 1% BSA) at 37°C for 1 hour. Recombinant human or mouse Progranulin (Adipogen) is biotinylated using the EZ-Link Micro NHS-PEG4 kit from ThermoScientific / Pierce. Biotinylated Progranulin is added at various concentrations to immobilize Sortilin and incubated at room temperature for 30 minutes. The plate is washed three times with washing buffer and incubated with streptavidin-HRP (1:200 in binding buffer, R&D Systems) for 20 minutes. The plate is washed three times again and incubated with TMB substrate solution until color develops. The reaction is stopped by adding 50 μl of 2N sulfuric acid and the color is quantified using a Biotek Synergy H1 plate reader. Data are analyzed and fitted in Prism.
[0293] In some embodiments, inhibition of the interaction between Progranulin and Sortilin by anti-Sortilin antibodies of the present disclosure is assessed using a competition assay, such as an in vitro competition assay. An exemplary competition assay uses the Forte Bio Octet Red384 system (Pall Forte Bio Corporation, Menlo Park, CA) with standard sandwich-format binning. A control anti-target IgG is loaded onto AHQ sensors, and unoccupied Fc binding sites on the sensors are blocked with an irrelevant IgG1 antibody. These sensors are then exposed to 100 nM of target antigen followed by a secondary anti-target antibody. Data are processed using ForteBio's data analysis software 7.0. Further binding of the secondary antibody after antigen association indicates an unoccupied epitope (non-competitor), while absence of binding indicates epitope blocking (competitor).
[0294] In some embodiments, the anti-Sortilin antibodies of the disclosure inhibit or reduce the interaction (e.g., binding) of Sortilin and Progranulin by reducing Sortilin levels or expression (e.g., as described herein).
[0295] In some embodiments, inhibition of the interaction (e.g., binding) of Sortilin and Progranulin by an antibody of the disclosure results in increased levels of Progranulin, e.g., as described below. In some embodiments, inhibition of the interaction (e.g., binding) of Sortilin and Progranulin by an antibody of the disclosure results in increased levels of extracellular Progranulin, e.g., as described below.
[0296] Decreased sortilin levels In some embodiments, the anti-Sortilin antibodies of the present disclosure reduce cellular levels of Sortilin. In some embodiments, the anti-Sortilin antibodies of the present disclosure reduce cellular levels of Sortilin by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100%, as assessed, for example, using any in vitro, cell-based, or in vivo method known in the art or described herein. In some embodiments, the reduction in cellular levels of Sortilin is a reduction in cell surface levels of Sortilin, a reduction in intracellular levels of Sortilin, a reduction in total levels of Sortilin, or any combination thereof.
[0297] In some embodiments, anti-Sortilin antibodies of the present disclosure reduce cell surface levels of Sortilin. Cell surface levels of Sortilin can be measured using any method known in the art, such as an in vitro cell assay or a suitable in vivo method. In some embodiments, anti-Sortilin antibodies of the present disclosure reduce cell surface levels of Sortilin if they show a 20% or greater reduction in cell surface levels of Sortilin, for example, when measured by any in vitro cell assay or suitable in vivo method described herein or known in the art. In some embodiments, anti-Sortilin antibodies of the present disclosure reduce cell surface levels of Sortilin if they show a reduction in cell surface levels of Sortilin at saturating antibody concentrations and / or compared to a control antibody, when measured by any in vitro cell assay or suitable in vivo method described herein or known in the art.
[0298] In an exemplary cell assay, cells expressing sortilin, such as human U-251 cells or mouse Neuro-2A (N2A) cells, are incubated with 50 nM of an anti-sortilin antibody for 72 hours. The cells are then harvested with trypsin, washed with PBS, and labeled with another primary anti-sortilin antibody (e.g., at a concentration of about 5 μg / ml). After incubating the cells with the primary antibody on ice for 1 hour, the cells are washed three times with PBS+2% FBS and then incubated with a secondary antibody, such as 5 μg / ml of an anti-human PE secondary antibody (Southern Biotech) or another suitable secondary antibody. The cells are then washed again, and cell surface sortilin levels are quantified using flow cytometry, for example, using a FACSCanto™ system, and measured as the median fluorescence intensity of PE.
[0299] In some embodiments, an antibody of the present disclosure induces at least about a 20%, at least about a 25%, at least about a 30%, at least about a 35%, at least about a 40%, at least about a 45%, at least about a 50%, at least about a 55%, at least about a 60%, at least about a 65%, at least about a 70%, at least about a 75%, at least about a 80%, at least about a 85%, at least about a 90%, at least about a 95%, at least about a 99%, or 100% reduction in cell surface levels of sortilin, as assessed, e.g., using an in vitro cell assay, e.g., as described herein. In some embodiments, an antibody of the present disclosure induces at least about a 51.6% reduction in cell surface levels of sortilin, as assessed, e.g., using an in vitro cell assay, e.g., as described herein. In some embodiments, an antibody of the present disclosure induces at least about a 87.82% reduction in cell surface levels of sortilin, as assessed, e.g., using an in vitro cell assay, e.g., as described herein. In some embodiments, the antibodies of the disclosure induce at least about an 89% reduction in cell surface levels of Sortilin, as assessed, e.g., using an in vitro cell assay, e.g., as described herein, using an anti-Sortilin antibody concentration of about 0.63 nM.
[0300] In some embodiments, cell surface levels of Sortilin may be assessed in vivo on, e.g., macrophages, dendritic cells, and / or leukocytes from an individual treated with an anti-Sortilin antibody of the present disclosure. Optionally, cell surface levels of human Sortilin may be assessed in vivo on, e.g., macrophages, dendritic cells, and / or leukocytes from a human treated with an anti-Sortilin antibody of the present disclosure. Optionally, cell surface levels of mouse Sortilin may be assessed in vivo on, e.g., macrophages, dendritic cells, and / or leukocytes from a mouse treated with an anti-Sortilin antibody of the present disclosure. Optionally, cell surface levels of cynomolgus monkey Sortilin may be assessed in vivo on, e.g., macrophages, dendritic cells, and / or leukocytes from a cynomolgus monkey treated with an anti-Sortilin antibody of the present disclosure. In some embodiments, the anti-Sortilin antibodies of the disclosure induce a decrease in cell surface levels of Sortilin of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100%, e.g., as measured by any in vivo method described herein or known in the art.
[0301] In some embodiments, anti-Sortilin antibodies of the present disclosure reduce intracellular levels of Sortilin. Intracellular levels of Sortilin can be measured using any method known in the art, such as an in vitro cell assay or a suitable in vivo method. In some embodiments, an anti-Sortilin antibody of the present disclosure reduces intracellular levels of Sortilin if it exhibits a 20% or greater reduction in intracellular levels of Sortilin, as measured by any in vitro cell assay or suitable in vivo method described herein or known in the art. In certain embodiments, an anti-Sortilin antibody of the present disclosure reduces intracellular levels of Sortilin if it induces a reduction in intracellular levels of Sortilin at saturating antibody concentrations and / or compared to a control antibody, as measured by any in vitro cell assay or suitable in vivo method described herein or known in the art. For example, intracellular levels of Sortilin can be assessed by an in vitro cell assay using cells expressing Sortilin, such as human U251 cells expressing human Sortilin or mouse Neuro2A cells expressing mouse Sortilin. In some cases, the intracellular level of Sortilin can be assessed by an in vitro cellular assay, e.g., using macrophages, dendritic cells, and / or leukocytes. In some cases, the intracellular level of human Sortilin can be assessed by an in vitro cellular assay, e.g., using human macrophages, human dendritic cells, and / or human leukocytes. In some cases, the intracellular level of Sortilin can be assessed in vivo, e.g., in macrophages, dendritic cells, and / or leukocytes obtained from an individual treated with an anti-Sortilin antibody of the present disclosure. In some cases, the intracellular level of human Sortilin can be assessed in vivo, e.g., in macrophages, dendritic cells, and / or leukocytes obtained from a human treated with an anti-Sortilin antibody of the present disclosure. In some cases, the intracellular level of mouse Sortilin can be assessed in vivo, e.g., in macrophages, dendritic cells, and / or leukocytes obtained from a mouse treated with an anti-Sortilin antibody of the present disclosure.In some cases, intracellular levels of cynomolgus monkey sortilin can be assessed in vivo, e.g., in macrophages, dendritic cells, and / or leukocytes from cynomolgus monkeys treated with an anti-Sortilin antibody of the disclosure. In some embodiments, an antibody of the disclosure induces a decrease in intracellular levels of Sortilin of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100%, as measured, e.g., by any in vitro or in vivo method described herein or known in the art. In some embodiments, an antibody of the disclosure induces at least about a 51.6% decrease in intracellular levels of sortilin, e.g., as measured by an in vitro cell assay described herein or known in the art, hi some embodiments, an antibody of the disclosure induces at least about an 89% decrease in intracellular levels of sortilin, e.g., as measured by an in vitro cell assay described herein or known in the art.
[0302] In some embodiments, an anti-Sortilin antibody of the present disclosure reduces total Sortilin levels. Total Sortilin levels can be measured using any method known in the art, such as an in vitro cell assay or a suitable in vivo method. In some embodiments, an anti-Sortilin antibody of the present disclosure reduces total Sortilin levels if it induces a 20% or greater decrease in total Sortilin levels, as measured by any in vitro cell assay or suitable in vivo method described herein or known in the art. In certain embodiments, an anti-Sortilin antibody of the present disclosure reduces total Sortilin levels if it induces a decrease in total Sortilin levels at saturating antibody concentrations and / or compared to a control antibody, as measured by any in vitro cell assay or suitable in vivo method described herein or known in the art. For example, total Sortilin levels can be assessed by an in vitro cell assay using cells expressing Sortilin, such as human U251 cells expressing human Sortilin or mouse Neuro2A cells expressing mouse Sortilin. In some cases, the total level of Sortilin can be assessed by an in vitro cell assay, e.g., using macrophages, dendritic cells, and / or leukocytes. In some cases, the total level of human Sortilin can be assessed in vivo, e.g., in macrophages, dendritic cells, and / or leukocytes obtained from a human treated with an anti-Sortilin antibody of the present disclosure. In some cases, the total level of mouse Sortilin can be assessed in vivo, e.g., in macrophages, dendritic cells, and / or leukocytes obtained from a mouse treated with an anti-Sortilin antibody of the present disclosure. In some cases, the total level of cynomolgus monkey Sortilin can be assessed in vivo, e.g., in macrophages, dendritic cells, and / or leukocytes obtained from a cynomolgus monkey treated with an anti-Sortilin antibody of the present disclosure.In some embodiments, an antibody of the disclosure induces a reduction in total sortilin levels of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100%, e.g., as measured by any in vitro or in vivo method described herein or known in the art. In some embodiments, an antibody of the disclosure induces a reduction in total sortilin levels of at least about 51.6%, e.g., as measured by an in vitro cell assay described herein or known in the art. In some embodiments, an antibody of the disclosure induces a reduction in total sortilin levels of at least about 89%, e.g., as measured by an in vitro cell assay described herein or known in the art.
[0303] In some embodiments, the total level of sortilin can be evaluated by an in vitro cell assay. In an exemplary assay, white blood cells such as primary monocytes, e.g., human primary monocytes, are isolated from blood, e.g., heparinized human blood, using RosetteSep Human Monocyte Enrichment Cocktail (STEMCELL Technologies) according to the manufacturer's protocol. The monocytes are seeded in RPMI (Invitrogen) containing 10% fetal bovine serum (Hyclone) and either 50 μg / ml M-CSF (Peprotech) to induce differentiation into macrophages or 100 μg / ml IL-4 + 100 μg / ml GM-CSF (Peprotech) to induce differentiation into dendritic cells. After 5 days, the cells are harvested. In the case of macrophages, only plate-bound cells are harvested using a cell scraper. In the case of dendritic cells, cells in suspension are harvested. After washing with PBS, the cells are seeded at 0.4 ml / well into a 12-well plate. 50 nanomolar of a control antibody or Fab, or a full-length anti-Sortilin antibody (IgG) or anti-Sortilin antibody Fab, such as an anti-Sortilin antibody or an anti-Sortilin antibody Fab of the present disclosure, is added to each well and incubated for 48 hours. Cells are then lysed on ice using RIPA buffer (Thermo Fisher Scientific) with protease inhibitors (Life Technologies). The lysate is collected and centrifuged at 10,000 x g for 10 minutes at 4°C. The supernatant is collected and the protein concentration is measured using a BCA kit (Thermo Fisher Pierce) according to the manufacturer's instructions. The cell lysate is then analyzed by immunoblotting.In some embodiments, an anti-Sortilin antibody of the present disclosure reduces total leukocyte sortilin levels by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or 100%, as assessed, e.g., using an in vitro cell assay, e.g., as described herein. In some embodiments, an antibody of the present disclosure induces a reduction of at least about 51.6% in total leukocyte sortilin levels as assessed, e.g., using an in vitro cell assay, e.g., as described herein. In some embodiments, the antibodies of the disclosure induce at least about an 89% reduction in total sortilin levels in leukocytes, as assessed, for example, using an in vitro cell assay, e.g., as described herein.
[0304] As used herein, the level of Sortilin may refer to the expression level of the gene encoding Sortilin; the expression level of one or more transcripts encoding Sortilin; the expression level of Sortilin protein; and / or the amount of Sortilin protein present in cells and / or on the cell surface. In some embodiments, the level of Sortilin refers to the effective concentration of Sortilin. Any method known in the art for measuring the level of gene expression, transcription, translation, and / or protein abundance or localization can be used to determine the level of Sortilin. In some embodiments, the cellular level of Sortilin protein, such as the cell surface level of Sortilin protein, the intracellular level of Sortilin protein, and / or the total level of Sortilin protein, is measured using any method known in the art, such as flow cytometry-based methods, immunoblotting methods such as Western blot, mass spectrometry, immunohistochemistry, imaging methods such as fluorescence microscopy, and immunoassays such as ELISA.
[0305] In certain embodiments, anti-Sortilin antibodies of the present disclosure may reduce cellular levels of Sortilin (e.g., cell surface levels of Sortilin, intracellular levels of Sortilin, and / or total levels of Sortilin) by inducing Sortilin degradation. Thus, in some embodiments, anti-Sortilin antibodies of the present disclosure induce Sortilin degradation. In certain embodiments, anti-Sortilin antibodies of the present disclosure may reduce cellular levels of Sortilin (e.g., cell surface levels of Sortilin, intracellular levels of Sortilin, and / or total levels of Sortilin) by inducing down-regulation of Sortilin. Thus, in some embodiments, anti-Sortilin antibodies of the present disclosure induce down-regulation of Sortilin. In certain embodiments, anti-Sortilin antibodies of the present disclosure may reduce cellular levels of Sortilin (e.g., cell surface levels of Sortilin, intracellular levels of Sortilin, and / or total levels of Sortilin) by inducing cleavage of Sortilin. Thus, in some embodiments, anti-Sortilin antibodies of the present disclosure induce cleavage of Sortilin. In certain embodiments, anti-Sortilin antibodies of the present disclosure may reduce cellular levels of Sortilin (e.g., cell surface levels of Sortilin, intracellular levels of Sortilin, and / or total levels of Sortilin) by inducing internalization of Sortilin. Thus, in some embodiments, anti-Sortilin antibodies of the present disclosure induce internalization of Sortilin. In certain embodiments, anti-Sortilin antibodies of the present disclosure may reduce cellular levels of Sortilin (e.g., cell surface levels of Sortilin, intracellular levels of Sortilin, and / or total levels of Sortilin) by inducing shedding of Sortilin. Thus, in some embodiments, anti-Sortilin antibodies of the present disclosure induce shedding of Sortilin.
[0306] In some embodiments, anti-Sortilin antibodies of the present disclosure induce desensitization of Sortilin. In some embodiments, anti-Sortilin antibodies of the present disclosure act as ligand mimetics to transiently activate Sortilin. In some embodiments, anti-Sortilin antibodies of the present disclosure act as ligand mimetics to transiently activate Sortilin before inducing a decrease in cellular levels of Sortilin and / or inhibition of the interaction (e.g., binding) of Sortilin with one or more Sortilin ligands. In some embodiments, anti-Sortilin antibodies of the present disclosure act as ligand mimetics to transiently activate Sortilin before inducing degradation of Sortilin. In some embodiments, anti-Sortilin antibodies of the present disclosure act as ligand mimetics to transiently activate Sortilin before inducing cleavage of Sortilin. In some embodiments, anti-Sortilin antibodies of the present disclosure act as ligand mimetics to transiently activate Sortilin before inducing internalization of Sortilin. In some embodiments, the anti-Sortilin antibodies of the present disclosure act as ligand mimetics, transiently activating Sortilin before inducing Sortilin efflux. In some embodiments, the anti-Sortilin antibodies of the present disclosure act as ligand mimetics, transiently activating Sortilin before inducing downregulation of Sortilin expression. In some embodiments, the anti-Sortilin antibodies of the present disclosure act as ligand mimetics, transiently activating Sortilin before inducing desensitization of Sortilin.
[0307] The anti-Sortilin antibodies of the present disclosure have median effective concentrations (EC ) in the micromolar, nanomolar, or picomolar range. 50 ) (e.g., as measured in vitro). In certain embodiments, the EC 50 In certain embodiments, the EC of the antibody is <1 μM, <100 nM, <10 nM, <1 nM, <0.1 nM, <0.01 nM, or <0.001 nM. 50is less than 100nM, less than 90nM, less than 80nM, less than 70nM, less than 60nM, less than 50nM, less than 40nM, less than 30nM, less than 20nM, less than 10nM, less than 9nM, less than 8nM, less than 7nM, less than 6nM, less than 5nM, less than 4nM, less than 3nM, less than 2nM, less than 1nM, less than 0.5nM, less than 0.1nM, less than 0.09nM, less than 0.08nM, less than 0.07nM In certain embodiments, the EC of the antibody is less than 0.06 nM, less than 0.05 nM, less than 0.04 nM, less than 0.03 nM, less than 0.02 nM, less than 0.01 nM, less than 0.009 nM, less than 0.008 nM, less than 0.007 nM, less than 0.006 nM, less than 0.005 nM, less than 0.004 nM, less than 0.003 nM, less than 0.002 nM, less than 0.001 nM, or less than 0.0009 nM. 50 For example, the EC of the antibody is about 0.086 nM as measured in vitro. 50 is less than any of about 1000 pM, about 950 pM, about 900 pM, about 850 pM, about 800 pM, about 750 pM, about 700 pM, about 650 pM, about 600 pM, about 550 pM, about 500 pM, about 450 pM, about 400 pM, about 350 pM, about 300 pM, about 250 pM, about 200 pM, about 150 pM, about 100 pM, about 50 pM, about 40 pM, about 30 pM, about 20 pM, about 10 pM, about 1 pM, about 0.5 pM, about 0.1 pM, or about 0.05 pM. 50is an upper limit of about 1000 pM, about 950 pM, about 900 pM, about 850 pM, about 800 pM, about 750 pM, about 700 pM, about 650 pM, about 600 pM, about 550 pM, about 500 pM, about 450 pM, about 400 pM, about 350 pM, about 300 pM, about 250 pM, about 200 pM, about 150 pM, about 100 pM, about 50 pM, about 40 pM, about 30 pM, about 20 pM, about 10 pM, about 1 pM, about 0.5 pM, or about 0.1 pM, and an upper limit of about 0.05 pM, about 0.1 pM, about 0.5 The EC of the antibody can be any of a range having an independently selected lower limit (provided that the lower limit is less than the upper limit) of about 1 pM, about 10 pM, about 20 pM, about 30 pM, about 40 pM, about 50 pM, about 100 pM, about 150 pM, about 200 pM, about 250 pM, about 300 pM, about 350 pM, about 400 pM, about 450 pM, about 500 pM, about 550 pM, about 600 pM, about 650 pM, about 700 pM, about 750 pM, about 800 pM, about 850 pM, about 900 pM, or about 950 pM. In some embodiments, the EC of the antibody can be any of a range having an independently selected lower limit (provided that the lower limit is less than the upper limit) of about 1 pM, about 10 pM, about 20 pM, about 30 pM, about 40 pM, about 50 pM, about 100 pM, about 150 pM, about 200 pM, about 250 pM, about 300 pM, about 350 pM, about 400 pM, about 450 pM, about 500 pM, about 550 pM, about 600 pM, about 650 pM, about 700 pM, about 750 pM, about 800 pM, about 850 pM, about 900 pM, or about 950 pM. 50 is about 1 pM, about 2 pM, about 3 pM, about 4 pM, about 5 pM, about 6 pM, about 7 pM, about 8 pM, about 9 pM, about 10 pM, about 15 pM, about 20 pM, about 25 pM, about 30 pM, about 35 pM, about 40 pM, about 45 pM, about 50 pM, about 55 pM, about 60 pM, about 65 pM, about 70 pM, about 75 pM, about 80 pM, about 85 pM, about 90 pM, about 95 pM, about In certain embodiments, the EC50 of the antibody is any of 100 pM, about 105 pM, about 110 pM, about 115 pM, about 120 pM, about 125 pM, about 130 pM, about 135 pM, about 140 pM, about 145 pM, about 150 pM, about 155 pM, about 160 pM, about 165 pM, about 170 pM, about 175 pM, about 180 pM, about 185 pM, about 190 pM, about 195 pM, or about 200 pM. 50 is approximately 86 pM.
[0308] Antibody EC 50 Various methods of measuring EC values are known in the art and include, for example, flow cytometry. 50is measured in vitro using cells that express sortilin, e.g., human sortilin or mammalian sortilin, e.g., cells engineered to express sortilin. In some embodiments, EC 50 is measured at a temperature of approximately 4° C. In some embodiments, EC 50 is measured at a temperature of approximately 25° C. In some embodiments, EC 50 is measur...
Claims
1. 1. An anti-Sortilin antibody for use in a method of treating or delaying the progression of a disease, disorder, or injury in an individual, the method comprising administering to the individual an anti-Sortilin antibody at a dose of at least about 6 mg / kg, the antibody comprising a light chain variable domain and a heavy chain variable domain, the heavy chain variable domain comprising HVR-H1 comprising the amino acid sequence of SEQ ID NO:6, HVR-H2 comprising the amino acid sequence of SEQ ID NO:7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:8, and the light chain variable domain comprising HVR-L1 comprising the amino acid sequence of SEQ ID NO:9, HVR-L2 comprising the amino acid sequence of SEQ ID NO:10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
11.
2. 1. An anti-Sortilin antibody for use in a method of increasing Progranulin levels in an individual having a disease, disorder, or injury, the method comprising administering to the individual an anti-Sortilin antibody at a dose of at least about 6 mg / kg, the antibody comprising a light chain variable domain and a heavy chain variable domain, the heavy chain variable domain comprising HVR-H1 comprising the amino acid sequence of SEQ ID NO:6, HVR-H2 comprising the amino acid sequence of SEQ ID NO:7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:8, and the light chain variable domain comprising HVR-L1 comprising the amino acid sequence of SEQ ID NO:9, HVR-L2 comprising the amino acid sequence of SEQ ID NO:10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
11.
3. An anti-sortilin antibody as described in claim 2, wherein in the method, the increase in progranulin levels includes an increase in progranulin levels in the individual's cerebrospinal fluid, the individual's plasma, or both.
4. An anti-sortilin antibody described in any one of claims 1 to 3, wherein the method comprises administering the anti-sortilin antibody by intravenous infusion or subcutaneous injection.
5. The method comprising: The anti-sortilin antibody (i) at a dose of at least about 6 mg / kg, at least about 15 mg / kg, at least about 30 mg / kg, or at least about 60 mg / kg; (ii) at a dose of about 6 mg / kg to about 30 mg / kg; or (iii) at a dose of about 6 mg / kg, about 15 mg / kg, about 30 mg / kg, or about 60 mg / kg; The anti-Sortilin antibody of any one of claims 1 to 4, comprising administration by intravenous infusion.
6. The method comprising: (a) administering said anti-Sortilin antibody by intravenous infusion at an initial dose of about 60 mg / kg, followed by administration of one or more lower doses of anti-Sortilin antibody of about 6 mg / kg to about 59 mg / kg, or about 6 mg / kg to about 30 mg / kg, or about 6 mg / kg to about 15 mg / kg; (b) administering the anti-Sortilin antibody by intravenous infusion at an initial dose of about 30 mg / kg, followed by administration of one or more lower doses of anti-Sortilin antibody of about 6 mg / kg to about 29 mg / kg, or about 6 mg / kg to about 15 mg / kg; (c) administering said anti-Sortilin antibody by intravenous infusion at an initial dose of about 15 mg / kg, followed by administration of one or more lower doses of anti-Sortilin antibody of about 6 mg / kg to about 14 mg / kg; (d) administering the anti-Sortilin antibody by intravenous infusion at an initial dose of about 6 mg / kg, followed by administration of one or more higher doses of anti-Sortilin antibody of about 7 mg / kg to about 30 mg / kg, about 15 mg / kg to about 30 mg / kg, or about 30 mg / kg to about 60 mg / kg; (e) administering the anti-Sortilin antibody by intravenous infusion at an initial dose of about 15 mg / kg, followed by administration of one or more higher doses of anti-Sortilin antibody of about 16 mg / kg to about 30 mg / kg, or about 30 mg / kg to about 60 mg / kg; or (f) administering the anti-Sortilin antibody by intravenous infusion at an initial dose of about 30 mg / kg, followed by administration of one or more higher doses of anti-Sortilin antibody of about 31 mg / kg to about 60 mg / kg. The anti-Sortilin antibody of any one of claims 1 to 4, comprising:
7. The anti-sortilin antibody of claim 5 or 6, wherein the method comprises administering the anti-sortilin antibody about once every 4 weeks or less frequently, or about once every 4 weeks, about once every 5 weeks, about once every 6 weeks, about once every 7 weeks, about once every 8 weeks, about once every 9 weeks, or about once every 10 weeks.
8. The method of claim 1, further comprising administering the anti-sortilin antibody by intravenous infusion. (i) at a dose of about 15 mg / kg about once every 4 weeks, about once every 6 weeks, or about once every 8 weeks; (ii) at a dose of about 30 mg / kg about once every 4 weeks, about once every 6 weeks, or about once every 8 weeks; or (iii) at a dose of about 60 mg / kg about once every 4 weeks, about once every 6 weeks, or about once every 8 weeks; The method of claim 1 or claim 2, comprising administering to a subject a method for treating a patient having a pulmonary syndrome.
9. The method according to claim 1, The anti-sortilin antibody is administered subcutaneously. (i) at a dose of at least about 270 mg; (ii) at a dose of about 150 mg to about 600 mg; or (iii) at a dose of any of about 150 mg, about 270 mg, about 300 mg, or about 600 mg; The method of any one of claims 1 to 4, comprising administering to a subject a method for treating a patient having a pulmonary syndrome.
10. The method of claim 1, 10. The anti-Sortilin antibody of claim 9, comprising administering the anti-Sortilin antibody by subcutaneous injection about every 2 weeks, about every 4 weeks, about every 6 weeks, or about every 8 weeks.
11. An anti-Sortilin antibody described in any one of claims 1 to 10, comprising a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 20 and a light chain variable domain having the amino acid sequence of SEQ ID NO:
21.
12. An anti-sortilin antibody described in any one of claims 1 to 11, having a human IgG1 isotype.
13. The anti-Sortilin antibody of claim 12, wherein the anti-Sortilin antibody comprises an Fc region comprising the amino acid substitutions L234A, L235A, and P331S, where the numbering of residue positions is according to EU numbering.
14. (i) a light chain comprising the amino acid sequence of SEQ ID NO: 30, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 or 32; (ii) a light chain comprising the amino acid sequence of SEQ ID NO: 30, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 32; or (iii) a light chain comprising the amino acid sequence of SEQ ID NO: 30, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 31; The anti-sortilin antibody according to any one of claims 1 to 13.
15. The method according to claim 1, (i) measuring the level of Progranulin in blood or cerebrospinal fluid samples obtained from an individual before and after said individual receives one or more doses of an anti-Sortilin antibody; and / or (ii) measuring sortilin levels in leukocytes of blood samples obtained from the individual before and after the individual receives one or more doses of an anti-sortilin antibody; and / or (iii) measuring levels of neurofilament light chain (NF-L), tau, one or more biomarkers of neuroinflammation, one or more biomarkers of inflammation, one or more biomarkers of complement function, and / or one or more biomarkers of microglial activity in blood or cerebrospinal fluid samples obtained from the individual before and after the individual receives one or more doses of an anti-sortilin antibody; Further comprising: In some cases, (a) the one or more biomarkers of neuroinflammation are selected from the group consisting of IL-6, SPP1, IFI2712A, CHIT1, YKL-40, GFAP, YWHAE, CSF1, AIF1, LY86, CD86, and TOP2A; (b) the one or more inflammatory biomarkers are selected from the group consisting of osteopontin (SPP1), YWHAE (14-3-3 protein ε), allograft inflammatory factor 1 (AIF1), colony stimulating factor 1 (CSF1), chitinase 1 (CHIT1), lymphocyte antigen 86 (LY86), and CD86; (c) the one or more biomarkers of complement function are selected from the group consisting of C1qb and C1qc; and / or (d) the one or more biomarkers of microglial activity are selected from the group consisting of YKL-40, GFAP and interleukin-6; The anti-sortilin antibody according to any one of claims 1 to 14.
16. 16. The anti-Sortilin antibody of any one of claims 1 to 15, wherein the disease, disorder, or injury is selected from the group consisting of frontotemporal dementia, progressive supranuclear palsy, Alzheimer's disease, vascular dementia, stroke, retinal dystrophy, amyotrophic lateral sclerosis (ALS), traumatic brain injury, spinal cord injury, dementia, stroke, Parkinson's disease, acute disseminated encephalomyelitis, retinal degeneration, age-related macular degeneration, glaucoma, multiple sclerosis, septic shock, bacterial infection, arthritis, and osteoarthritis.
17. The anti-Sortilin antibody of claim 16, wherein the individual is at risk for the disease, disorder, or injury.
18. The anti-Sortilin antibody of any one of claims 1 to 17, wherein the disease, disorder, or injury is Parkinson's disease or sporadic Parkinson's disease.
19. 19. The anti-Sortilin antibody of claim 18, wherein the individual has at least one pathogenic mutation in the GBA1 gene, optionally wherein the individual is homozygous or heterozygous for at least one pathogenic mutation in the GBA1 gene, and further optionally wherein the at least one pathogenic mutation in the GBA1 gene is selected from the group consisting of c.1226A>G, c.1448T>C, IVS2+1G>A, RecNciI, 84insGG, and any combination thereof; or wherein the at least one pathogenic mutation in the GBA1 gene is a mutation in the GBA1 gene that results in an amino acid substitution in the GBA1 gene product selected from the group consisting of N370S, L444P, R120W, H255Q, D409H, E326K, T369M, R496H, and any combination thereof.
20. the disease, disorder, or injury is frontotemporal dementia (FTD); Optionally, the individual (a) heterozygous for one or more mutations in the GRN gene, optionally wherein the one or more mutations are loss-of-function mutations; (b) heterozygous for the C9orf72 hexanucleotide repeat expansion; (c) having symptoms of FTD, having no symptoms of FTD, or having pre-symptomatic FTD; and / or (d) having FTD-GRN, or FTD, caused by one or more mutations in the GRN gene; Furthermore, in some cases, (a) the individual has pre-symptomatic FTD and (i) has an increased level of one or more biomarkers selected from the group consisting of Nfl, SPP1, YWHAE, AIF1, CSF1, CHIT1, and LY86, and / or (ii) has a decreased level of one or more biomarkers selected from the group consisting of NAGK and CTSB; or (b) the individual has no symptoms of FTD, and (i) is heterozygous for one or more mutations in the GRN gene, and / or (ii) has reduced levels or function of PGRN; The anti-sortilin antibody according to any one of claims 1 to 17.
21. The anti-Sortilin antibody of any one of claims 1 to 17, wherein the disease, disorder, or injury is Alzheimer's disease or ALS.
22. The anti-Sortilin antibody of any one of claims 1 to 21, wherein the individual is a human.
23. 1. A pharmaceutical composition comprising an anti-Sortilin antibody at a dose of at least about 6 mg / kg for use in a method of treating or delaying the progression of a disease, disorder, or injury in an individual, said antibody comprising a light chain variable domain and a heavy chain variable domain, said heavy chain variable domain comprising HVR-H1 comprising the amino acid sequence of SEQ ID NO:6, HVR-H2 comprising the amino acid sequence of SEQ ID NO:7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:8, and said light chain variable domain comprising HVR-L1 comprising the amino acid sequence of SEQ ID NO:9, HVR-L2 comprising the amino acid sequence of SEQ ID NO:10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
11.
24. 1. A pharmaceutical composition comprising an anti-Sortilin antibody at a dose of at least about 6 mg / kg for use in a method for increasing progranulin levels in an individual having a disease, disorder, or injury, said antibody comprising a light chain variable domain and a heavy chain variable domain, said heavy chain variable domain comprising HVR-H1 comprising the amino acid sequence of SEQ ID NO:6, HVR-H2 comprising the amino acid sequence of SEQ ID NO:7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:8, and said light chain variable domain comprising HVR-L1 comprising the amino acid sequence of SEQ ID NO:9, HVR-L2 comprising the amino acid sequence of SEQ ID NO:10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
11.
25. 13. The use of an anti-Sortilin antibody at a dose of at least about 6 mg / kg in the manufacture of a medicament for treating or delaying the progression of a disease, disorder, or injury in an individual, wherein the antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO:6, HVR-H2 comprising the amino acid sequence of SEQ ID NO:7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:8, and the light chain variable domain comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO:9, HVR-L2 comprising the amino acid sequence of SEQ ID NO:10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
11.
26. 13. The use of an anti-Sortilin antibody at a dose of at least about 6 mg / kg in the manufacture of a medicament for increasing Progranulin levels in an individual having a disease, disorder, or injury, wherein the antibody comprises a light chain variable domain and a heavy chain variable domain, the heavy chain variable domain comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO:6, HVR-H2 comprising the amino acid sequence of SEQ ID NO:7, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:8, and the light chain variable domain comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO:9, HVR-L2 comprising the amino acid sequence of SEQ ID NO:10, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:11.
